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1.1 Hip replacement for younger and active patients. 
Hip replacement surgery is one of the most successful medical procedures 
performed in an elderly population suffering from disabling osteoarthritis (OA).1 
The current hip replacement surgery has excellent long term results1, in the 
Netherlands about 21.000 THA are implanted annually2 and worldwide an 
estimated 750.000 Total Hip Arthroplasty (THA) procedures are carried out every 
year.3 Despite these large numbers, implant survival and optimal postoperative 
functioning of both the artificial joint as well as the patient are still challenges in 
THA. As for the artificial joint, wear-resistance of the bearing surfaces is still a key-
issue and one of the challenges, especially in the physically demanding younger 
patient.4,5 
During the nineteen-nineties of the last century, Ultra High Molecular Weight 
Polyethylene (UHMWPE) was considered the benchmark for surface bearings in 
THA. At that time in our clinic, younger, physically active patients with severe hip 
osteoarthritis (OA) were treated with an uncemented THA with a standard 
UHMWPE acetabular liner (ArComTM, Biomet, Warsaw, USA, Figure 1.1).  
This type of UHMWPE was compression molded and Argon packaged, to prevent 
ageing of the material before implantation. The in vivo wear rate of compression 
molded PE was shown to be 50% less than the more commonly used UHMWPE 
machined from extruded bars.6 In a further effort to reduce PE wear, cross-linking 
of UHMWPE by heat-treatment was developed during the 1990s and quite 
recently anti-oxidant treatment of this (highly) cross-linked UHMWPE was 
introduced, by infusion of vitamin E into the UHMWPE material (Figure 1.2). 
Figure 1.1, Acetabular metal shell, 




Also around the millennium, Metal-on-Metal (MoM) was reintroduced as a 
bearing surface in THA and was promoted to be especially wear resistant in 
younger- and more active patients. MoM arthroplasty could either be applied as a 
resurfacing technique or as a ball and socket stemmed THA. Both were used in 
our clinic, replacing the uncemented THA with a standard, compression molded 
Argon packaged UHMWPE bearing, with a MoM prostheses for indicated patients. 
The latter would in theory have not only lower wear rates but also, due to the 
larger femoral head, reduced dislocation rates, as well as preservation of femoral 
bone stock if a MoM resurfacing design was used (Figure 1.3). 
 
1.2 Bearing surface issues 
The orthopaedic literature from 2000 to 2010 is not conclusive on which bearing 
surface is superior in physically demanding, mostly younger, patients. The 
discussion on the limited longevity of standard UHMWPE bearings in younger 
patients5,7 and the demand for a better range of motion stimulated the 
reintroduction of MoM bearings, which eventually failed dramatically compared 
Figure 1.2, Acetabular metal shell with vitamin 
E infused UHMWPE acetabular liner showing 
typical orange colouring. 
Figure 1.3, Metal-on-Metal bearing surfaces in 
a hip resurfacing design. 
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to UHMWPE liner THA designs.8,9,10 The latter initiated the studies in this 
manuscript on MoM Total Hip Prostheses.  
 
1.3 Aim of this thesis 
This thesis addresses four main topics related to hip arthroplasty in young active 
patients with special emphasis on the use of MoM bearing surfaces: (1) A clinical 
and radiographic evaluation of THA survival in young active patients; (2) A 
systematic review of the different MoM hip resurfacing systems; (3) A study on 
the prevalence of Adverse Reaction to Metal Debris (ARMD) with MoM bearings, 
and; (4) Validation and quantification studies on presence of ARMD after MoM 
hip arthroplasty at MRI. 
 
1.4 Outline of this thesis 
First, to put current issues with MoM bearings in the proper context, a critical 
review on the development and market (re-)introduction of MoM bearings was 
done (chapter 2). Next, a retrospective study on radiological liner wear and 
implant survival of our first 200 uncemented THA procedures with standard 
UHMWPE in younger, more active patients (chapter 3) was done. At the 
introduction of MoM hip resurfacing in our clinic (2004), all treated patients were 
included in a prospective clinical follow up study on implant survival and 
functional outcomes. Since little was known on survival and outcome of most 
types of resurfacing hip arthroplasty, prior to analysing the short to mid-term 
results of this cohort (chapter 5), we systematically reviewed the peer-reviewed 
literature on implant survival of MoM hip resurfacing (chapter 4). By the end of 
the first decade of this century, an increasing number of papers were published 
on the adverse reactions related to in vivo release of metal wear particles. Clarke 
is recognized as first to start serious discussions on the possible downsides of the 
“modern” MoM total hip arthroplasty, expressing concern regarding the long 
term toxicological systematic effects such as immune modulation, chromosomal 
damage and carcinogenesis in 2003.11 The first occurrence of ARMD in response 
to in vivo released metal ion particles was described in 200812, with Clayton using 
the term “pseudotumor”13 in relation to current MoM bearings, a term previously 
introduced by Picard in 1997.14 
These adverse reactions (pseudotumors) appeared to be related to a variety of 
factors including implant design characteristics, implant positioning, edge loading 
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and implant size. These pseudotumors, defined as a peri-articular mass caused by 
an immunological delayed hypersensitivity response to metal particles and 
characterised by a lymphocyte-dominated histological pattern15 lead to worse 
clinical outcomes after revision surgery compared to other reasons for MoM 
revision.16 Since pseudotumors are soft tissue masses, they are usually not 
detected with standard radiographs, although this was until recently the standard 
method to evaluate MoM case series. At first, most studies focussed on metal ion 
concentrations as an indicator for the amount of wear to predict the occurrence 
of ARMD. To evaluate the occurrence of pseudotumors in our own cohort of well 
documented hip resurfacing arthroplasty (HRA) patients, a pilot study using an 
intensified screening protocol based on Metal-Artefact Reducing Sequence 
(MARS) MRI was performed (chapter 6). In this study we compared the 
prevalence of pseudotumors in a subgroup of MoM HRA patients with high risk 
for pseudotumor to a group with low risk for pseudotumor formation. The validity 
of pseudotumor classification systems was evaluated as well (chapter 7), and 
clinical pseudotumor dimension measurements were validated with a three-
dimensional region-of-interest based method (chapter 10). 
Screening our whole cohort of MoM hip resurfacing patients using metal ions 
analysis and MARS-MRI for every patient (chapter 8) provided detailed 
information on the prevalence of pseudotumors. A study on clinical symptoms 
and differences in MRI findings in unrevised MoM patients with repeated MARS-
MRI scans at six to twelve months was done to elaborate on the clinical effect of 
presence of pseudotumors (chapter 9). A general discussion reflecting on the 
results of different implant designs and bearing surfaces of the last two decades, 
the results from studies of this thesis, and directions for future research is 





1. Learmonth ID, Young C, Rorabeck C. The operation of the century: total 
hip replacement. Lancet 2007;370:1508-19. 
 
2. No authors listed. LROI-Rapportage 2007-2011. Registreren voor een 
betere zorg. 2012; ’s Hertogenbosch. 
 
3. Haenle M, Gollwitzer H, Ellenrieder M, Mittelmeier W, Bader R. Peri-
prosthetic infection following total hip arthroplasty. Eur Musculoskel Rev 
2010;5:60–63. 
 
4. Haidukewych GJ, Petrie J. Bearing surface considerations for total hip 
arthroplasty in young patients. Orthop Clin North Am;2012;43:395-402. 
 
5. Howcroft D, Head M, Steele N. Bearing surfaces in the young patient: out 
with the old and in with the new? Curr Orthop 2008; 22:177-84. 
 
6. Bankston, A.B., Keating, E.M., Ranawat, C., Faris, P.M., Ritter, M.A., “The 
Comparison of Polyethylene Wear in Machined vs. Molded Polyethylene,” 
Clin Orthop Rel Res 1995;317:37-43. 
 
7. Shetty V, Shitole B, Shetty G, Thakur H, Bhandari M. Optimal bearing 
surfaces for total hip replacement in the young patient: a meta-analysis. 
Int Orthop 2011; 35:1281-7. 
 
8. Australian Orthopaedic Association National Joint Replacement Registry. 
Annual report 2012. https://aoanjrr.dmac.adelaide.edu.au/nl/annual-
reports-2012. 
 
9. Van Raaij J.J.A.M., Uncemented resurfacing hip arthroplasty. Clinical 
studies and failure analaysis. 1995; Leiden University, thesis. 
 
10. Deutman R. Experience with the McKee-Farrar total hip arthroplasty. 
1974; Leiden University, thesis. 
17 
 
11. Clarke MT, Lee PT, Arora A, Villar RN. Levels of metal ions after small- and 
large-diameter metal-on-metal hip arthroplasty. J Bone Joint Surg [Br] 
2003;85:913-7. 
 
12. Pandit H, Glyn-Jones S, McLardy-Smith P, Gundle R, Whitwell D, Gibbons 
CL, Ostlere S, Athanasou N, Gill HS, Murray DW. Pseudotumours 
associated with metal-on-metal hip resurfacings. J Bone Joint Surg [Br] 
2008;90:847-51. 
 
13. Clayton RA, Beggs I, Salter DM, Grant MH, Patton JT, Porter DE. 
Inflammatory pseudotumor associated with femoral nerve palsy following 
metal-on-metal resurfacing of the hip. A case report. J Bone Joint Surg 
[Am] 2008;90:1988-93. 
 
14. Picard F, Montbarbon E, Tourne Y, Leroy JM, Saragaglia D. Pseudotumor 
manifestation of metallosis in a hip prosthesis. Int Orthop 1997;21:352-4. 
(Article in French). 
 
15. Willert HG, Buchhorn GH, Fayyazi A, Flury R, Windler M, Köster G, 
Lohmann CH. Metal-on-metal bearings and hypersensitivity in patients 
with artificial hip joints. A clinical and histomorphological study. J Bone 
Joint Surg [Am] 2005;87:28-36. 
 
16. Grammatopolous G, Pandit H, Kwon YM, Gundle R, McLardy-Smith P, 
Beard DJ, Murray DW, Gill HS. Hip resurfacings revised for inflammatory 










Hip arthroplasty bearing choice and implant performance 
Durability and performance of Total Hip Arthroplasty (THA) implants are still a 
challenge in younger and physically more demanding patients.1 Serious progress 
has been made since the “low-friction bearing” concept developed by Sir John 
Charnley in the early sixties of the last century2, resulting in a “forgotten” joint for 
many THA-patients nowadays.3 But especially in the younger and more active 
patients the longevity of the bearing surfaces is the limiting factor for long term 
implant survival.4-6 Since younger patients tend to be physically more active than 
elderly patients, their implants have to withstand higher biomechanical stress and 
these stresses also need to be endured for a more prolonged period of time, 
leading to a higher risk of dislocation and accelerated wear of the bearing surface. 
To improve implant fixation and durability and to reduce the risk of other 
complications (i.e. dislocation, infection), surgeons, engineers and scientists have 
developed new materials and new surgical techniques, but also introduced new 
coatings and finishes (i.e. polished) of implants, and designed different implant 
forms such as collared stems, femoral resurfacing components and modular 
components. To reduce implant wear, different bearing surfaces were developed. 
For this purpose, hard-on-hard bearings such as Ceramic-on-Ceramic and 
especially Metal-on-Metal (MoM) surface bearings have a long tradition in THA. In 
this chapter we give a brief overview of the development of MoM surface 
bearings in the history of THA, and discuss how different generations of MoM 
surface bearings were introduced into clinical practice. 
 
First generation Metal-on-Metal hip arthroplasty 
After orthopaedic surgeons experimented with many different interposition 
materials, such as muscle, celluloid, silver plates, rubber struts and magnesium, 
Berliner Professor T. Glück (1853-1942) led the way in the development of hip 
implant fixation using an ivory ball and socket joint that he fixed to bone with 
nickel-plated screws.7 The first total hip implant with a MoM articulation is 
attributed to the British orthopaedic surgeon P. Wiles who, in 1938, implanted a 
bearing couple made of stainless steel, fixed to the bone with screws and bolts. 
His results with stainless steel were however disappointing.7 During this same 
period, Smith-Petersen introduced the concept of resurfacing the femoral head, 
using glass, celluloid and pyrex before settling on vitallium in 1938.6 Vitallium is a 
chrome-cobalt alloy which is remarkably inert. Wiles at that time however 
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preferred stainless steel and McKee, another pivotal orthopaedic surgeon in MoM 
arthroplasty, preferred brass and stainless steel at first.6 In the 1950s McKee and 
Watson-Farrar adopted a MoM articulation with a modified Thompson stem, 
which is considered the start of the first generation of MoM THA.8 McKee and 
Watson-Farrar initially treated 50 patients with this MoM prosthesis in which both 
the acetabular and the femoral component were made of Vitallium, later on they 
switched to a cobalt-chromium-molybdenum alloy in which both components 
were fixated to the bone using cement. Although later research showed 
unacceptably high revision rates9, MoM arthroplasty was widely used in the 
1960s, with besides the McKee-Farrar design the Ring design (also in the UK), the 
Mueller-Huggler implant in Switzerland, and the Sivash design in the Soviet 
Union.10 
Although many years later retrieval studies of first-generation MoM hips 
demonstrated low wear rates in individual cases, a tissue reaction to metal 
particles around MoM total hip prostheses was noticed with some retrieval 
cases.11,12 Large numbers of macrophages with metal particles in tissues around 
MoM prostheses were seen13, with dark tissue staining and osteolysis after MoM 
arthroplasty being associated with impingement or with loose components.10 In 
studies using metal-on-polyethylene prostheses, a wide variety of marked tissue 
changes were also present around the hip implant, but these tissue response 
were associated with bone loss, rather than with soft tissue damage.13 
The disappointing results, poorly understood at that time, and the extraordinary 
mentoring of the "low friction" THA developed by Charnley, using metal-on-
polyethylene bearings, 'red lined' the MoM bearing, and consequently the 
concept was abandoned before the reasons for its failure had been effectively 
analyzed.14 Later studies attributed the failure of MoM bearings to the factor of 
"high friction" resulting from inadequate manufacturing.15 By the mid-1970s, 
MoM had all been rejected in favour of Charnley’s technique for low-friction 
arthroplasty of the hip using polyethylene (PE).2 A full recounting of the historical 
events leading up to the ‘‘discovery’’ of PE for hip arthroplasty in 1962 by Sir John 
Charnley and his engineering associate, Harry Craven, can be found in Charnley’s 
monograph16 and biography17, but it is instructive to briefly recall Ultra High 
Molecular Weight Polyethylene (UHMWPE) arrived in orthopaedics by chance 
rather than by design.18 Only after the catastrophic clinical failure of 
polytetrafluoroethylene (PTFE) and failure of his initial choices, glass-filled 
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variants of PTFE, that Charnley sought bearing material alternatives. With the 
introduction of UHMWPE particles in the body, resulting from inevitable wear on 
the implant bearing surface, the mechanism of osteolysis was described.19 In this 
process, UHMWPE wear products are thought to cause massive osteolysis by 
triggering foreign-body granuloma formation at the bone-cement interface, 
resulting in implant loosening and ultimately, implant failure.19 Long term implant 
survival results of standard UHMWPE are as a result often disappointing, 
especially for the acetabular component.20 In retrospect it was recognized that 
the results of "the McKee" could in fact differ only little from the results of "the 
Charnley". Some MoM implants by McKee-Farrar and Ring continued functioning 
extremely well and were "rediscovered" in the 1980s by Swiss and British 
surgeons.7 By the late 1980s, concerns over osteolysis attributed to PE wear 
debris led to the reintroduction of MoM bearings, the development of highly 
cross-linked PE and the more widespread use of Ceramic-on-Ceramic (CoC) 
bearings.10 
CoC bearing surfaces were developed in the early 1970s in France and Germany21 
to reduce wear particles and subsequent osteolysis occurring with polyethylene 
THA bearings.22 CoC tribological properties are explained by its low surface 
roughness, high hardness for major scratch resistance, high wettability and fluid-
film lubrication.23 The initial use of CoC bearings resulted in a high rate of aseptic 
loosening of the cemented socket and risk of component fracture, mainly related 
to bad design and material flaws.21,24 Incremental improvements in the 
manufacturing process, design, and quality control have since significantly 
decreased the risk of fracture to approximately 0.02% to 0.1%.24 However, there 
are still concerns regarding fracture of sandwich ceramic liners, squeaking, and 
impingement of the femoral neck on the rim of the ceramic liner leading to 
chipping, especially in younger and physically active patients, and according to a 
recent systematic review by Gallo et al, the use of CoC bearings leads to 
equivalent but not improved survivorship at 10 years follow-up compared to the 
best non-CoC THA.22 This is also shown in the 2012 Annual report of the Australian 
Joint Replacement Register, where the Yearly Cumulative Percent Revision rate 
for CoC bearing at 10 years is 4.8% for fixed femoral neck types, 9.8% for 
exchangeable femoral neck types and 4.6% for Metal-on-Polyethylene (MoP) 
bearing devices.25 Randomized clinical trials comparing CoC versus PE bearings 
also show similar clinical outcomes and dislocation rates between both groups.26 
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Second generation Metal-on-Metal hip arthroplasty 
After identifying the "polyethylene disease" in the beginning of the 1980s, MoM 
bearings were considered again as an alternative to PE.27 An elaborate analysis of 
the first generation MoM failures led Weber to initiate and then promote a 
second generation of MoM, cemented at first, then rapidly followed by non-
cemented prostheses.14 At that time, the advantages of MoM were put into 
perspective due to survivorship analysis of the Charnley versus McKee-Farrar 
prostheses. Analysis of these results supported the reintroduction of MoM 
bearings in 1988.28 It was stated that significant numbers of MoM bearings were 
surviving at long term, due to polar bearing, a component orientation which 
avoided impingement and good cementation.29  
At the time of re-introduction, wear simulation tests showed that wear rates of 
second generation MoM bearings were 20 to 100 times lower compared to metal-
on-conventional polyethylene30,31, and MoM bearing couples started to 
experience widespread clinical use in both hip resurfacing and total hip 
arthroplasty. The material properties allowed the use of large heads in thin 
acetabular shells, promising of a reduced incidence of hip dislocation in younger 
and more active patients. From their arrival in the orthopaedic market in 1997, 
MoM bearings were strongly marketed as the latest advance in hip replacement 
and were targeted at young active patients who needed a hip that would last a 
whole lifetime.32 In the case of MoM hip resurfacing, patients organised 
themselves on internet and started forums on this topic, as for example 
www.surfacehippy.info. In the same time, critical reports on the limitations of 
MoM hip resurfacing discussed poor medium term outcomes, with a two- to 
threefold difference in revision rate between different makes, based on the 
observation that prostheses were different in many details, such as shape, sizing, 
head coverage, clearance, metal alloy used, heat treatment, instrumentation, and 
so on.33 During the first years of the reintroduction however, resurfacings became 
very popular and the number of implantations rose to about 10-20% of all primary 
hip replacements in countries such as the UK, Australia, and the Netherlands.33 
There remained a concern on the metal ion release over time and the potential 
detrimental effects of accumulated metal ions in the body.31 Its particular 
complication, Aseptic Lymphocytic Vasculitis-associated Lesions (ALVAL), was 
documented by Willert.34 From the beginning, serious concerns because of the 
risks associated with an increased level of circulating metal ions slowed down 
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further development of this bearing, although at the time of introduction no 
complication could be attributed to this phenomenon.14 Throughout literature a 
variety of nomenclature describing implant failure mode as a reaction to metal 
wear particles is used, most notably the terms ALVAL34, pseudotumor35 and 
metallosis.36 Langton et al described a new umbrella term for these modes of 
failure: Adverse Reaction to Metal Debris (ARMD), to include MoM joint failures 
associated with pain, a large sterile effusion of the hip and/or macroscopic 
necrosis and metallosis.37 The end modes of failure requiring revision are ALVAL (a 
histological diagnosis made from tissue sampling at the time of surgery identifying 
an abundance of lymphocytes in the local pericapsular tissue)34 and pseudotumor 
(the development of a cystic mass in the periarticular region, which has a direct 
communication with the joint).35 These pseudotumors can be very large, extend 
into the pelvic region, can involve destruction of bone and muscle tissue, and 
compress vital surrounding structures such as nerves and blood vessels.38-40 
Another concern with the toxicity of released chromium and cobalt is the 
increased risk for cancer but large comparative studies have demonstrated so far 
that patients with MoM hip prostheses were not at increased overall risk for 
cancer.41,42 
 
Complexity of introducing new bearing devices into clinical practice  
Since there is an increasing necessity for innovative surgical techniques and 
designs for orthopedic surgeons to meet the demands of increasingly younger and 
more demanding patients, there is an inherent risk in the introduction of these 
innovations. Under current regulations, clinically important unknown modes of 
failure for newly introduced devices may not become known for several years 
after widespread adoption, affecting a large number of patients.43 There is a 
conflicting interest of making promising new hip implant materials and designs 
available so patients can benefit as soon as possible, and the fact that these same 
joint replacement devices have to perform well for over more than 10 years and 
preferably more than 20 years after implantation in the patient. These 
requirements make it difficult to design a model for market introduction that 
effectively and safely guards these requirements, without delaying the needed 
innovations. For example if more clinical trials are needed in one country before a 
device can be used in clinical practice, patients might prefer to have surgery in 
neighbouring countries where these specific requirements are absent. If a medical 
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device company spends more time on clinical research, including longer follow up 
studies before releasing new implant designs, other companies might actually 
introduce comparable devices with less clinical support in the mean time.  
Another concern is the absence of a clear definition of what is considered a new 
implant design. Typically, hip replacement devices undergo minor design 
alterations several times during their lifespan, for example CCD angle, conus, 
coating or just the manufacturing process. Although one has to bear in mind all 
this work is done with the benefit for patients in mind, it is not always clear how 
these minor design changes will effect implant performance. 
When adopting more extensive regulations for the introduction of medical 
devices, it is therefore important this should be done in collaboration with all 
stakeholders involved. Of course the company which has developed the new 
implant, notified bodies, competent authorities (national authorities such as the 
Food and Drug Administration in the United States), the orthopaedic surgeons 
who have to start using this particular device, and last but not least the patient 
receiving the new implant. Increasingly, health insurance companies and hospital 
administrators are also influencing which devices are used by the professionals.  
In general, we can conclude that the process of bringing medical devices into 
clinical practice is complex due to a discrepancy between the interest of 
introducing newer designs fast, the need for long term clinical data collection on 
implant performance, the involvement of many stakeholders, and lack of 
consensus on the definition of a new implant. There is both room to improve 
market introduction (or re-introduction) regulation and supervision by post 
market clinical research. A more gradual introduction of new implants, with the 
appropriate research modality should strike a balance in encouraging new 
technology which might improve clinical outcomes, while protecting patients from 
being exposed to new products which may produce unexpected complications. As 
witnessed with the re-introduction of MoM bearings in THA, serious 
complications which were unforeseen at the time of introduction became only 
known after a large number of patients worldwide (an estimated 1 million 
patients)32 had become at risk. In this particular case, RadioStereometric Analysis 
(RSA) studies which are nowadays considered an integral part of gradual 
introduction into practice did not detect these unforeseen complications of 
adverse soft-tissue reactions.44 However, better analysis of-, and anticipation on-, 
previous failure modes probably would have detected possible down sites of 
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MoM earlier. Consensus on who has to collect, manage and report this data is 
however not easily reached, with different interests of involved stakeholders on 
this topic. It is however clear that increasing post marked clinical research efforts 
in orthopaedic surgery might protect patients from unnecessary harm, reduce 
costs by preventing expensive revision surgery and by preventing loss of mobility 
and productivity in patients.  
In conclusion, MoM surface bearings have a long history of use in total hip 
arthroplasty, with two distinct generations of these bearings. Reduced wear 
volume, the major advantage of the second generation MoM as seen with in vitro 
testing, was seriously challenged with in vivo use where less than optimal implant 
positioning resulted in edge loading and unexpected high wear. The released wear 
particles induced an, initially less known, local tissue response which is now 
generally known as ‘Adverse Reaction to Metal Debris’, of which the clinical 
importance is not yet fully understood. This unexpected failure mechanism has 
raised concern on how medical devices, including hip implants, are introduced 
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Uncemented total hip prostheses were introduced some 40 years ago, after 
disappointing results with cemented hip prostheses in young and active 
patients.4,8,10,56 In orthopedic literature, research on uncemented hip prostheses 
has focused on the survival of the uncemented femoral stem, and in general, 
excellent results were reported.1,35,37,42 Although the femoral component showed 
excellent performance, recent in vivo studies have reported increased wear of the 
polyethylene (PE) liner of the uncemented acetabular cup.6,18,25,32 This PE wear 
results in PE particles being distributed in the tissue surrounding the prosthesis, 
with macrophages being activated by these particles. These activated 
macrophages induce osteolysis (Figure 3.1) which in the end results in aseptic 
loosening of the prosthesis.19,27,29,46,54,60  
 
Although uncemented hip prostheses vary greatly in design, they all have a metal-
backed acetabular cup (Figure 3.2). This metal-backing is needed since direct 
contact between bone and PE results in osteolysis.23,29,51 Metal-backed cups are 
made more biocompatible by applying coatings which stimulate bone ingrowth. 
These coatings are either porous or hydroxyapatite (HA) coatings. When metal-
backed cups were developed, a better force distribution with less peak forces was 
expected along the bone-prostheses interface.  
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Recent studies however stated there was less stress shielding with cemented cups 
than with uncemented cups.14,44 Another possible disadvantage from metal-
backed cups is the dislocation or rotation of the PE liner from the metal-backing, 
resulting in additional wear and an increased number of released PE particles. This 













Increased PE wear is most likely a multifactorial process influenced by, for 
example, the manner in which PE is produced and sterilized, the time between 
production and implantation (known as “shelf life”), the inclination angle of the 
cup, and the activity levels of the patient. Since we had concerns on the frequency 
of observed wear in our patient population, we retrospectively reviewed our first 
200 uncemented hip prostheses using the Mallory-Head design (Biomet Inc., 
Warsaw, USA). The long-term survival of the femoral component of this particular 
prosthesis is well documented and has excellent results. Only a few studies report 
on acetabular wear and survival using this design. Yamamota et al found a mean 
liner wear of 0.3 mm after 3 years, 0.55 mm after 5 years, and increasing to 0.7 
mm after almost 7 years of follow-up.61 Kurtz concluded that the threshold for 
osteolysis is a head penetration rate of >0.1 mm per year. He also reported that 
osteolysis could not be detected with a head penetration rate of <0.05 mm per 
year.32 Other studies reported an osteolysis threshold at a head penetration rate 
of 0.1–0.2 mm per year.15,16,33,53,55 We therefore used a head penetration rate of 
>0.2 mm per year to classify any case as excessive wear. The primary objective of 
our study was to evaluate how many of the 200 implanted prostheses showed a 
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liner wear of more than 0.2 mm per year. The frequency of any osteolysis and 
implant survival was also evaluated. 
 
Patients and Methods 
Our first consecutive 200 uncemented total hip prostheses (Mallory-Head), 
implanted between November 1997 and September 2002, were retrospectively 
analysed (Table 3.1). 
 
Table 3.1, Patient demographics  
Male (n)      98 (49%) 
Female (n)     102 (51%) 
Age (years)     54.6 (range: 29-69) 
BMI (kg/m
2
)     26.9 (range: 17.6-37.5) 
Bilateral (n)     36 (18%) 
Diagnosis:  OA     187 (93.5%) 
                    AVN     11 (5.5%) 
                    FC     2 (1%) 
*OA: osteoarthritis; AVN: Avascular Necrosis; FC: fractured collum 
In all cases, an uncemented porous-coated femoral stem was used with a 28-mm 
ceramic head and a porous-coated ringloc acetabular cup. The liner was made of 
conventional ultra-high molecular weight polyethylene (UHMWPE) (ArCom®, 
Biomet Inc., Warsaw), manufactured with compression molding and sterilized 
with gamma radiation in argon gas. Liner thickness ranged from 4.8 (cup size 48) 
to 11.8 mm (cup size 62). Mean shelf life was four months (range: 0 to 41). All 
prostheses were implanted through the posterolateral approach. All patients 
were asked to return for clinical follow-up including a standard anteroposterior 
(AP) radiograph. Medical file data were collected on primary diagnosis, BMI, 
complications and details of the used components. Of all patients, 89% completed 
a Duke Activity Index26 to measure current activity levels. There were 36 patients 
lost to follow-up (37 prostheses): 9 were deceased, 16 were revised, and we were 
unable to contact 10 patients. This left us with 163 prostheses (81.5%) available 
for analysis of PE wear. Liner wear was evaluated by measuring the two-
dimensional displacement of the femoral head relatively to the cup position using 
software (Pro 3D software, Draftware Inc. Vevay, USA). We used the most recent 
AP radiograph (Figure 3.3). To check for interobserver reliability, a sample of ten 
37 
 
radiographs was measured by an experienced evaluator of Draftware Inc., and all 




This is possible by using edge-detection features in the software, limiting the 
observer input on the obtained measurements. Besides the use of software, we 
retrospectively checked medical files if PE wear was noted by the orthopedic 
surgeon. We set the threshold for acceptable wear at <0.2 mm per year. A 
sensitivity analysis with a threshold of 0.1 mm per year was also calculated. We 
calculated the correlation between wear and the following subgroups: age, BMI, 
activity level, cup inclination angle, acetabular component size, liner thickness, 
and shelf life. Differences in wear between male and female patients were tested 
using an unpaired Student’s t-test. Implant survival was calculated using the 
Kaplan-Meier (KM) method. All statistics were performed using SPSS software 
(SPSS Statistics, version 17.0, IBM Corporation, Somers, USA). The most recent AP 
radiograph was screened for any radiolucency or osteolysis according to the zones 
described by DeLee and Charnley for the acetabular component and the zones 





Figure 3.2, Measurements 




Wear and Osteolysis 
The mean-measured PE wear was 0.2 mm per year (range: 0.07 to 0.5), after a 
mean follow-up of 8.3 years. In 53.4% of all cases, the PE wear was 0.2 mm per 
year (Figure 3.4), and if the threshold for acceptable wear was set at 0.1 mm per 






Figure 3.4, Boxplot of wear 






There was a significant correlation between PE wear and cup inclination angle and 
between PE wear and component size (Table 3.2). Mean PE wear was significantly 
higher in male patients than in female patients (respectively, 0.22 mm per year 
versus 0.19 mm per year, p = 0.02). On average, 24.3% of the original liner 
thickness was lost to PE wear (range: 10.7 to 42.7%). In 41 cases, PE wear was 
observed during routine clinical follow-up and noted in the medical file (24.8%), 
with a mean of 93 months after index surgery (range: 40 to 120). Osteolysis was 
observed in five cases (Table 3.3). The measured PE wear in these five patients 




Table 3.2, Sub analyses PE wear   
  Correlation p-value 
Age      - 0.4 0.61 
BMI     0.056 0.48 
Activity level                   0.166 0.053 
Acetabular inclination                  0.236 0.002* 
Shell size     0.156 0.046* 
Shelf life                    0.065 0.41 
 
Table 3.3, Osteolysis   
  N % 
Femoral component   
- None  160 98.2 
- Gruen zone 1 or 7  3   1.8 
- Gruen zone 2 – 6 0   0 
Acetabular component   
- None 158 96.9 
- DeLee & Charnley zone 1 2   1.2 
- DeLee & Charnley zone 2 2   1.2 
- DeLee & Charnley zone 3 1   0.6 
 
Implant Failure 
Of the 200 prostheses, 16 were revised, and one was scheduled for revision. Most 
frequent reason for revision was PE liner wear (N=10), see tables 3.4 and 3.5. Of 
the ten patients revised for liner wear, a straightforward cup exchange was done 
in nine cases. In two cases, the liner was detached from the metal-backing, and in 
one of these two cases, metallosis was observed. In the other case, a fibrous 
tissue layer was observed between the PE liner and the metal-backing. Four cases 
needed bone impaction grafting for an acetabular cyst. Mean time to revision was 
108 months (range: 77 to 144), and the mean observed wear in the revised 
patients was 0.28 mm per year (range: 0.21 to 0.45). The KM probability estimate 
of survival, with revision for any reason as end point, was 90.7% after 12 years of 
follow-up (95%–CI: 85.6–94.2). With only revision cases due to wear as end point, 
the KM survival estimate was 93.1% after 12 years follow-up (95%–CI: 79.9–100), 




Table 3.4, Overview of revision cases  
Reason for revision   N (%) 
A-septic loosening    1 (0.5) 
Liner exchange     9 (4.5) 
Dislocation     4 (2) 
Wound infection     1 (0.5) 
Breakage ceramic head    1 (0.5) 
Total      16 (8) 
 
Table 3.5, Wear related revision 
Casus Months to revision Details 
1 77 Liner exchange, components well fixed 
2 104 Liner exchange, components well fixed 
3 107 Liner exchange, components well fixed 
4 107 Liner exchange, components well fixed 
5 109 Liner exchange, components well fixed 
6 109 Liner exchange, components well fixed 
7 110 Liner exchange, components well fixed 
8 144 A-septic cup loosening 
9  Unknown Revised in other hospital, patient deceased 


















In our study, we report a high proportion (53.4%) of UHMWPE liners with a wear 
rate of 0.2 mm per year, after a mean follow-up of 8.3 years. In contrast, implant 
survival after 12 years is acceptable (KM 90.1%). However, it is disturbing that in 
literature the liner wear rate is reported to be nonlinear, with an increase in PE 
wear 7 to 8 years after index surgery.26,63 These findings suggest that we have to 
expect an increasing number of revisions within the next few years of follow-up. 
Parvizi conducted a study with longer mean follow-up than our study and found a 
revision rate of 20% after 11 years of follow-up.47 And McLaughlin reported a 
revision rate of 65% after 16 years.41 A possible explanation for the measured 
amount of wear can be found in the type of PE used. Free radicals, formed during 
the sterilization process, negatively influence the characteristics of conventional 
UHMWPE. Before and after implantation, these free radicals react to oxygen. This 
oxidation leads to accelerated wear rates. Wear can be reduced by using highly 
cross-linked polyethylene (HXLPE). Compared to conventional PE, HXLPE shows a 
significant reduction of the head penetration rate in several clinical 
studies.30,40,43,50 Currently, we do not know if in the long term, free radicals are 
released from HXLPE and can still cause oxidation. A recent method to prevent 
this happening is the infusion of vitamin E into (highly cross-linked) PE to 
scavenger any free radicals. This method is too new for clinical studies to be 
available. Alternatively, other bearing materials may be used such as metal or 
ceramics. Although there are some benefits of Metal-on-Metal (MoM) bearings 
such as low dislocation rates (due to the large diameter) and very low wear rates 
reported in in vitro studies2,9,11,21 these benefits are outweighed by the occurrence 
of serious complications due to an adverse reaction to metal debris (ARMD), as 
reported in recent clinical studies.12,34,36 In general, recent clinical studies using 
MoM bearings report higher revision rates than expected with the introduction of 
these bearings.49 Clinical studies with ceramic bearings have good long-term 
results, but the use of ceramics is limited by high cost, “squeaking,” and difficult 
revision after liner fractures.7,45,48,58,59 The choice of material for the femoral head 
does not influence the PE wear rate significantly; only small differences in liner 
wear were observed between different materials for the femoral head.57 Wear is 
not only dependent on the used materials but indeed multifactorial. In our study 
cohort, more wear was observed in cups with a steeper inclination angle and in 
male patients. This corresponds with earlier publications.5,20,61 In contrast to 
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earlier studies, we observed more wear with larger sizes of acetabular cups. We 
could not identify any possible explanation for this observation. We explored the 
hypothesis that larger cups would be more difficult to place, resulting in steeper 
cup placement. However, there was no significant difference in cup inclination 
angle between smaller (54 mm) and larger (56 mm) cup sizes. From our analysis 
on different subgroups, we could not detect any relation between age, BMI, shelf 
life or activity level, and the measured PE wear in our study cohort. This was 
unlike findings from other studies.5,52,61 There is however a large heterogeneity in 
number and characteristics of the included patients, making it difficult to compare 
these results. In our study, shelf life was quite short with an average of four 
months. The measured wear in all patients revised because of liner wear was 
more than 0.2 mm per year. However, 82.5% of all our patients with a PE wear 
rate of >0.2 mm per year had no radiolucent zones, no cyst formation, or such 
clinical symptoms that revision surgery was indicated. This might be due to the 
genetic profile of these patients, which makes them resistant to osteolysis.19,23 
The observed wear in our study is comparable to other studies using metal-
backed cups.17,22,28,38 Considering this comparable high wear rate, the number of 
cases with aseptic loosening (0.5%) and the number of observed osteolysis (5.5%) 
in our series is low in comparison to other studies. Although, most of these other 
studies had longer follow-up the retrospective nature of our study which makes it 
more difficult to classify aseptic loosening. Another explanation might be that the 
osteointegration of the coating is so effective that the acetabular component 
appears to be well fixed in place during revision surgery. Even if only a small area 
is integrated into the bone tissue, the optimal treatment if wear is observed and 
the best timing to perform revision surgery are clinical issues described in a 
treatment algorithm by Goosen et al (Figure 3.6).22  Strong points of our study are 
the large number of included prostheses, the use of a validated method to 
measure wear, and the analyses of multiple variables which might influence than 
our series. For example, Emms et al found a 17.1% osteolysis rate and a wear-
related revision percentage of 20% after 11.5 years of follow-up.18 The fact that 
we only used the most recent radiograph for PE wear evaluation, might explain 
we only observed osteolysis instead of any radiolucency. It is also striking that the 




Figure 3.6, Treatment algorithm for uncemented metal-backed acetabular 
components by Goosen et al (reprinted with permission).22 
 
This might either be because we revised patients early or by wear. Our study is 
limited by the retrospective design, the lack of a control group, the loss to follow-
up, and the limited duration of the follow-up. Based on our results and the 
current literature, we strongly question the use of conventional UHMWPE in 
uncemented total hip prostheses with metal-backed cups. Detailed follow-up, 
especially in the long term, can prevent serious complications due to the use of 
conventional PE. Studies with longer follow-up, preferably more than 10 years, 
are necessary to validate the safety of conventional UHMWPE in uncemented 
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We systematically reviewed the peer-reviewed literature to relate the survival of 
hybrid Metal-on-Metal hip resurfacing arthroplasty devices to a National Institute 
of Clinical Excellence (NICE) benchmark for choosing a primary total hip 
replacement, which is a survival rate of 90% at a follow-up of ten years. A total of 
29 articles (10 621 resurfaced hips) met the inclusion criteria. The mean follow-up 
ranged from 0.6 to 10.5 years and the survival of the implant ranged from 84% to 
100%. Of the 10 621 hips, 370 were revised (3.5%), with aseptic loosening as the 
most frequent mode of failure. None of the hip resurfacing arthroplasty implants 
used to date met the full ten-year NICE benchmark of survival. A total of 13 




Hip resurfacing arthroplasty (HRA) has regained popularity since the introduction 
of the third generation of implants in the mid-1980s. Both the first- (Metal-on-
Polyethylene) and the second-generation (cementless Metal-on-Metal) 
resurfacings failed because of high rates of wear and aseptic loosening.1 The 
current third generation hip resurfacing implants consist of a cemented femoral 
component and a press-fit acetabular component.1 Some surgeons are hesitant to 
use HRA because of the failure rates of the first- and second-generation 
implants2,3 and the complications, which include fracture of the femoral neck, 
metal hypersensitivity and increased serum levels of metal ions.4-7 Those in favour 
of the technique indicate the possible advantages of conserved femoral bone 
stock, minimal wear and a reduced risk of dislocation due to the large diameter of 
the components.8-12 These advantages would suit the lifestyle of younger 
patients.13,14 With HRA promoted for use in young active patients, its use may not 
be entirely comparable with total hip replacement (THR).15 There remains a 
continuing debate on the possible advantages of HRA.16 The National Institute for 
Health and Clinical Excellence (NICE), as part of the National Health Service (NHS) 
for England and Wales, has indicated that a revision rate of 10% or less at ten 
years should be regarded as the current benchmark of the satisfactory 
performance of a primary THR. This applies to all forms of replacement including 
both conventional and resurfacing implants.17 Prostheses unable to satisfy these 
requirements should be appropriately investigated. In its appraisal of THRs, 
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implants may also be recommended if their reported implant revision rate at a 
follow-up of at least three years is consistent with this ten year benchmark.17 
Although several reviews on HRA have been published recently, no studies have 
compared the survival of the HRA implant with an objective benchmark.18,19 In our 
systematic review, we hypothesised that primary hybrid Metal-on-Metal HRA is 
compliant with the NICE benchmark of a revision rate of 10% or less at a follow-up 
of ten years. 
 
Materials and Methods 
The Cochrane Library, EMBASE and MEDLINE electronic bibliographic databases 
were searched by an independent librarian. The search was conducted using 
standard software (Pubmed 2009 database for searching MEDLINE, OVID software 
(OvidSP_U102. 03.00.130; Ovid Technologies, Sandy, Utah) for searching 
EMBASE). The electronic search included articles published until June 2010. In 
combination with the booleans ‘AND’, ‘NOT’ and ‘OR’ the following search terms 
were used, with asterisks indicating where truncated search terms were used to 
yield the widest ranges of results: hip, femur head, femoral head, femur neck, 
femoral neck, resurfac*outcome*, follow-up, FU, prosthesis failure, treatment 
failure, re-operation, longevity, success, recovery of function, range of motion, 
joint instability, osteonecrosis, osteoarthritis, pseudotumor, pseudotumour, 
mechanical stress, gait, patient satisfaction, activity, activities, surviv* and risk 
factors. Reference lists in the included studies were hand searched for other 
relevant studies. Although only peer-reviewed publications were considered for 
inclusion, we tried to include all available studies by asking all implant 
manufacturers if they were aware of any (un-)published data. Also, experts in this 
field were contacted to determine if there were unpublished data. All the titles 
and abstracts were examined to assess their relevance. Only studies meeting the 
following eligibility criteria were included: any systematic review, clinical trial or 
case series using a Metal-on-Metal resurfacing prosthesis with a cemented 
femoral component and an uncemented acetabular component implanted after 
1988; reports of the survival of the implant defined as time to revision; a 
minimum requirement of 75 HRA procedures to ensure that the learning curve 
was completed;20-26 basic clinical details including age, gender and aetiology; 
validated patient reported outcomes of pain, stiffness, functional impairment and 
quality of life such as the Harris hip score (HHS)27, the Oxford hip score28, the 
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University of California, Los Angeles (UCLA) hip rating system29, the score of Merle 
d’Aubigné and Postel30; and the mechanisms of failure such as fracture of the 
femoral neck and aseptic loosening. No language restrictions were applied. A 
native speaker was consulted for articles published in languages other than 
English. Case reports and articles published before 1988 were excluded, since 
current implants on the market had been introduced after 1988.1 The inclusion 
and exclusion criteria were checked in all identified abstracts by two independent 
reviewers (WvdW,TS). In case of disagreement, a third reviewer was consulted. 
The full texts were retrieved and further checked for inclusion and exclusion 
criteria. If articles described the same series of patients, only the most recent with 
the largest number of patients was included. Extraction of data focused on the 
baseline clinical details and aetiology, the types of implant used, details of follow 
up, standardised clinical scores, radiological findings, implant survival rates, 
complications not requiring revision and the modes of failure. Data extraction was 
undertaken by one author (WvdW) and validated by a second (TS). A third was 
consulted if there was disagreement. All the extracted data were summarized and 
pooled whenever possible. The survival rate of the implants was plotted against 
the follow-up mean for comparison with the NICE benchmark. The quality of the 
evidence was judged using the Grading of Recommendations Assessment, 
Development and Evaluations (GRADE) recommendations, resulting in the grading 
of quality as high, moderate, low or very low.31 In order to compare different 
clinical scores, we normalized the scores to a new score whenever possible, 
ranging from 0 to 100, with 100 being the best possible score.  
 
Results 
We identified 539 abstracts. Data were extracted from 29 papers. A flow chart, 
compliant with the Quality of Reporting of Meta-Analysis statement, detailing the 
study selection, is presented in figure 4.1. Four studies investigated the ASR hip 
resurfacing device (DePuy Orthopaedics Inc., Warsaw, Indiana), 13 the BHR (prior 
to October 2008: Finsbury Orthopaedics, Leatherhead, United Kingdom; 
thereafter Smith & Nephew Inc., Memphis, Tennessee), four the Conserve Plus 
(Wright Medical Technology Inc., Arlington, Tennessee), two the Cormet 2000 
























Figure 4.1, Study flow. 
 
One study described the use of both the McMinn (Corin Group PLC) and the BHR 
device11 and another a second-generation McMinn prosthesis (McMinn Hybrid 
Resurfacing; Corin Group PLC), which was only in use around 1996.55 Data were 
thus presented on five of 11 resurfacing devices on the market. We could not 
identify studies which met our inclusion criteria describing the use of the Accis 
(Implantcast GmbH, Buxtehude, Germany), Adept (Finsbury Orthopaedics), Eska-
Bionik (Eska Implants, Lubeck, Germany), Icon (International Orthopaedics, 
Geisingen, Germany), Mitch (Stryker, Kalamazoo, Michigan) or ReCap (Biomet Inc., 
Warsaw, Indiana) resurfacing devices. The studies included one randomised, 
Potentially relevant articles identified and screened for retrieval (n=539) 
- Medline: n=442 
- Embase: n=83 
- Cochrane Library: n=0 
- Hand Search: n=14 
Articles excluded on abstract (n=377) 
- Not studying MoM hip resurfacing: n=105 
- Less than 75 HRA: n=102 
- No implant survival presented: n=170 
Articles retrieved for more detailed information (n=106) 
Articles excluded, with reasons (n=133) 
- Duplicate series: n=60 
- Insufficient implant survival details or clinical scores: n=56 
- Less than 75 HRA: n=17 
Articles  with usable information (n=29) 
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clinical trial, 27 prospective case series and one retrospective case series.9-11,22-25,33-
42,44-55 The mean follow-up ranged from 0.6 to 10.5 years. The highest reported 
loss to follow-up was 8.3%50 and 11 studies reported no loss to follow-
up.11,22,25,34,35,42,48,49,52-54 The survival of the implant ranged between 84% and 100% 
(Figure 4.2). In 13 of 17 studies with a follow-up of between three and 11 years, 
the survival rate was compliant with the NICE benchmark.9-11,35,37-39,43,44,46,47,49,54 
These 13 studies used either the BHR implant (eight), the Conserve Plus (two), the 
Durom (one), the Cormet 2000 (one) or both the McMinn and the BHR implants 
(one). The four studies not compliant with this benchmark, but with  
Figure 4.2, Implant survival versus time. 
 
follow-up of more than three years, used either the ASR device (two), the BHR 
(one) or the second-generation McMinn device11,33,34,40 (Figure 4.2). The only 
randomised, controlled trial reported a lower survival rate for the HRA group 
compared with the THR group, 96.3% versus 98% at 5.6 years.54 The mean follow-
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up was less than three years in 12 studies.22,24,25,36,41,42,45,48,50-53 Details on the 
number of hips per study, the clinical details, the duration of follow-up, the loss to 
follow-up and implant survival are presented in table 4.1. Careful patient selection 
based on gender, age and the preoperative diagnosis is important for HRA.34,56 In 
two of the 29 studies which were included, most of the patients were female, 
reporting a survival rate of 88.7% at one year and of 94.2% at a mean of 2.8 
years.22,24 With these results, neither study was compliant with the NICE 
benchmark. The mean age of the patients in the included studies ranged from 42 
to 58 years. In six studies the mean age was more than 55 years, and three of 
these studies had an implant survival rate higher than that required by the three-
year entry NICE benchmark.22,25,34,42,44,49 In three studies, all the included patients 
had a preoperative diagnosis of primary osteoarthritis.11,22,43 Two were compliant 
with the NICE benchmark.11,43 In two less than 50% of patients had primary 
osteoarthritis as the pre-operative diagnosis. One was compliant with the NICE 
benchmark, the other was not.45,54 Four studies presented details on the surgeon’s 
learning curve. All reported that there were fewer cases of revision at the end of 
the series compared with the beginning.22,25,41,48 According to the GRADE 
recommendations, the quality of the evidence was very low. The clinical outcome 
was presented in a very heterogeneous manner, using six different scoring 
systems, some in modified form. Most frequently used (22 studies) was the HHS 
and in those studies, the mean score improved by 40.8 points (95% confidence 
interval (CI) 36.6 to 45.2), from 52.2 pre-operatively to 93.0 post-operatively. The 
clinical score improved significantly in all studies (Table 4.2). The radiological 
findings were also reported very heterogeneously. Seven studies did not report 
any radiological details.11,33,35,39,42,43,49 A summary of the radiological findings is 
shown in table 4.3. The postoperative levels of metal ions in the blood were not 
reported in any of the included studies. That by Ollivere et al44 investigated the 
association between early clinical failure with metallosis and soft-tissue necrosis. 
This response was possibly due to an acquired sensitivity to metal ions, leading to 
aseptic lymphocytic-vasculitis associated lesions (ALVAL). At follow-up at five 
years the rate of revision which was related to the metallosis was 3.1%. The 
reported risk factors for metallosis were female gender, a small femoral 
component, a high abduction angle and obesity. Three other studies reported a 
marked inflammatory response when performing a revision procedure for  
pain.10,43,48 The 29 studies represented a total of 10 621 HRA procedures. A total 
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of 370 were revised (3.5%). The reported reasons for failure were aseptic 
loosening (1.4%), fracture of the femoral neck (1.1%), infection (0.2%), avascular 
necrosis of the femoral head (0.2%), ALVAL (0.13%), persistent pain (0.1%), 
dislocation (0.08%), malpositioning of a component (0.08%) or other unspecified 
reasons (0.2%). The study by Daniel et al55 using a specific series of double-heat-
treated resurfacing devices, which are no longer in use, can be regarded as an 
outlier. In this series, 16% of hips were revised for aseptic loosening. In all other 
studies, this percentage was less than 6% (Table 4.3). Clinical complications and 
adverse events without the need for revision were reported in 25 of the 29 
studies. In these 25 studies (9446 patients), 529 complications were reported 
(5.6%). Steffen et al10 reported no major complications without providing further 
details. In their series of 337 HRAs, Stulberg et al50 reported hip-related 
complications in 83 (24.6%) and implant-related complications in 32 (9.5%), 
without further details. Beaulé et al47 reported re-operation on 28 patients 
(24.1%) because of loosening of the internal fixation in seven and complete 
removal of the fixation because of bursitis in 21. Both reasons for reoperation 
were specifically associated with the Ganz approach used in this series. Based on 
the remaining studies involving HRAs (8338) in which the complications were 
reported in detail, the most frequent was painless clicking of the hip (1.2%) 
followed by a nerve palsy (0.8%), deep-vein thrombosis (0.6%), dislocation (0.3%), 
squeaking (0.2%), wound infection (0.1%) and pulmonary embolism 
(0.1%).9,11,22,24,25,33,34,36-43,45,46,48,49,51-55 Heilpern et al37 and Witzleb et al45 each 
reported one patient with an undisplaced fracture of the femoral neck which 



















































































































































































































































































































































































































































































































All but one of the implants studied had insufficient follow-up to be compliant with 
the NICE benchmark, of a revision rate of less than 10% at ten years, for choosing 
a prosthesis for primary THR. The study reporting a follow-up of longer than ten 
years had a revision rate of 16%, mainly for aseptic loosening of the implant. This 
high failure rate was attributed to the double-heat-treatment manufacturing 
process which is no longer in use.55 The prosthesis was superseded by the Cormet 
2000 implant in 1996. Compared with the three-year NICE entry-benchmark of 
implant survival ≥ 97%, 13 studies (44.8%) showed satisfactory survival. Eight used 
the BHR implant, two the Conserve plus, one the Durom, one the Cormet 2000 
and one both the McMinn and BHR implants.9-11,35,37-39,43,44,46,47,54 There appeared 
to be a difference in the performance of the implants, with only the ASR 
appearing below the benchmark in four studies, in two of which the follow-up was 
very short. The BHR appeared above the line in 12 of 13 studies. Both the 
Conserve plus (four studies) and the Cormet implant (two studies) had an equal 
number above and below the line. The Durom implant had three studies above 
and one below the line. Since we excluded studies with incomplete learning 
curves, these results are more likely to be attributed to the characteristics of the 
implant such as the design and manufacturing process (Figure 4.2). No survival 
data were analysed for six of 11 HRA devices on the market (Accis, Adept, Eska, 
Icon, Mitch and Recap). However, the implants in the studies which were included 
represented most of the HRA implants worldwide.57-59 Aseptic loosening was the 
most frequent cause of failure (1.4%), followed by fracture of the femoral neck 
(1.1%). The variation in frequency of fracture of the femoral neck among studies 
was large, between 0% and 16.3% compared with the frequency of aseptic 
loosening (0.0% to 5.5%). Clinical outcome scores were reported very 
heterogeneously, but all studies showed a significant improvement from the pre-
operative score. In all of the included studies on HRA the patients were relatively 
young with the mean age ranging between 42 and 58 years. This is important 
when comparing the failure rates of HRA with those of conventional THR, since 
most patients within this age range will be considerably more active than those 
aged more than 60 years. National Joint Registries are useful for this comparison 
since they combine different types of conventional THR and publish their data 
stratified by age.57-60 Our pooled revision rate of 3.5% is higher than the revision 
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rates at three years for conventional THRs in patients aged under 55 years 
reported in the sixth annual report from the National Joint Registry for England 
and Wales57, but lower than that for HRA of 4.5% (95% CI 3.9 to 5.3).57 Both the 
cumulative revision rate at eight years for THR and for HRA in patients aged less 
than 55 years in The Australian National Joint Replacement Registry Report (4% 
and 4.7%, respectively) are higher than our pooled revision rate.61 As with the 
results for HRA presented in our review, there is much variation in reported 
survival rates for THR, ranging from less than 80% to 99% at ten years for patients 
aged less than 55 years.24,58 However, the pattern of the modes of failure is 
different. For HRA, fracture of the femoral neck is a unique mode of failure, but 
according to our results aseptic loosening occurs slightly more frequently, 1.1% 
versus 1.4% respectively. According to the Finnish Arthroplasty Registry, in 
patients under 55 years of age with primary osteoarthritis, the survival rate at ten 
years of less than 80% for THR is mainly due to wear of the liner. This required 
only its exchange at revision surgery.62 Excessive wear in HRA leads to increased 
levels of metal ions in the blood with ALVAL as a possible serious consequence. 
This is not unique to HRA. In a randomised trial, Garbuz et al63 reported a 46-fold 
increase in metal ion concentrations in the blood in patients with large-diameter 
Metal-on-Metal THRs, compared with a tenfold increase in patients who had 
undergone HRA.63 Failure due to dislocation, a common cause of revision of THR, 
is rare in HRA. In our review, only 27 of 10 621 HRAs were revised for dislocation 
(0.3%). Arguably, the same low rate of dislocation could be achieved using a large-
headed THR, but without the perceived benefit of retained femoral bone stock. 
However, the use of bearings of large diameter appears to be effective against the 
risk of dislocation. In 2002 two systematic reviews of the literature up to 2001 
were published, both presenting the results of one literature search.64,65 Based on 
the publication date, our systematic review included 29 new studies. Compared 
with several recent reviews on HRA, our study was designed as a systematic 
review focusing on survival of the implant compared with the NICE 
benchmark.18,19 The strengths of our review included a comprehensive and 
reproducible search strategy, exclusion of duplicate case series and studies with 
an incomplete learning curve, contact with authors for clarification, a comparison 
with an objective revision rate benchmark and the use of the GRADE system for 
assessment of quality. Finally, survival of the implant defined as years to revision 
surgery was an objective and patient-relevant endpoint. Our study is limited since 
72 
 
28 of the 29 were case series, possibly introducing bias. A requirement of a 
minimum of 75 treated patients resulted in the exclusion of studies describing 
metal ion release. These are expensive to perform and accordingly restrict the 
number of patients studied. The few which included this information and had 
more than 75 patients were excluded since they did not present data on survival 
of the implant. The quality of the included studies was very low according to the 
GRADE system, which is mainly based on the design of the study and 
heterogeneous reporting of clinical scores and radiological findings. Based on our 
findings there remain concerns on the long term effectiveness and safety and 
longer follow-up is needed. The large variation in the incidence of fracture of the 
femoral neck as a mode of failure in studies is poorly understood. However, the 
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The purpose of our study was to prospectively report the clinical results of 280 
consecutive hips (240 patients) who received a ReCap Hip Resurfacing System 
implant (Biomet Inc., Warsaw, USA) in a single district general hospital. Literature 
reports a large variation in clinical results between different resurfacing designs 
and published results using this particular design are scarce. 
 
Methods 
Mean follow up was 3.3 years (1.0 to 6.3) and four patients were lost to follow-up. 
All patients were diagnosed with end-stage hip osteoarthritis, their mean age was 
54 years and 76.4% of all patients were male. 
 
Results 
There were 16 revisions and four patients reported a Harris Hip Score <70 points 
at their latest follow up. There were no pending revisions. Kaplan-Meier implant 
survival probability, with revision for any reason as endpoint, was 93.5% at six 
years follow-up (95%-CI: 88.8-95.3). There were no revisions for Adverse 
Reactions to Metal Debris (ARMD) and no indications of ARMD in symptomatic 
non-revised patients, although diagnostics were limited to ultrasound scans. 
 
Conclusions 
This independent series confirms that hip resurfacing is a demanding procedure, 
and that implant survival of the ReCap hip resurfacing system is on a critical level 




Hip resurfacing arthroplasty (HRA) has been widely used in recent years. Possible 
advantages of conserved femoral bone stock, low wear rates and low dislocation 
rates were the main reasons for surgeons to use HRA. Recent concerns on the use 
of Metal-on-Metal (MoM) bearings have intensified the discussion on HRA. The 
reported increase of metal ion levels after HRA with subsequent local Adverse 
Reactions to Metal Debris (ARMD) and poor results with revision for this 
complication have diminished the support for HRA.1-4 In the published literature 
there is a wide range of clinical results between different HRA designs.3,5,6 
Although numeral clinical studies report short- and mid-term survival of different 
HRA systems, these studies focus on a limited number of HRA designs. To our 
knowledge, there are four studies published using the ReCap Hip Resurfacing 
System (Biomet Inc., Warsaw, USA). Gagala reported there were no significant 
complications after a maximum follow up (FU) of 20 months, using this implant 
design (n=23).7 Baad-Hansen reported no significant translation or rotation using 
this implant design (n=25), after two year FU using RadioStereometry Analysis 
(RSA).8 A larger number of ReCap procedures (n=137) with a three year FU are 
described in the Australian National Joint Replacement Registry. In this report a 
cumulative percent revision rate of 7.6% is presented for this specific HRA design.9 
Recently, Gross and Liu presented the mid-term results of 740 hip resurfacings 
with a 3.4% revision rate.10 In this prospective study, we report the clinical results 
of 280 consecutive HRA’s using the ReCap Hip Resurfacing system, with a 
maximum FU of six years (range: 1 to 6). We hypothesised that implant survival 
would be compliant with the National Institute for Health and Clinical Excellence 
(NICE) benchmark (a revision rate of 10% or less at ten years, or consistent 
survival if only shorter FU is available).11 We further hypothesised that the risk for 
revision in subgroups based on gender, age and component size is comparable to 




Between September 2004 and September 2010 our first 280 consecutive, non-
selected HRA procedures (240 patients) in a general district hospital were 
included in a prospective cohort study (Table 5.1). Patients diagnosed with end 
stage osteoarthritis (OA) were indicated for HRA. The entire group involved 240 
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patients (280 resurfacings) with a mean follow-up of 3.3 years (1 to 6.3) of whom 
45 were followed-up for five years and 30 for six years. Prior to surgery, a dual 
energy X-ray absorptiometry (DEXA) scan was made of all female patients and in 
all male patients suspected of osteoporosis. When T and Z values were below 
normal, patients were excluded from HRA. After informing the patient on the  
 
Table 5.1, Demographics of the Study Group 
 Mean Range 
Age at surgery (yr) 54 28 to 76 
BMI 26.5 19 to 46 
Hospital stay (days) 3.5 2 to 9 
Follow up (months) 39 12 to 75 
 
Sex (n=240 patients) Count % 
       Males 187 77.9 
       Females 53 22.1 
 
Diagnosis (n=280 hips) 
  
      Primary OA* 258 92.1 
      DDH** 19 6.8 
      Posttraumatic OA 3 1.1 
*OA indicates osteoarthritis;**DDH, developmental dysplasia of the hip 
 
expected benefits and risks associated with HRA, informed consent on the surgery 
procedure and on study participations was obtained from all patients. Our study 
was approved by the Institutional Review Board. Patients with renal failure, 
femoral cysts, osteoporosis or a-vascular necrosis (AVN) of the femoral head were 
excluded. Female patients with a possible child wish were also excluded. 
 
Surgical technique and rehabilitation 
Two experienced joint arthroplasty surgeons (HJH,TS) used the ReCap Hip 
Resurfacing System (Biomet Inc., Warsaw, USA) in all patients in a standard 
manner. Prophylactic antibiotics were administered on induction. Both the press-
fit acetabular component and the cemented femoral component are 
manufactured from “as-cast” cobalt chrome (Co-Cr-Mo) with a high carbon 
content (>0.2%). The acetabular outside is a full-hemisphere design and has four 
87 
 
pairs of fins for initial rotational stability. It has a titanium porous plasma spray 
surface coating (Figure 5.1). The outer geometry of the cemented femoral 
component extends approximately 23 degrees beyond a full-hemisphere. The 
critical inner bearing surface has a coverage arc ranging from 155–164 degrees 
from smallest to largest component. The posterolateral approach was used in all 
procedures. After dislocating the hip joint, acetabular osteophytes were removed, 
the acetabulum was reamed and the acetabular component was impacted into 
the anatomical position.  
 
Next, a femoral guide wire was inserted into the femoral head, directed with a jig. 
The femoral head was then circumferentially reamed and the bone-bed was 
prepared with drill holes and pulse lavage for cementing. After applying high 
viscosity cement (Refobacin® Bone Cement R, Biomet Europe, Dordrecht, 
Netherlands) to the inner surface, the femoral component was carefully put in 
place. Patients were mobilised the first post-operative day using two crutches and 
weight bearing as tolerated. All patients received antibiotic prophylaxis with a 
cephalosporin preoperatively and 24 hours post-operatively, fourteen days of 
indometacin for periarticular ossification prophylaxis, diclophenac for pain 
management and thrombosis prophylaxis with dalteparine 5000 units for six 
weeks postoperatively. Patients were discharged if the patient was fully mobile 
and the wound was without problems. Physiotherapy was prescribed to all 
patients. Patients were instructed to avoid all high impact activities in the first six 
months and discouraged to participate in high impact sports. All bilateral 
procedures were staged interventions with at least a three months interval. 




Patients were recruited at the time of surgery and prospectively followed six 
weeks after surgery and yearly thereafter. Bilateral cases were followed up as 
separate cases. Standard antero-posterior (AP) and lateral radiographs, and the 
Harris Hip Score12 were collected at each visit, except for the six week FU. Only 
radiographs were collected at this visit. Any patient who was symptomatic post-
operatively was analysed with a diagnostic ultrasound scan to check for ARMD. On 
the AP radiograph, the acetabular angle of inclination and femoral stem shaft 
angle were measured as described by Beaulé et al.13 Radiolucensies were 
measured in millimeters and acetabular radiolucency was classified in three zones 
according to DeLee and Charnley (Figure 5.2).14 Any femoral radiolucencies were 
classified in the three zones as described by Beaulé et al. (Figure 5.2).13 
Heterotopic bone formation was classified as described by Brooker et al.15 Neck 
narrowing was measured as described by Grammatopoulos et al., using the first 
post-operative radiograph and the most recent radiograph for comparison.16 
Clinical and radiological FU and statistical analyses were done by an independent 
observer, with a sample set of radiographic measurements audited by an 
experienced radiologist. 
 
Figure 5.2, Acetabular zones 
according to DeLee  
&Charnley and femoral 





Revision for any reason was the primary endpoint of this study. Kaplan-Meier 
survivorship curves were calculated. Since we support the recent notion in 
literature that implant survivorship is a limited endpoint to define a successful 
outcome for joint arthroplasty17, a HHS score of <70 points on the latest FU (two 
years or more) was also used as an endpoint for implant failure. The NICE 
benchmark (a revision rate of 10% or less at ten years, or consistent survival if 
only shorter FU is available) was used to evaluate survivorship.11 Relative risks 
(RR) were calculated to evaluate sub-group results based on gender, age, 
component size and acetabular inclination angle. A femoral head size <50 mm and 
an acetabular inclination angle of ≥ 550 were considered to be a risk factor for 
ARMD and therefore revision.18-20 SPSS software (SPSS Statistics, version 17.0, IBM 
Corporation, Somers USA) was used for all statistical analyses. The occurrence of 
femoral neck narrowing as a consequence to head downsizing can also be 
indicative for ARMD, as described by Grammatopoulos et al.16 Neck narrowing 
values were calculated as a percentage and ranges were presented for the whole 
cohort and for the patients who were revised > six months after index surgery. 
 
Results 
Four patients were deceased for reasons not related to the HRA procedure (four 
prostheses, 1.4%) and no other patient was lost to FU. Three patients were 
contacted by phone since they were unable to return for FU. Therefore, 
radiological FU was complete for 277 patients. There were 16 revisions at the time 
of final FU. Seven were for fracture of the femoral neck, five for aseptic loosening 
of the acetabular component, two for component malpositioning (one femoral 
and one acetabular) and two for persistent pain (Table 5.2). The Kaplan-Meier 
implant survival probability with revision for any reason as endpoint was 93.5% at 
six years FU (95%-CI: 88.8-95.3) (Figure 5.3). The mean time to revision was 14 
months (range: 0 to 56) with eight out of 16 revisions within two months from 
index surgery. Female patients had a RR for revision of 1.1 compared to male 
patients (95%-CI: 0.92-1.06). The RR for revision in the group of patients with a 
femoral head <50 mm, was 1.1 compared to the group of patients with larger 
components (95%-CI: 0.98-1.09). In the patients younger 55 years the RR for 




Table 5.2, Revision details 
Failure mode Gender Age Fem.comp. Months to revision Revision details 
FN#* Male 61 48mm 0.5 Femoral revision 
FN# Female 55 46mm 0.5 Femoral revision 
FN# Male 57 52mm 1 Femoral revision 
FN# Male 57 50mm 1 Femoral revision 
FN# Male 60 52mm 1 Femoral revision 
FN# Male 54 50mm 2 Femoral revision 
FN# Male 48 48mm 18 Femoral revision 
Mal Fem Comp** Male 60 52mm 0 Both comp. revised 
Mal Acet Comp
#
 Male 67 50mm 12 THP other hospital 
Asep Loosening
##
 Male 58 54mm 1 Both comp.revised 
Asep Loosening Male 64 50mm 23 Both comp. revised 
Asep Loosening Female 49 44mm 32 Both comp.revised 
Asep Loosening Male 28 50mm 43 Both comp.revised 
Asep Loosening Female 49 42mm 56 Both comp.revised 
Persistent pain Male 43 50mm 7 THP other hospital 
Persistent pain Female 52 50mm 27 Both comp.revised 
*FN# indicates fracture of the femoral neck; **Mal Fem Comp: malpositioned femoral 
component; 
#
Mal Acet Com: malpositioned acetabular component; 
##
Asep Loosening: 
Aseptic loosening; Fem comp: femoral component size; 
 




In all seven femoral neck fracture cases, the acetabular shell was left in situ and a 
stemmed, uncemented femoral prosthesis was inserted. Six out of seven neck 
fractures occurred within two months of the index surgery, one case was a late 
neck fracture 18 months post-operatively. During revision surgery of this one case 
it was observed that the femoral component was loose, which was thought to be 
caused by avascular necrosis of the femoral head. In all other cases both 
components were replaced. All cases of aseptic loosening only involved the 
uncemented acetabular component. Of the none-revised patients, there were 
four patients with a HHS score <70 points at their latest FU (two at two years and 
two at three years FU). Revision and clinical score combined as endpoint for 
implant failure, resulted in 20 failed prostheses at the time of final FU. During 
revision surgery no metallosis, soft tissue cysts or solid masses were observed, 
although postoperative histopathological analyses showed chronic inflammatory 
signs including synovial hyperplasia en some metallosis in both patients revised 
for persistent pain, indicating adverse local tissue reaction to metal debris. A 
diagnostic ultrasound was made in 27 patients (9.6%) with unexplained hip or 
groin pains, all were normal. In our series there were 81 patients with an 
acetabular inclination angle of 55°-65° (of which 23 had a femoral head size <50 
mm) and 10 patients with an acetabular inclination angle of >65° (of which four 
had a femoral head size <50 mm). In none of these patients any signs of ARMD 
were observed during any revision surgery or additional diagnostic ultrasound 
scans. 
 
Complications without need for revision 
There were 30 (10.7%) complications without need for revision (Table  5.3). The 
majority of these complications were transient such as post-operative bleeding 
(n=18). There was one deep wound infection which was eradicated after surgical 
debridement and antibiotic treatment. Seven other patients with signs of a post-
operative wound infection were treated successfully with antibiotics. There was 
one patient with persistent paraesthesia and pareses of the foot due to a sciatic 
nerve lesion. One other patient had a transient nerve palsy of the sciatic nerve. 
Another patient was treated conservatively for a non-displaced fracture of the 
femoral neck, which he sustained due to a fall three months after surgery. He 





stress fracture was discovered with routine FU two years post-operatively (Figure 
5.4A and 5.4B). This patient had experienced some groin pain after running, which 
completely resolved when he did not run for a couple of weeks. There were no 
dislocations or thromboembolic events in our series. 
 
Table 5.3, Complications without need for revision 
Complication N (%) 
Nerve damage 2 (0.7%) 
Non-displaced femoral neck fracture 2 (0.7%) 
Deep wound infection 1 (0.4%) 
Superficial wound infection 7 (2.5%) 
Post-operative bleeding 18 (6.4%) 
Total 30 (10.7%) 
 
Figure 5.4A, Undisplaced femoral 
neck fracture. 





At one year FU, mean HHS had improved significantly from pre-operative scores 
(from 49.3 to 92, p <0.0001, Table 5). At six year FU, 36 patients had an 
“excellent” HHS (66.7%), 16 a “good” HHS (29.6%) and two a “fair” HHS (3.7%). 
For the revised patients, the mean HHS after revision was 77 (range: 41 to 91). 
 
Radiological findings 
At one year FU, the mean implant femoral shaft angle was 135.10 (range: 1160 to 
1560). Mean acetabular angle of inclination was 51.30 (range: 260 to 770). With 
further FU, no radiolucensies were observed. Ectopic bone formation was noted 
in 13.8% of all cases. Mean HHS for patients who had a Brooker grade two or 
three ectopic bone formation was 91 points (range: 74 to 91) (Table 5.4). Neck 
narrowing was observed in 136 patients with a mean of 2.3% (range: 0% to 
18.5%). In the patients with revisions later than 6 months after index surgery, 
neck narrowing was present in 3 out of 9 patients. One patient had 2.5% neck 
narrowing and two patients had 6% neck narrowing. 
 
Discussion 
Our KM-survival probability of 93.5% at six years FU (95%-CI: 88.8-95.3) is not 
compliant with the three year entry NICE benchmark. Longer FU is needed to 
compare our results with the full 10-year benchmark. Of the non-revised patients, 
there were only four patients with implant failure based on their HHS score. The 
combined endpoints of revision (n=16) and HHS score <70 points (n=4), resulted in 
20 failed prosthesis (7.1%). Since no other studies on MoM hip resurfacing have 
combined implant survival and Patient Reported Outcome scores to define 
Table 5.4,  Clinical and radiographic findings 
 HHS Fem. Pos. Cup abd. Angle Brooker 1/2/3/4 (n) 
Pre op (n=280) 49.3 n/a n/a n/a 
6 wks   (n=280) - +2.20 51.30 13/2/0/0 
1 yr      (n=280) 92 - - 29/7/2/0 
2 yrs    (n=221) 88.3 - - 26/5/3/0 
6 yrs    (n=54) 89.3 - - 11/3/1/0 
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implant performance, we cannot compare this result to other studies. We were 
able to identify all failure modes, including those from patients revised in other 
hospitals. Most frequent reasons for revision were fracture of the femoral neck ( 
n=7) and aseptic loosening (n=5). All cases of aseptic loosening occurred relatively 
early and involved only the uncemented acetabular component. We think that 
insufficient seating of the acetabular component, which might occur due to 
deformation of the relatively thin cup during the impaction procedure, may have 
caused these early revision cases. In our series we have not observed any signs of 
ARMD during revision surgery, although post revision surgery two patients revised 
for persistent pain had histopathological evidence of adverse local tissue reaction 
(ALTR) to metal debris. Neither have we observed any signs of ARMD with 
diagnostic ultrasound scans in patients who were post-operatively symptomatic. 
We cannot completely rule out the presence of ARMD in our series, but since we 
observed two cases of ALTR, future follow-up will include routine metal ion 
analysis. Our complete FU, our detailed information on revision cases and the 
excellent clinical scores at the time of final FU are in contrast to other designs of 
HRA, of which failure rates of 25% for ARMD after six years FU are reported.21 Risk 
factors for ARMD are the inclination angle of the acetabular cup, implant design, 
small component sizes and occurrence of neck narrowing. Steep inclination angles 
and an acetabular cup with less than hemispherical coverage result in a small 
contact patch area (CPA), which increases the wear rate. Another risk factor is 
component size, with small sizes resulting in more friction, releasing more metal 
debris.18-20 In our series there were 81 patients with such risk factors, but no 
ARMD was observed in any of these patients, neither with a diagnostic ultrasound 
scan nor during revision surgery. The critical inner bearing surface of the ReCap 
has a coverage arc ranging from 155–164 degrees from smallest to largest 
component which is similar to other designs with a larger CPA such as the 
Birmingham Hip Resurfacing design (Smith and Nephew PLC, London, UK), the 
Conserve plus (Wright Medical Technology, Inc., Arlington, USA) and the Cormet 
resurfacing design (Corin Group PLC, Cirencester, UK). Our findings on ARMD are 
in line with several other studies. Malviya found a 0.15% incidence of 
pseudotumors using the Birmingham Hip Resurfacing (BHR).22 Beaulé et al found a 
0.1% prevalence of pseudotumors with MoM resurfacing after surveying nine 
Canadian Academic centers.23 Glyn-Jones et al extensively studied the risk factors 
for pseudotumor formation in a large series of hip resurfacings. Gender and age 
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had a significant independent influence on the revision rate for pseudotumor 
formation, and the incidence increased with time, with a mean time to 
pseudotumor revision of 3.5 years (1 to 8.3 years).24 In the series presented by 
Steffen et al, there were three revision cases possibly related to metal debris. Two 
of these cases were revised around two years post-operatively, the other one at 
5.6 years after surgery.25 These mean times to pseudotumor revision are within 
the maximum follow-up time of our case series (6.3 years), but we will have to 
stay alert on ARMD occurrence with longer follow-up. Grammatopoulos reported 
a mean 10.1% neck narrowing in patients revised for pseudotumors. In our cohort 
the mean percentage of neck narrowing was considerably lower (2.3%), although 
individual cases had greater neck narrowing. We did observe neck narrowing in 
three out of the nine patients who were revised > six months after index surgery, 
but these three patients had less than 10% neck narrowing. Neck narrowing data 
from our cohort is supplementary to the observations by Gross and Liu. They also 
report <1% revisions for adverse wear and based on their report and on data from 
our cohort we believe that the risk for adverse wear using this resurfacing design 
is low. Gross did report a lower revision rate compared to our study (3.4% versus 
7.3%) but in his series the learning curve was avoided since the surgeon had 
performed 400 hip resurfacings before the presented series was started.10 As 
noted in the study by Gross, we also now have begun recommending routine 
metal ion tests in all our patients. Strong points of our study are its prospective 
study design, a large consecutive study cohort, limited lost to FU and comparison 
to an objective benchmark. There is detailed FU on all revised patients including 
those revised in other hospitals, and both clinical outcome scores and radiological 
FU were analysed. Another advantage is that this study was conducted in a 
general district hospital rather than a design institution. Our study also has 
limitations: FU time is limited and there is no control group. We also have to bear 
in mind that the NICE-benchmark is applied to an OA population of all ages, and 
literature describes higher revision rates in younger patients.26-28 Metal ion levels 
were not obtained and there were no diagnostic ultrasounds made to check for 
ARMD in non-symptomatic patients. Compared to published literature, our study 
reports the clinical results on more patients with longer FU using the ReCap Hip 
Resurfacing system than any other study. Gagala et al studied 25 patients (mean 
FU 11 months, range: 10 to 20) and found good short-term clinical results without 
significant complications.7 Baad-Hansen et al conducted a radiostereometric 
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analysis (n=23). There was no statistically significant translation or rotation of the 
femoral component observed after two years FU.8 The absence of any revisions in 
these series might be due to the small number of patients and the short FU. In the 
evaluation of risk factors for early failure with HRA, the Australian Arthroplasty 
Register reported on 137 procedures between 1999 and 2008 using the ReCap hip 
resurfacing system.9 Their cumulative percent revision rate of 7.6% at three year 
FU using this system was worse than our implant survival at three years. A 
possible explanation might be that those 137 procedures were done by a large 
number of orthopedic surgeons in an extended period of time, limiting the 
individual expertise using this system. However, despite further enquiry, no more 
details could be provided by the Australian Arthroplasty Register. Regarding 
patient selection, in our series the RR for revision was slightly higher for female 
and for older patients, although statistically the difference was not significant. 
Patients with smaller component sizes had a higher risk for revision, but this was 
also not statistically significant. This is in line with several other publications which 
show a significantly higher risk for revision in female patients, older patients, and 
in patients with small components.5,29-32 The possible absence of ARMD in our 
series might explain the equal risk for revision in patients with small or large 
component sizes. Looking at diagnosis, literature reports that the best HRA results 




Although implant survival rate in our series is below the NICE benchmark, patient 
reported outcomes are excellent in the non-revised patients. Also, we were not 
able to detect signs of ARMD with standard radiographs and clinical outcome 
scores. As with other resurfacing designs, this resurfacing system should be 
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We intensified our screening protocol for the presence of pseudotumors in a 
consecutive series of patients with a hip resurfacing arthroplasty (HRA), to 
establish whether we should be alert to the presence of ‘silent’ pseudotumors. 
Patients categorised with high risk (11 hips) and low risk (10 hips) for 
pseudotumor development and a control group (23 hips) were screened with 
Metal-Artefact Reduction Sequence (MARS) magnetic resonance imaging (MRI). 
The Anderson classification to grade any Metal-on-Metal (MoM) disease present 
on MARS-MRI images was used. In 15 out of 44 MRI scans pseudotumors were 
observed (34.1%), of which six were graded with mild (13.6%), eight with 
moderate (18.2%) and one with severe MoM disease (2.3%). Twelve 
pseudotumors were present in asymptomatic patients (27.3%). Metal ion levels 
were normal in 80% of the MARS-MRI screened patients. As a consequence of our 
intensified screening protocol, one patient was revised for pseudotumor 
formation and another patient was scheduled for revision. Silent pseudotumors 
were observed in all three groups. Before our intensified screening protocol was 
initiated, no pseudotumors were encountered in our cohort of 289 HRAs. We 
concluded that clinical outcomes and plain radiographs for screening MoM 
patients underestimates the presence of pseudotumors in MoM patients. The 





Metal-on-Metal (MoM) bearings have been widely used in hip arthroplasty. 
Although wear rates are low, these bearings still release cobalt and chromium 
particles which may result in a periprosthetic soft tissue reaction, requiring 
revision surgery.1,2 This periprosthetic soft tissue damage, known as adverse 
reaction to metal debris (ARMD) compromises aseptic lymphocytic vasculitis-
associated lesions (ALVAL), metallosis and pseudotumor formation.3  Revision 
surgery for pseudotumors is sometimes difficult and post-revision surgery clinical 
outcomes are less satisfying.4 The reported incidence of pseudotumors varies, 
depending on patient characteristics, type of follow-up and implant design 
features.5,6 Earlier MoM hip arthroplasty studies relied on clinical outcome scores 
and radiographs of large case series to report on good implant performance and 
excellent functional outcomes.7-9 Recently published data, however, report on a 
much higher incidence of pseudotumors in patients with MoM implants after all 
patients have been screened for the presence of these adverse peri-prosthetic 
reactions with Metal-Artefact Reduction Sequence (MARS) magnetic resonance 
imaging (MRI) or ultrasound.10,11 Suspicion arises that there may be a relatively 
large number of ‘silent’ pseudotumors present in otherwise well-functioning 
implants. There is reason to believe that the occurrence of pseudotumors is not 
solely observed with malpositioned implants with relatively high metal ion levels 
and poor clinical outcome.11 From this growing unease we decided to intensify our 
screening protocol for the presence of pseudotumors in a consecutive series of 
patients with HRA. The aim of this study was to clarify whether we should be alert 
to the presence of ‘silent’ pseudotumors in our cohort of hip resurfacing patients. 
According to previously defined patient and implant characteristics6,11, we 
categorised high and low risk patients for pseudotumor development, together 
with a non-stratified control group. Subsequently, in all three groups MARS-MRI 
screening for pseudotumors was performed. 
 
Patients and methods 
Patients 
Between September 2004 and September 2010 we included 298 consecutive HRA 
procedures (240 patients) in a prospective cohort study. Females <60 years of age 
and males <65 years of age were the primary candidates for HRA if diagnosed with 
end stage osteoarthritis (OA) and had an active lifestyle. Older patients with 
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sufficient bone quality and an active lifestyle were considered for HRA on an 
individual basis. Dual energy X-ray absorptiometry was used to exclude patients 
with osteoporosis. Patients with renal failure, femoral cysts, avascular necrosis 
(AVN) of the femoral head and female patients trying to conceive were also 
excluded. Procedures were followed in accordance with the ethical standards of 
the responsible committee on human experimentation and with the Helsinki 
Declaration of 1975, as revised in 2000. After informing the patient on the 
expected benefits and risks associated with HRA, informed consent on the surgery 
procedure and on study participation was obtained. Our study was approved by 
the Institutional Review Board (IRB nr. 08.013, 18th December 2008). 
 
Implant system 
All procedures were performed by one of two experienced hip arthroplasty 
surgeons (TS, HH). The ReCap hip resurfacing system (Biomet Inc, Warsaw, USA) 
was implanted by a posterolateral approach. The press-fit acetabular component 
and the cemented femoral component are manufactured from “as-cast” cobalt-
chrome (Co-Cr-Mo) with a high carbon content (>0.2%) without any heat 
treatment. The acetabular outside is a full hemisphere design and has four pairs 
of small fins for initial rotational stability. It has a titanium porous plasma spray 
surface coating facilitating bone ingrowth. The system offers 2 mm increment 
sizing. The surgical technique has been described earlier by Gross and Liu.12 All 
patients received antibiotic prophylaxis with a cephalosporin preoperatively and 
24 hours post-operatively, fourteen days of indometacin for periarticular 
ossification prophylaxis, diclophenac for pain management and thrombosis 
prophylaxis with dalteparine 5000 units for six weeks postoperatively. Patients 
were rehabilitated with immediate unrestricted weight bearing according to the 
patient’s tolerance. All bilateral procedures were staged interventions with at 
least a three month interval. 
 
Study design 
To evaluate the occurrence and incidence of pseudotumor formation we defined 
three different groups of patients. The first group had a perceived high risk for 
pseudotumor formation based on gender, component size and cup inclination 
angle.6,11,13 Cup inclination angle was measured on the latest available standard 
anteroposterior radiograph using earlier described methods.14 Eventually we 
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allocated 11 female patients with a cup inclination angle >45° and a femoral 
component size <50 mm to this ‘high risk’ group. Five patients in this group had 
bilateral HRA; one patient fulfilled all high risk criteria bilaterally, four patients 
only unilaterally, and therefore 12 hips were included in the high risk group for 
MARS-MRI screening. The ‘low risk’ group consisted of 10 asymptomatic male 
patients with a unilateral HRA, cup inclination angle <45° and femoral component 
size >50 mm. The third group consisted of 19 patients (22 hips) who, regardless of 
risk factors, were scheduled for routine follow-up between November 2011 and 
May 2012 and acted as a ‘control’ group without risk stratification (Table 6.1). In 
all three groups, blood serum samples were collected and assessed on cobalt and 
chromium concentrations. Samples were collected in metal-free vacutainers; the 
first 5 mL blood was discarded to eliminate metal contamination from the needle. 
Tubes were stored at 2-8°C and sent to an external laboratory (Ziekenhuis Groep 
Twente, Hengelo, Netherlands) for analysis. The metal ion levels in whole blood 
were determined using Atomic Absorption Spectrophotometry (AAS) analysis. 
Cobalt levels were classified according to guidelines by the Dutch Orthopaedic 
Society15 with normal Cobalt <40 nmol/L, slightly elevated 40-85 nmol/L, elevated 
85-170 nmol/L and extremely elevated >170 nmol/L. All MARS-MRI examinations 
were performed on a 1,5T MRI (Philips Medical Systems, Best, Netherlands). Scan 
parameters are listed in table 6.2. All MARS-MRI images were judged by an 
experienced musculoskeletal radiologist (KB) and validated by a second 
musculoskeletal radiologist (RH), who were both unaware of the clinical status of 
the patients. We used the description by Matthies et al of a pseudotumor being a 
sterile inflammatory lesion found in the soft tissues surrounding a MoM hip 
arthroplasty.16 Grading of MARS-MRI findings was based on the method described 
by Anderson et al17 (Table 6.3). Since Harris hip scores (HHS), Oxford hip scores 
(OHS)18,19 and anteroposterior and lateral radiographs were collected yearly as 
part of routine follow-up, these were available for all patients. The OHS results 
were calculated using the original scoring system (12 points being best possible 









Descriptive statistics were used to compare the three study groups. Metal ion 
data distributions were asymmetric and are expressed as a group median with 
range. Symmetrical data are represented by a mean and standard deviation (SD). 
The significant level α is defined as .05 in this study. A post hoc analysis was used 
to measure the statistical power of the observed difference in pseudotumor 
occurrence between groups. SPSS software (SPSS Statistics, version 17.0, IBM 
Corporation, Somers USA) was used for all statistical analyses. 
 
Results 
Patient characteristics are shown in table 6.1. Before the intensified screening 
protocol was implemented, no pseudotumors had been detected in our cohort of 
298 HRAs. With the MARS-MRI screening completed, pseudotumors were 
observed in all three groups (Table 6.4). The risk for pseudotumor development in 
the high risk group was 0.45, 0.33 in the low risk group and 0.3 in the control 
group. However, the statistical power to detect a true significant difference in risk 
ratios between groups was low (0.11). Overall, in 15 cases of the 44 MARS-MRIs 
available for analysis, pseudotumor formation had occurred. In total 29 MARS-
MRI images were classified as grade A, none as grade B, six as grade C1, eight as 
grade C2 and one grade as C3. In contrast to the MARS-MRI images, the cobalt 
levels were normal in 80% of the patients. Two patients had slightly elevated 
metal ion levels, four patients had elevated levels and two patients had extremely 
elevated levels. Median Cobalt level for all patients was 24 nmol/L (min-max: 11-
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1897 nmol/L). Out of the 15 pseudotumors which were observed on MARS-MRI, 
there were 12 silent pseudotumors. These patients did not complain of any pain 
or other symptoms and had excellent clinical outcome scores (HHS >90, Oxford 
Hip Score <16) with normal radiographs. One female patient from the high risk 
group with severe MoM disease underwent revision surgery, and one male 
patient from the control group with moderate MoM disease is scheduled for 
revision. The revised patient had bilateral HRA: seven years after implantation on 







There was no pseudotumor observed on her right side but on her left side she had 
a pseudotumor measuring 105 mm craniocaudally, 71 mm anteroposteriorly and 
80 mm mediolaterally (Figure 6.1). Her Cobalt level was extremely elevated (1897 
nmol/L). Her HHS score was 91 points and she never complained of pain after 
HRA. She did however regularly noticed squeaking on the left side, something we 
had not observed in any other patient from our series. Both cups had a steep 
inclination angle (left 700, right 590). During revision surgery a large fluid filled cyst 





Figure 6.1, Large fluid filled cyst left hip, indicating Anderson grade 2 




In our study group of patients with a Recap HRA the prevalence of pseudotumors 
appeared to be high, with pseudotumor occurrence even in the group defined as 
having a low risk for ARMD. With an established pseudotumor incidence of 34.1 
percent in this concise exploratory study group, we can expect another 87 
pseudotumors using an intensified MARS-MRI screening protocol on our entire 
group of 298 resurfacing hip arthroplasties. Of these 87 pseudotumors, an 
expected 17 would classify as a grade C2 or C3 pseudotumor with an increased 
revision risk. As confirmed by other authors, pain was not a very useful indicator 
for pseudotumor occurrence.20.21 Compared to the extent of damage noticed on 
MARS-MRI and at revision surgery, one has to wonder by which mechanism 
pseudotumors develop relatively pain free. Mild symptoms and relatively low 
metal ion levels can contribute to the difficulty of convincing patients to have 
their HRA revised. However, recent media attention about the negative effects of 
MoM bearings has scared many MoM patients, who even ask for revision surgery 
in absence of any symptoms. Although several authors report on pseudotumor 
rates, the number of studies using other imaging modalities than plain 
radiographs to detect pseudotumor occurrence is very limited. High rates of 
pseudotumor occurrence have been found in other studies which used MARS-MRI 
or computer tomography (CT) scanning. Wynn-Jones reported a similar 
pseudotumor rate of 36% using the ASR resurfacing device.21 Compared to MoM 
hip resurfacing, higher pseudotumor rates are reported for MoM total hip 
arthroplasty. Mistry reported a 58.3% pseudotumor rate using the Ultima TPS 
design20 and Bosker found a 39% pseudotumor rate in MoM THA patients who 
received the M2a-Magnum femoral head and ReCap acetabular component.10 
Langton described a 13.6% revision rate for ARMD with the ASR design, but use of 
MRI or CT scanning was not reported in this paper.6 Malviya found a pseudotumor 
incidence of just 0.15% using the BHR resurfacing device, although it is not clear 
from his paper if all patients routinely were scanned using MARS-MRI22 To our 
knowledge, there are no other studies which have investigated the prevalence of 
pseudotumors with this particular HRA design using imaging modalities other than 
plain radiographs. The studies by Baad-Hansen and Gagala were limited to 23 and 
25 HRA patients respectively with a maximum follow-up of 24 months.23,24 Gross 
and Liu recently published a case series of 740 consecutive procedures with the 
ReCap HRA design with a follow-up of seven years maximum.25 The reported 
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Kaplan-Meier survivorship with any revision as an end point was 96.4% at 7 years, 
with only two revisions (0.3%) for adverse wear. Follow-up was limited to clinical 
outcomes and plain radiographs, but as the possibility of more adverse wear 
failures was acknowledged by the authors, they started taking metal ion samples 
routinely. There remains uncertainty on the risk factors for pseudotumor 
formation with current MoM hips. Studies have suggested that edge-loading 
resulting from adverse cup orientation and implant design leads to a higher wear 
of the components and subsequently increases blood metal ion levels.26,27 Clinical 
studies and reports from arthroplasty registers also implicate smaller components 
in connection with increased metal ion levels.13,28 Based on these finding, the use 
of MoM prostheses is supported for appropriately trained surgeons who select 
appropriate patients.29 Recently, studies have debated risk factors for 
pseudotumor formation. Kwon et al and Mistry et al showed that pseudotumors 
can be observed in asymptomatic patients with well positioned and well 
functioning prostheses.20,30 Recently, Matthies et al reported that pseudotumors 
are common in well positioned MoM prosthesis.16 These results are confirmed by 
our study in which pseudotumors were commonly found in asymptomatic 
patients with well positioned, large components. This suggests that development 
of pseudotumors is more likely to be dependent on patient susceptibility than on 
factors such as component size, component positioning or implant design. The risk 
for pseudotumor formation is higher for any patient with any MoM prosthesis 
than previously thought. Until now, clinical signs, radiographic evaluation and 
metal ion levels have been used to identify patients at risk for pseudotumor 
formation. The best protocol for detecting pseudotumors is not yet defined, but 
ultrasound scans, CT or MARS-MRI scans are commonly used. Our study indicates 
that follow-up methods of clinical outcomes and radiographs underestimate the 
prevalence of pseudotumors after MoM HRA. Moreover, metal ion levels alone 
are also not sufficient to detect all cases of ARMD. Our findings, especially those 
from the low risk ARMD group, have prompted us to start using MARS-MRI scans 
for our whole MoM cohort. Our findings suggest that radiographic screening with 
MARS-MRI, CT or ultrasound on all patients with a hip resurfacing might be the 
only option to discover the real magnitude of pseudotumor formation after MoM 
arthroplasty. There are several limitations of our study. Most importantly, the 
number of patients is small since we report on an exploratory study at this stage. 
In spite of this limited number of patients we still feel the need to report on our 
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preliminary findings of the high number of pseudotumors found on MARS-MRI 
even in low risk patients with few or no symptoms. In our study group, there were 
quite a few patients with a steep cup inclination angle, which is considered the 
only risk factor for ARMD by some authors.31 However, despite the fact that we 
differentiated amongst other factors between high and normal cup inclination, we 
still found pseudotumors with normally inclined cups. We believe that 
conventional radiological and clinical follow-up together with metal ion analyses 
will underestimate the true prevalence of MoM-disease. An intensified screening 
protocol for pseudotumors with MRI, CT scan or ultrasound is likely to become 
unavoidable. There is no consensus yet on the clinical relevance of pseudotumors 
and it may be possible that only some become problematic. There is increasing 
evidence that the incidence of pseudotumor formation with large diameter (>36 
mm) MoM may be higher than assumed so far and the use of these implants has 
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Objective. Follow up of pseudotumors observed with Metal-Artefact Reducing 
Sequence (MARS)-Magnetic Resonance Imaging (MRI) following Metal-on-Metal 
Total Hip Arthroplasty (MoMTHA) depends on how severe these pseudotumors 
are graded. Several pseudotumor grading systems for MARS-MRI have emerged 
but little is known of their validity. We studied the intra- and interobserver 
reliability of three different pseudotumor grading systems in a single cohort of 
MoMTHA. 
 
Patients and Methods. Two experienced musculoskeletal radiologists 
independently used three different pseudotumor grading systems for classifying 
MARS-MRI results of the same cohort of 42 MoMTHA patients (49 hips, mean 
follow-up 5.2 years). Intraobserver and interobserver reliability for each grading 
system was measured using Cohen’s Kappa (κ). Variance in pseudotumor severity 
grading between systems was analysed. 
 
Results. Intraobserver reliability on grading pseudotumor severity with the 
Anderson, Matthies and Hauptfleisch grading system scored 0.47, 0.10 and 0.35 
(observer 1), and 0.75, 0.38 and 0.42 (observer 2) respectively. Interobserver 
reliability scores for pseudotumor severity were 0.58, 0.23 and 0.34 respectively. 
 
Conclusion. Intraobserver reliability for grading pseudotumor severity on MARS-
MRI ranged from poor to good, dependent on observer and grading system used. 
Interobserver reliability scored best with the Anderson system. A more succinct 





Although Metal-on-Metal (MoM) hip arthroplasty gained huge popularity in the 
beginning of this century, critical reports about Adverse Reactions to Metal Debris 
(ARMD) were published, eventually leading to a recall of some MoM designs1, and 
a stop of its use in some countries due to too many questions about its value and 
safety.2,3 Manifestations of ARMD include the occurrence of pseudotumors 
(Figure 7.1 and Figure 7.2), which may cause severe symptoms, can be locally 
destructive and might require revision surgery in a proportion of patients.4-6 
Pseudotumors, defined as a peri-articular mass caused by an immunological 
delayed hypersensitivity response to metal particles and characterised by a 
lymphocyte-dominated histological pattern7, lead to worse clinical outcomes after 
revision surgery compared to other reasons for MoM revision.8 Besides the 
debate about risk factors, incidence and optimal management of pseudotumors, 
there is no consensus on how to grade the severity of pseudotumors observed on 
Computer Tomography (CT) or Magnetic Resonance Imaging (MRI) scans. 
Identified pseudotumors are graded to standardise and summarize results to 
allow concise management of treatment options for each individual patient. 
Grading is also of importance to determine changes in the severity of the 
pseudotumors more accurately when managed conservatively.  
Few studies were done on the validity of scoring systems for these pseudotumors 
and controversy exists.9,10 The purpose of this paper is to validate three currently 
used pseudotumor grading systems by measuring their intraobserver and 
interobserver reliability in a single cohort of Metal-on-Metal Total Hip 
Arthroplasty (MoMTHA) patients. 
 
Patients and Methods 
We retrospectively reviewed a cohort of 42 consecutive MoMTHA patients (49 
hips) with a Mallory Head femoral component, a Magnum M2A femoral head and 




















Sequence (MARS)-Magnetic Resonance Imaging (MRI) scanning, using a scanning 
protocol described in table 7.1. Since 2011, MARS-MRI scanning and metal ion 
analysis (determined with Atomic Absorption Spectrophotometry), is part of 
routine follow-up of MoM patients in our institution, regardless of symptoms. This 
Figure 7.1A Transverse PDW 
MARS-MRI of a 60-year- old 
female showing a large, thick-
walled pseudotumor 6 years 
after Metal-on-Metal total hip 
arthroplasty. 
This pseudotumor was graded 
C3 (Anderson classification) 
and grade 3 (Matthies and 
Hauptfleisch classification) by 
both observers. 
Figure 7.1B PDW MARS-MRI of 




approach is based on recent publications describing a high prevalence of 
asymptomatic pseudotumors after MoM hip arthroplasty.15,16 Clinical 
examinations (history taking and standard anteroposterior and lateral 
radiographs) were prospectively collected before surgery, 6 weeks and one year 
post-surgery and yearly thereafter. Study approval was obtained from the 
Hospital Ethical Committee. Demographic characteristics of patients are 
summarized in table 7.2. Two musculoskeletal radiologists (KB, RH), experienced 
in using pseudotumor grading systems11, independently reviewed all MARS-MRI 
















Figure 7.2A, Transverse PDW MARS-MRI 
of a 40-year-old man 7 years after 
Metal-on-Metal total hip arthroplasty 
showing a small peri-articular 
pseudotumor located medial of the hip 
joint. This pseudotumor was graded C2 
(Anderson classification), grade 2A 
(Matthies classification) and grade 2 
(Hauptfleisch classification) by both 
observers. 
Figure 7.2B, PDW MARS-MRI of the 




Both radiologists scored each MARS-MRI on three separate occasions, using a 
different pseudotumor grading system on each occasion. For intraobserver 
reliability testing, this was repeated two months later with observers blinded to 
their first reading and cases placed in random order. The used grading systems 
were described by Anderson et al9, Matthies et al12, and Hauptfleisch et al.13 
Pseudotumor grading system details are compared in table 7.3, thereby grouping 
each severity grade into mild, moderate or severe. This was done according to the 
original publication9, or by consensus if not described in the original  
 
publication.12,13 Descriptive statistics were used to report metal ion levels, 
symptoms and the number of identified pseudotumors per grading system. 
Differences in median metal ion levels were analysed between groups using the 
Kruskal-Wallis test. Intraobserver and interobserver reliability on grading 
pseudotumor severity was calculated for each grading system using Cohen’s 
Kappa (κ), excluding cases with no pseudotumor observed in this analysis. We also 
calculated κ per observer on pseudotumor severity grading (mild, moderate or 
severe) between grading systems. Arbitrary, κ <0.40 was considered poor, 0.40 to 
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0.75 as fair to good and >0.75 as excellent. Descriptive statistics were also used to 
describe complete agreement between observers on pseudotumor severity per 
grading system. Complete agreement was defined as both observers classifying 
one patient exactly the same (i.e. both observer 1 and 2 rate the same patient as 
having a grade 2a pseudotumor). A 95% Confidence Interval (C.I.) was provided 
were appropriate. A p<0.05 level was considered significant. All statistics were 




In this single cohort of 49 MoMTHA hips, observer 1 identified 23 pseudotumors 
(46.9%), regardless of the grading system used. Observer 2 identified 21 
pseudotumors using the Anderson grading system (42.9%), 22 pseudotumors 
using the Matthies grading system (44.9%) and 20 using the Hauptfleisch grading 
(40.8%). Interobserver reliability on whether a pseudotumor was present or not 
was 0.92 (p <0.001) with the Anderson system, 0.84 (p <0.001) with the Matthies 
128 
 
system and 0.79 (p <0.001) with the Hauptfleisch system. Intraobserver reliability 
for grading pseudotumor severity with the Anderson, Matthies and Hauptfleishch 
grading system was 0.47 (p=0.001), 0.10 (p=0.257) and 0.35 (p=0.08) for observer 
1, and respectively 0.75 (p<0.001), 0.38 (p<0.001) and 0.42 (p=0.001) for observer 
2. Interobserver reliability for pseudotumor severity with the Anderson, Matthies 
and Hauptfleisch grading system was 0.58, (p =0.001), 0.23 (p =0.001) and 0.34 
(p=0.015) respectively. A 60% complete agreement between observer 1 and 
observer 2 was reached for Anderson C1, 64% for Anderson C2 and 0% for 
Anderson C3. (Table 7.4).  
 
Table 7.4, Complete agreement (N) between observer 1 and 2 using the Anderson 
classification. 
Observer 2 A B C1 C2 C3 
Observer 1      
A 24 - 1 - - 
B - 1 - - - 
C1 3 - 6 - - 
C2 - - 4 9 1 
C3 - - - - - 
 
Table 7.5, Complete agreement (N) between observer 1 and 2 using the Matthies 
classification. 
Observer 2 No pseudotumor 1 2a 2b 3 
Observer 1                
No pseudotumor 25 1 - - - 
1 1 3 - -  
2a - 5 3 - 1 
2b 1 3 1 2 1 





Table 7.6, Complete agreement (N) between observer 1 and 2 using the Hauptfleisch 
classification. 
Observer 2   No pseudotumor 1 2 3 
Observer 1               
No pseudotumor  25 1 - - 
1 3 6 1 1 
2 1 4 4 1 
3 - - - 2 
 
For the Matthies system, 23% complete agreement between observer 1 and 
observer 2 was reached for grade 1, 40% for grade 2a, 25% for grade 2b and 50% 
for grade 3 (Table 7.5). For the Hauptfleisch system, 38% complete agreement 
between observer 1 and observer 2 was reached for grade 1, 36% for grade 2 and 
50% for grade 3 (Table 7.6). For observer 1, κ on grading pseudotumor severity 
between the Anderson and Matthies system was 0.32 (p=0.56), 0.14 (p=0.12) 
between the Anderson and Hauptfleisch system, and -0.24 (p=0.796) between the 
Matthies and Hauptfleisch system. For observer 2 these scores were 0.11 
(p=0.274), 0.03 (p=0.77) and 0.7 (p=<0.001) respectively. 
Of the 49 hips, 4 were symptomatic. One patient had moderate symptoms but no 
evidence of pseudotumor on MARS-MRI, 3 patients had mild symptoms with small 
to moderately sized pseudotumor visible on MARS-MRI. Median Chromium and 
Cobalt levels were 54 (range: 10 to 344) and 37.5 (range: 10 to 526) nmol/L 
respectively. For the patients without a pseudotumor present, these values were 
46 (range: 10 to 236) and 32.5 (range: 10 to 174) nmol/L respectively and for the 
patients with a pseudotumor present these values were 59 (range: 17 to 344) and 
51.5 (range: 10 to 526) nmol/L (Table 7.7). Pseudotumors were treated based 
upon Anderson classification, combined with metal ion levels and symptoms. All 
C1 and C2 pseudotumors were scheduled for repeated MARS-MRI, one patient 
with a C3 pseudotumor had extremely elevated metal ion levels but no 
symptoms. After second opinion this patient was revised. All patients without 




Table 7.7, Metal-ion details per pseudotumor grading system 
Anderson A C1 C2 C3  p* 
Chrome (nmol/L) 46 45 96 344  0.47 
Cobalt (nmol/L) 37 43 72 526  0.58 
       
Matthies No pseudotumor 1 2A 2B 3 p* 
Chrome (nmol/L) 52 59 89.5 194.5 148 0.81 
Cobalt (nmol/L) 37 49.5 44.5 288 123.5 0.65 
       
Hauptfleisch No pseudotumor 1 2 3  p* 
Chrome (nmol/L) 52 60 108 148.5  0.73 
Cobalt (nmol/L) 38 53 50 123.5  0.83 
* Kruskal-Wallis test 
 
Discussion 
Pseudotumors can be detected after MoM hip arthroplasty with MARS-MRI, but 
major clinical questions on severity grading of these pseudotumors are still open 
for debate. Little consensus exists on follow up of MoM prostheses and their 
optimal treatment policy (i.e. wait and see versus revision surgery).14 Even the 
relevance of elevated metal ion levels in the absence of symptoms or a 
pseudotumor, the necessity to screen a-symptomatic MoM patients with cross-
sectional imaging, or the required frequency of such screening protocols are on 
debate. This uncertainty on the optimal management of MoM disease in general 
and pseudotumors in particular, might be partially due to the term pseudotumor 
being used for a broad variety of a spectrum of lesions, ranging from fluid-filled 
cysts (Figure 7.3A and B) which might be normal in artificial hip joints to large, 
complex, and destructive lesions with solid components (Figure 7.4A and B).5 The 
use of unvalidated pseudotumor grading systems might contribute to the 
controversy in the clinical management of problematic MoM implants. In clinical 
practice, the decision to revise or not will not be a sole consequence of CT or MRI 
results. 
Therefore it is important to validate MARS-MRI based pseudotumor grading 
systems. Three frequently used pseudotumor grading systems for CT or MRI 
exists, which had a poor (Matthies and Hauptfleisch grading system) to fair 
(Anderson grading system) interobserver reliability when grading severity of 






Intraobserver reliability was not only dependent on observer, but also on the 
system used, with the Anderson system scoring fair for both observers, while 
observer 2 scored fair for both the Matthies and Hauptfleisch system and 
observer 1 scored poor with both these systems. For the Anderson system Chang 
et al also found a moderate interobserver reliability while Anderson et al found 
good interobserver reliability. These differences might be explained by the used 
methodology (we excluded the MARS-MRIs on which no pseudotumor was seen 
Figure 7.3A, Transverse PDW MARS-
MRI of a 59-year-old man 3 years after 
Metal-on-Metal total hip arthroplasty 
showing a thin-walled pseudotumor 
located dorsal of the collum femoris 
with a high T2 signal, indicating fluid 
content. Observer 1 graded this 
pseudotumor as Anderson C2, 
Matthies 2A and Hauptfleisch 2. 
Observer 2 rated this as grade C2, 1 
and 1 respectively. 
Figure 7.3B STIR MARS-MRI in 




from analysis) but might also occur since the differences between the 
pseudotumor grades are rather subjective. On observer reliability of the Matthies 
or Hauptfleisch grading systems, no results could be found in literature. Anderson 
et al described their system based on a retrospective review of 59 patients (73 
MoM hips) and reported that the strongest reliability appeared to be for the 
grade A, C2 and C3 categories, while the most disagreement appeared to be for 
categories B and C1.9 In our study, agreement was slightly higher for C2 than for 
C1 (64% vs. 60%), while the number of C3 cases was too small to draw any 
conclusions on observer reliability. Matthies et al retrospectively reviewed 105 
revisions of a current-generation MoM hip prosthesis with MARS-MRI12 and 
classified pseudotumor contents according to the signal intensity on T1-weighted 
and T2-weighted images into four different categories. This grading system was 
later used in a study by Hart et al, who found comparable pseudotumors rates 
and discussed the high prevalence of fluid-filled cysts. It was hypothesized that 
these cysts might reflect the required capsulotomy during hip implantation 
resulted in a pathway of low resistance, allowing the formation of encapsuled 
fluid collections. As a result they placed less clinical importance of these types of 
pseudotumors and concluded that a fluid-filled periprosthetic lesion 
(pseudotumor) may not necessarily indicate the need for revision arthroplasty. No 
guidelines on clinical follow up based on type of pseudotumor could be deluded 
from the study by Matthies et al or Hart et al.12,15 Hauptfleisch et al 
retrospectively observed 33 hips with a pseudotumor13 which they divided into 
type I, II or III. They considered any solid or cystic mass, in continuity with the hip 
joint, as a pseudotumor. Isolated distension or thickening of a non-communicating 
trochanteric bursa was not included. A common characteristic of these grading 
systems was the analysis of pseudotumor content (i.e. fluid or solid), but other 
than this each system analysed different pseudotumors details such as size 
(Anderson system), apposition of walls and shape (Matthies system), or wall 
thickness (Matthies and Hauptfleisch system). In our experience, strong points of 
the Anderson grading system are the detailed description of each pseudotumor 
grade and the incorporation of grade A, allowing a grade for normal MRI scans. Its 
disadvantages are the absence of a clear description of normal appearance 
(including seromas and small haematomas), not taking pseudotumor wall 
thickness in account (which might be an important factor for predicting clinical 
outcome) 12, and the 5.0 cm cut-off is rather arbitrary. In our study, the Matthies 
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The grading system by Hauptfleisch had the advantage of having the least number 
of grades, making it a straightforward system to use. In our study we observed a 
Figure 7.4A, Transverse PDW MARS-MRI 
of a 65-year-old female 6 years after 
Metal-on-Metal total hip arthroplasty 
showing a pseudotumor with mixed 
signal intensity 6 years after Metal-on-
Metal hip arthroplasty. Both observer 
rated this as a Anderson C2, Matthies 
grade 3 and Hauptfleisch grade 3 
pseudotumor. 
Figure 7.4B, PDW MARS-MRI of the 
same patient in the coronal plane. 
134 
 
high incidence (41% to 47%, depending on observer and grading system) of 
pseudotumors after reviewing 49 MoM large head hip arthroplasty cases. Most 
were asymptomatic (19/23). This is higher than the 36% prevalence rate reported 
by Wynn-Jones et al16, but lower than the 65% found by Anderson et al.9 This 
might be explained by a twice as long mean follow up in our study compared to 
the cohort described by Wynn-Jones et al (62 versus 31 months), while the cohort 
described by Anderson et al retrospectively selected MARS-MRI’s for review, 
possibly resulting in a higher pseudotumor incidence. Our study was limited since 
only a very small number severe pseudotumors was included. However this 
closely reflects daily clinical practice where the difficulty in grading mild to 
moderate pseudotumors is more of an issue than grading very large, extensive 
pseudotumors. Strong points of our study are the analysis of both intra and 
interobserver reliability of all current pseudotumor grading systems. In 
conclusion, our study is the first which validates different pseudotumor grading 
systems by applying these different systems to a single cohort of MoM total hip 
arthroplasties. Both intraobserver reliability and interobserver reliability for 
grading severity of pseudotumors is limited with all three pseudotumor grading 
systems. Further validation of all three classification systems on their prognostic 
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Peri-prosthetic pseudotumor formation can be a severe complication following 
Metal-on-Metal hip resurfacing arthroplasty (MoMHRA), with limited data on the 
optimal management of this complication. The aims of this study were (1) to 
evaluate the prevalence and severity of pseudotumors in a consecutive cohort of 
248 MoMHRA (214 patients, mean follow-up 4.6 years, range: 1 to 8.2), and (2) to 
present a clinical guideline for their treatment based on severity grading with 
Metal-Artefact Reduction Sequence Magnetic Resonance Imaging, metal ion 
levels and symptoms. Pseudotumor prevalence was 36.3%: 61 mild, 25 moderate 
and four were graded severe. Five revisions followed, all in symptomatic patients 
with elevated metal ion levels. Pseudotumor severity grading allowed us to be 




Recently controversies occur on the benefit of metal on metal arthroplasty 
(MoM), due to an increasing number of studies on pseudotumors occurrence next 
to these types of hip replacements.1-3 Adverse peri-prosthetic soft tissue reactions 
following MoM hip arthroplasty can include metallosis, Asymptomatic 
Lymphocyte Vasculitis-Associated Lesions (ALVAL) or pseudotumor formation.4 
Pseudotumors, defined as a solid or fluid mass which has developed in the peri-
prosthetic soft tissue5, are considered a severe complication of these MoM 
implants, which may cause pain, swelling, deep vein thrombosis and extensive 
soft tissue damage.6-8 Interestingly, not all MoM prostheses seem to develop 
these pseudo tumor sequelae, a debate exists on the prevalence of these 
pseudotumors, which ranges from less than 1% to 39%.9,10 Currently the only 
treatment option in case of pseudotumors is revision surgery, during which the 
MoM articulation is replaced by a non-MoM articulation. However, outcome of 
revision surgery for pseudotumor is poor compared to MoM revision surgery for 
other reasons.11 Incomplete pseudotumor resection and recurrence of 
pseudotumor, both a reason for re-operation, is reported by Liddle et al12 while de 
Steiger et al found infection to be a major cause for re-revision surgery in MoM 
hip arthroplasty.13 In clinical practice, symptoms (both general health as well as 
local at the hip region) and metal ion levels are also used next to MARS-MRI 
pathology about the hip, to guide not only surgical treatment, but also follow up 
of these patients, despite that controversy exists on the validity of these 
variables.2,14-16 Furthermore, only poor consensus exists on detection of these 
MoM pseudotumors.2,17,18 The aim of this study was to evaluate the prevalence 
and severity of pseudotumors in a consecutive cohort of MoM hip resurfacings 
using MARS-MRI. Secondly, a clinical guideline for the treatment of these MoM 
pseudotumors will be presented based on pseudotumor severity as graded with 
MARS-MRI, combined with metal ion levels and symptoms. 
 
Patients and Methods 
A consecutive cohort of 258 patients (296 MoM hip resurfacing procedures) who 
had surgery between September 2004 and November 2011. The MoM prosthesis 
in all patients was the ReCap resurfacing hip (Biomet, Bridgend, South Wales, UK). 
Data was prospectively collected as part of an Investigational Device Exemption 
study for this specific MoM hip resurfacing design (Registration: NCT00603395), 
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before surgery, 6 weeks and one year post-surgery and yearly thereafter. Clinical 
outcomes and radiographs were collected per protocol from 2004 onwards. The 
study protocol was extended in 2011 to include baseline cross-sectional imaging 
(MARS-MRI or ultrasound) and metal ion blood analysis for each patient 
scheduled for follow up, as a response to the concerns raised on adverse reactions 
to metal debris. Forty-one patients had a bilateral MoM hip implant, two of these 
had a different design contra lateral hip resurfacing from another hospital, one 
received a contra lateral MoM Total Hip Arthroplasty (THA) in our hospital. These 
three MoM hips were excluded from analyses, all other bilateral cases (n=38) 
were analysed as separate cases. At the last follow-up in 2012, 17 patients (18 
hips) had been revised of which details were published before.19 After excluding 
21 patients (24 hips) for reasons explained in figure 8.1, pseudotumor prevalence 
using MARS-MRI could be evaluated in 214 patients (248 hips). Mean age of the 
235 invited patients was 53.7 years (range: 31 to 76), mean follow up was 4.6 
years (range: 1.0 to 8.2). In seven patients (eight MoM hips) a contra-indication 
for MRI was present, these patients were examined using ultrasound examination 
of the hip area. Ultrasound examinations were performed in supine, prone and 
left or right side position with different planes (coronal, transversal and saggital) 
to detect hydrops and/or peri-articular masses and fluid collections; if needed 
duplex ultrasound was used to differentiate between vascular and non vascular 
lesions. Clinical examination was done using the Oxford Hip Score (OHS)20 and 
physical examination (i.e. hip Range of Motion, groin swelling and palpation 
tenderness). Patients were also questioned about their general health. Since 
public awareness existed on possible general symptoms of the MoM, questions on 
symptoms which could be attributed to the MoM implant, were nevertheless 
posed: “Did general health changed since their hip surgery” in a dichotomous 
way. Special notice was given to symptoms derived from the NHS advise on 
follow-up for MoM patients: chest pain or shortness of breath, numbness or 
weakness, changes in vision or hearing, fatigue, feeling cold or weight gain.21 An 
anterior-posterior radiograph of the pelvis and a lateral hip were made annually. 
At the latest follow up, particular attention was given to radiolucency, evidence of 
peri-articular masses and peri-prosthetic bone resorbtion. Radiographs were 
scored for position of the prosthesis (i.e. inclination of the cup, neck thinning etc). 
Blood serum samples were collected and assessed on cobalt and chromium 
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concentrations. Samples were collected in metal-free vacutainers; the first 5mL 
blood was discarded to eliminate metal contamination from  
the needle. Tubes were stored at 2-8°C and sent to an external laboratory 
(Ziekenhuis Groep Twente, Hengelo, the Netherlands) for analysis. 
 
Figure 8.1, Study flow. 
 
The metal ion levels in serum blood were determined using Atomic Absorption 
Spectrophotometry (AAS) analysis. The Medicines and Healthcare products 
Regulatory Agency (MHRA) statutory body that regulates resurfacing devices in 
the UK advocates 7 parts per billion (ppb) for chromium and cobalt after MoM hip 
arthroplasty as a safe upper limit.22 All MARS-MRI examinations were performed 
on a 1,5T MRI (Philips Medical Systems, Best, The Netherlands). Scan parameters 
are listed in table 8.1.  
MARS-MRI images were judged by one experienced musculoskeletal radiologist 
and validated by a second radiologist. If patients had two cysts observed on MRI, 
the maximum diameters of both were added up. In case of disagreement 
consensus was reached by discussion. Pseudotumor findings were classified 
according to the grading system described by Anderson (Table 8.2), which has a 
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good interobserver reliability (κ=0.78, 95% confidence intervals: 0.68–0.88).18 We 
defined pseudotumors to be asymptomatic if patients scored no pain on the 
Oxford Hip Score (OHS) pain question and if the total OHS score was less than 
1920. Our study was approved by the Institutional Review Board (IRB nr. 08.013, 
18th December 2008). 
 
Statistical analysis 
Descriptive statistics were used to report patient characteristics, clinical outcomes 
and radiographic measurements the number of (asymptomatic) pseudotumors 
detected with MRI scanning. Serum metal ion data are non-normally distributed, 
therefore median with interquartile ranges (IQR) were used. Normally distributed 
data are represented as mean and range. A priori sub analyses were planned on 
the odds ratios for pseudotumor prevalence based on gender, unilateral or 
bilateral MoM implants, cup inclination angle (550 or higher was considered a cut-
off point for too steep), component size (femoral component less than 50mm was 
considered small), neck thinning (neck thinning versus no neck thinning), and 
elevated blood metal ion levels. The Pearson correlation coefficient between cup 
inclination and both chromium and cobalt serum levels was determined. The 
significant level α is defined as .05. All statistics were carried out using SPSS 19.0 









Pseudotumors identified with MARS-MRI 
In 90 hips (85 patients) pseudotumors were detected at MARS-MRI (36.3%, table 
8.3). The mean follow-up of these patients was 4.8 years (range: 1.0 to 8.2). No 
pseudotumors were detected in the seven patients scanned with ultrasound. 
There were no significant risk groups identifiable (Table 8.4) and there were 80 
pseudotumors visible on MRI in patients with low chromium or cobalt levels 
(Tables 8.5 and 8.6). 
 
Table 8.3, Pseudotumor severity grading 
 C1 C2 C3 Total 
Total (n) 61 (23.8%) 25 (9.8%) 4 (1.6%) 90 (35.2%) 
Symptomatic (n) 11 (4.3%) 8 (3.2%) 2 (0.8%) 20 (7.8%) 
 Silent (n) 50 (19.5%) 17 (6.6%) 2 (0.8%) 70 (27.3%) 
 
Fluid collections not graded as MoM disease 
There were 41 cases of fluid-filled cysts observed on MR images which were 
graded normal (Anderson grade ‘A’). The mean size of these cysts was 26mm 
(range: 8 to 62). 
 
Metal ion levels 
Median chromium and cobalt values were 1.82 ppb (IQR: 1.1-3.2) and 1.47 ppb 
(IQR: 1.1-2.40), but increased per pseudotumor severity group (table 8.7). Eight 
patients had chromium and cobalt levels >7 ppb, another five patients had 
chromium values of >7 ppb but cobalt values of <7 ppb. No patients with cobalt 
values of >7 ppb had Chromium values <7 ppb. Bilateral patients had median 
chromium and cobalt levels of respectively 2.92 ppb (IQR: 1.82-4.46) and 2.35 ppb 
(IQR: 1.65-3.49) compared to 1.51 ppb (IQR: 0.98-2.19) and 1.29 ppb (IQR: 0.94-
1.71) for unilateral patients. The Pearson correlation between acetabular cup 
inclination angle and chromium blood-levels was 0.22 (p <0.001). See figure 8.2A. 
The Pearson correlation between acetabular cup inclination angle and cobalt 







Table 8.4, Odds ratio’s for pseudotumor prevalence 
 OR (95% CI) p 
Female 0.91( 0.5 – 1.64) 0.74 
Unilateral MoM 1.25 (0.61-2.55) 0.06 
Femoral head <50mm 1.3 ( 0.78-2.2) 0.30 
Cup inclination angle of <55
0
 0.94 (0.53-1.66) 0.83 
General symptoms present 0.71 (0.35-1.45) 0.35 
Femoral neck thinning 1 (0.6-1.67) 0.10 
 
Table 8.5, 2 x 2 table for Chromium level and pseudotumor occurrence 
 No pseudotumor Pseudotumor 
Chromium <7ppb 161 80 
Chromium >7ppb 4 11 
 
Table 8.6, 2 x 2 table for Cobalt level and pseudotumor occurrence 
 No pseudotumor Pseudotumor 
Cobalt <7ppb 163 84 











Figure 8.2A, Chrome 


















Pain in or around the hip area (as a domain of the Oxford Hip score), was reported 
in 23.6% (n= 60) of all 256 cases, ranging from slight (n=32, 12.6%), mild (n=16, 
6.3%), moderate (n=9, 3.5%) or marked (n=3 hips, 1.2%). A wide variety of general 
symptoms were reported by 44 of all 221 patients (19.9%) and ranged from poor 
vision, general fatigue, hypertension and other cardiovascular diseases to skin 
disease, strength loss, weight loss and stomach aches. General health symptoms 
as specified in the NHS advice on MoM implants are given in table 8.8. Eleven 
patients reported other cardiovascular symptoms than chest pain, such as 
hypertension or coronary bypass surgery. Another six patients reported tinnitus. 
 
Plain radiographs 
In none of the 221 patients, plain radiographs were indicative for MoM disease. 
The contrast between plain radiographs and MARS-MRI is seen in figure 8.3A and 
8.3B. 
 
Revision case description  
Severe MoM disease 
Of the four patients with a C3 pseudotumor, two were revised and one is 
scheduled for revision surgery. Besides a C3 pseudotumor these patients 
presented with either symptoms and/or metal ion levels >7 ppb. In both revision 




cases a large, fluid filled cyst was excised, which was thick-walled in one patient. 
Post operative histopathology confirmed metallosis for each revised 
pseudotumor. In both cases an uncemented THA with a ceramic-on-polyethylene 
bearing was inserted. Metal ion levels dropped significantly six weeks after 
revision surgery (a 20-fold decrease in one patient and a 10-fold decrease in the 
other patient). One patient who was without general or hip symptoms and had 
metal ion levels <7ppb, was treated conservatively. This patient was hesitant to 
undergo revision surgery and pseudotumor evaluation, including MRI and metal 
ion levels, is scheduled after six months. 
 
Moderate MoM disease 
One patient was revised for a C2 pseudotumor with mild hip pain but no general 
symptoms, during which a fluid-filled cyst was excised. ALVAL was confirmed with 
post-operative histopathology. For one other patient with a C2 pseudotumor, mild 
hip pain but no general symptoms, revision surgery is scheduled. Repeated MR 
scanning and metal ion sampling with an interval of six months was scheduled for 
all non-revised patients with a C2 pseudotumor. 
 
Mild MoM disease 
We revised no patients for a C1 pseudotumor, and no revisions are pending for 
this reason. One patient with elevated metal ion levels (13.7 and 8.88ppb 
respectively) had no pain the first five post-operative years, but developed 
increasing pain around the hip during the last two years, which is now moderate. 
The observed pseudotumor had a maximum 49mm diameter (>50mm will classify 
as a C2 pseudotumor). Repeated MR scanning and metal ion sampling was 
scheduled for all patients with a C1 pseudotumor with a time interval of one year.  
 
Total MoM disease in our cohort 
Before this study, two patients were revised for persistent pain who post-
operatively had histopathological evidence of ALVAL to metal debris and two 
patients were revised for pseudotumor diagnosed with MARS-MRI following our 
pilot study. Combined with the 90 pseudotumors detected with MR scanning, this 
results in 94 cases of MoM disease (36.7%) in our total cohort of 256 hips 
(excluding deceased, lost to follow up and unwilling patients). Until now, seven 
hips were revised and two revisions are pending Mom disease (3.5%). 
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Follow-up of patients without a pseudotumor on MR scanning 
Patients without a pseudotumor seen with MR scanning are followed up yearly 





Figure 8.3B, PDW MARS-MRI of same 
patient showing large  pseudotumor. 
Figure 8.3A, Plain anteroposterior 





























































MRI screening a complete cohort of MoM hip arthroplasty patients, we found a 
high prevalence of pseudotumors, the majority (70/90) asymptomatic. Other 
authors have confirmed the high prevalence (up to 30%) of asymptomatic 
pseudotumors in MoM patients, although screening for pseudotumors is generally 
advised if symptoms are present (FDA) or if the serum metal ions levels are above 
a certain threshold (UK).2,23 Based on our results and from previous reports, we 
believe that commonly used follow up methods (clinical examination and plain 
radiographs) will give a gross underestimation of (asymptomatic) pseudotumors 
in MoM hip arthroplasty. This conventional approach might result in late surgery 
for pseudotumor, increasing the risk of poor outcome of revision surgery. The 
early and low-threshold use of cross-sectional imaging might prevent this. In the 
discussion about the clinical value of both symptomatic and asymptomatic 
pseudotumors the true incidences are important facts to know. Furthermore, only 
13 patients (5.9%) had metal ion levels >7 ppb, the latter also a threshold to 
initiate MRI screening. This confirms that ion levels do not correlate with 
visualized adverse local tissue reaction, either noted at the time of revision or on 
MRI. As for the usefulness of metal ions levels to detect pseudotumors, MacNair 
found a pseudotumor prevalence of 24% in patients with normal metal ion 
levels16 and Matthies found that patients revised with pseudotumors had similar 
whole-blood metal ion levels to those who were not revised.24 These findings, 
together with the findings of our study, underline the importance of cross-
sectional imaging in MoM patients. The high prevalence of up to 30% or more of 
asymptomatic pseudotumors in MoM hip arthroplasty, does raise ethical concerns 
both for the patients as well as for society.25,26 However, there is little knowledge 
about the clinical relevance of these silent pseudotumors and the natural course 
of pseudotumors. Further, there is no validated follow-up for detected 
pseudotumors. We propose a conservative approach for mild to moderate 
pseudotumors (Anderson grade C1 and C2) which are asymptomatic and have 
normal metal ion levels. Since there is no clear consensus on the optimal 
treatment of pseudotumors, and revision surgery of these pseudotumors result in 
poor outcome11-13, future studies with multiple follow-up time points including 
cross-sectional imaging are needed to validate the optimal management of 
pseudotumors. Until the optimal management of conservatively treated 
pseudotumors is established, we suggest that cross-sectional imaging is repeated 
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every six months until lesion stability is confirmed. This will provide new insight in 
the yet unknown natural history of conservatively treated pseudotumors, while at 
the same time minimizing the burden for both patients and for society (economic 
costs). The management of pseudotumors after MoM hip resurfacing is hindered 
at this moment since only a few, unvalidated, qualitative grading systems 
exist.2,17,18 Although the interrater reliability of the Anderson grading system is 
good (κ=0.78, 95% confidence intervals: 0.68–0.88)18, the clinical validation of this 
grading system is still limited. This is also the case for other published 
pseudotumor grading systems.2,17 The importance of a validated management of 
pseudotumors is stressed even more since it is estimated that more than a million 
large diameter MoM implants were inserted worldwide.27 Using a validated 
quantitative pseudotumor grading system would also prevent an overly aggressive 
surgical treatment of pseudotumors. We advocate an approach of conservative 
policy with intensified follow up if a moderate to mild (Anderson class C1 or C2) 
pseudotumor at MRI is present with low metal ion levels (<7 ppb) and no 
symptoms. We based revision surgery of pseudotumors primarily on 
pseudotumor appearance on MRI (Anderson grade C3), and secondly on metal ion 
levels (>7ppb) and symptoms. 
 
Limitations 
Since our study is cross-sectional in design, no conclusions on the development of 
pseudotumors throughout follow-up can be made. The natural course of adverse 
reactions to metal debris is unclear, but based on two studies Fary et al suggested 
the likelihood of progression.15 Sequential MR scanning will be needed to evaluate 
any change in pseudotumor size, shape and location.  
Despite the problems with these MoM implants some authors still claim they are 
useful in the correct setting and if the implant is correct.10 But, this approach is 
only possible when all risk factors for pseudotumor formation are well 
understood. We found an increased risk (however not significant) in men, for 
smaller components and for unilateral MoM hip resurfacing. In previous studies, 
female patients and age <40 years were found as risk factors for pseudotumors.20 
 A second limitation is, that a small number of patients did not have MR scanning 
due to contra-indications or unwillingness to participate. However, the complete 
follow up of MARS-MRI, metal ion levels and hip and general symptoms of the 
remaining, consecutive series of this large cohort with a single hip resurfacing 
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design has not been presented before. One has to keep in mind that the amount 
of wear depends on details of each specific resurfacing design such as acetabular 
arc of cover and clearance, thereby limiting the ability to extrapolate our results 
to other resurfacing designs.28,29 
In conclusion, although prevalence of pseudotumors in a single design MoM hip 
resurfacing is high, the majority of these patients having subclinical appearance of 
the pseudotumors, and chromium and cobalt levels <7ppb. In contrast to 
guidelines from national orthopedic boards, we believe that clinical examination 
and plain radiographs only have a limited role in the detection of pseudotumors. 
On the other hand, only a small number of pseudotumors is graded severe on 
MRI. For now, this allows us to be conservative in the management of detected 
pseudotumors. Data on the future development of mild to moderate 
pseudotumors is however lacking and there is a clear need for studies presenting 
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We aimed to establish the natural course of unrevised asymptomatic 
pseudotumours after Metal-on-Metal (MoM) hip resurfacing during a six to 
twelve month follow-up period. We used repeated Metal-Artefact Reduction 
Sequence (MARS)-Magnetic Resonance Imaging (MRI) scanning, metal ion analysis 
and clinical examination to study 14 unrevised cases (mean age 52.7 years) with 
pseudotumour and a control group of 23 cases (mean age 52.8 years) without 
pseudotumour. Mean postoperative time to the first MARS-MRI was 4.3 years 
(range: 2.2 to 8.3), mean time between first and second MARS-MRI was 8 months 
(range: 6 to 12). With the second MRI, 35 out of the 37 hips (95%) had not 
changed in pseudotumour severity, one new pseudotumour (Anderson C2 score, 
moderate) was observed and one pseudotumour was downgraded from C2 
(moderate) to C1 (mild). In general, pseudotumour details were hardly changed. 
Repeated MARS-MRI within one year follow-up in unrevised patients with 
asymptomatic pseudotumours after MoM hip resurfacing shows little to no 
variation. In 23 controls without pseudotumour, one new pseudotumour was 
detected (4%). Since this is the first longitudinal study on pseudotumours using 





Metal on Metal prostheses caused a tremendous change in thought on 
performance of hip arthroplasty. Although problems with this type of implant are 
now known to society, the policy on what to do with the aftermaths of this 
implant are still obscure. A simple revision has mediocre results, the effect of the 
existing pseudotumours caused by these MoM implants is unknown since no 
follow-up studies are available. There is ample debate on the prevalence of 
pseudotumours following Metal-on-Metal (MoM) hip replacement.1-4 
Pseudotumours are believed to develop in reaction to the release of metal debris 
of the articulating metal surfaces. A retrieval study by Doorn et al report that 
about one trillion small nanoparticles are released per year in a MoM bearing 
(14,000 times more particles than with a polyethylene low friction articulation),5 
but little is known of the biological effects of the metals—predominantly cobalt, 
chromium, and molybdenum—that are released into the body by these implants.6 
Unlike most organic chemicals, metals cannot be eliminated from tissues by 
metabolic degradation, but only by renal or gastrointestinal excretion.7 The 
formation of pseudotumours is believed to be either an allergic response to a 
normal level of metal wear particles, or a toxic effect of a very high level of 
particles.8 Currently the only treatment of a pseudotumour is revision surgery in 
which the MoM articulation is replaced by a non-MoM articulation. Outcome 
studies on MoM revision surgery are scarce and have short follow up, but tend to 
report moderate results9, with even a 25% re-revision rate being reported.10 The 
clinical relevance of smaller pseudotumours detected with MARS-MRI is 
unknown. Moreover, there is a lack of knowledge on when and how fast 
pseudotumours develop, since all cross-sectional imaging studies on 
pseudotumours except one, have been retrospective in design with only one 
follow up. Almousa et al recently published the natural history of 15 
pseudotumours in a sample unrevised asymptomatic patients using ultrasound 
examination, and observed both increase (n=6) in pseudotumour size, decrease 
(n=1) and complete disappearance of pseudotumours (n=3).11 However, we do 
not know if and when new pseudotumours are detected with repeated cross-
sectional imaging, and, in case of a pseudotumour without the need for 
immediate revision surgery, (i.e. smaller, less severely graded pseudotumours in 
asymptomatic patients with (near) normal metal ion levels), what the short term 
natural history of these pseudotumours is. Our primary aim was to study the 
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natural course of unrevised mild to moderate pseudotumours in unrevised 
patients during a six to twelve month follow-up period, using MARS-MRI; Our 
secondary aim was to study if new pseudotumours were observed in this follow-
up period. 
 
Patients and Methods 
From a previously published cohort of 44 MoM hip replacements12, 37 cases were 
available for prospective follow-up, who all had a second MARS-MRI (Table 9.1). 
Two cases were revised after the first MARS-MRI, and four patients (5 hips) 
refused further MARS-MRI scanning. MARS-MRI scan parameters are given in 
table 9.2, all MARS-MRI examinations were performed on a 1.5T MRI (Philips 
Medical Systems, Best, The Netherlands. Each patient had received a MoM hip 
resurfacing arthroplasty (ReCap, Biomet, Warsaw, USA) for primary hip 
osteoarthritis (OA). MARS-MRI was used to score severity of pseudotumours, 
which was graded by an experienced musculoskeletal radiologist (KB) and 
validated by a second musculoskeletal radiologist (RH), using the Anderson 
method (Table 9.3). This method has good interobserver reliability (κ=0.78, 95% 
confidence intervals: 0.68 to 0.88) as shown in the original publication by 
Anderson et al.13 At follow-up, clinical examination, Oxford Hip Score,14 and a 
MARS-MRI was made at mean 4.3 years (range: 2.2 to 8.3). Mean time between 
the first and second MARS-MRI was 8 months (range: 6 to 12). Pseudotumour 
details (classification, maximum diameter, localisation with respect to the hip 
joint -anterior, lateral or posterior-, wall thickness and solidity) are shown in table 
9.4. We defined a pseudotumour as a peri-prosthetic cavity, either fluid-filled or 
having a solid content, which in case of being fluid-filled communicates with the 
hip joint. Pseudotumour wall thickness was measured at the site were wall 
thickness appeared to be thickest: ≥3mm was considered to be thick, <3mm was 
considered thin.15 High MRI signal intensity was associated with fluid, low signal 
intensity with solid pseudotumour content. Bone marrow edema and compromise 
of nerve or blood vessel structures was systematically analysed for each MRI scan 
by both radiologists. Serum ion samples (Chromium and Cobalt) were collected at 
both MRI time points and analyzed as previously described.12 Since little is known 
on short term variability of chromium and cobalt levels, a difference of +/- 5% 
between metal ion levels was considered a true difference. This was based on the 
findings by Khan that a short exercise bout resulted in 11% to 13% increased 
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metal ions concentration. The Oxford Hip Score (OHS) ranges between 48 (least 






















































































































Descriptive statistics were used to report patient characteristics and observations 
such as the number, size and appearances of pseudotumours detected with MRI 
scanning. Metal ion data and pseudotumour dimension distributions were 
asymmetric and are expressed as a group median with interquartile range (IQR). 
Normal distributed data are represented by a mean and range. A qualitative 
analysis was done for each change in pseudotumour details. Differences in mean 
values were tested with (two-sided) t-test, differences in median values with the 
Mann-Whitney test. Significance level was defined at 0.05, 95% Confidence 
Intervals (C.I.) are provided were appropriate. 
Results 
Details of the 14 pseudotumours observed with the first MRI are given in table 
9.4. At first MARS-MRI, the majority of pseudotumours (10/14) were fluid-filled 
cysts, only four showed a mixed MRI signal intensity indicating a more solid 
content. Three out of four solid pseudotumours were thick-walled, whereas all 10 
fluid-filled pseudotumours were thin-walled. Maximum diameter ranged from 
18mm to 80mm. One pseudotumour was graded as Anderson score C3 (severe 
MoM disease), six as Anderson C2 (moderate MoM disease) and 7 as Anderson C1 
(mild MoM disease). Median Chromium and Cobalt for the solid pseudotumours 
was 3.1ppb (IQR: 1.7-5.6) and 2.1ppb (IQR: 1.8-4.5) versus 3.0 (IQR: 1.6-5.1) and 
2.3 (IQR: 1.1-5.1) for the fluid-filled pseudotumours. There were no changes 
observed in pseudotumour position, wall thickness or content (based on MRI 
signal intensity) for any of the pseudotumours between both time points. Median 
pseudotumour diameter decreased from 50 mm (IQR: 32-70) to 46mm (IQR: 37-
69). There were five pseudotumours where the maximum diameter had not 
changed, five pseudotumours had become smaller (mean absolute change -
13mm, range: -32 to -2mm), and four had grown (mean absolute change +26mm, 
range: 7 to 33mm) (Figure 9.1). Thirty-five out of the 37 hips had not changed 
according to the Anderson grading system. In two cases (5%), the Anderson 
pseudotumour grade had changed between the two MRI scans: one C2 
pseudotumour was observed on the second MRI, which had not been there at the 
first MRI scan (Figure 9.2A and 9.2B). One pseudotumour was downgraded from 
C2 to C1 (Figure 9.3A and 9.3B). See table 9.5. Median chromium increased from 
1.7 ppb (IQR: 1.0-3.8) to 2.1 ppb (IQR: 1.1-3.6) and median cobalt decreased from 
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1.4 ppb (IQR: 0.9-2.5) to 1.3 ppb (IQR: 0.9-3.5) but no metal ion level had changed 
more than +/– 5%. In the pseudotumour group, mean OHS improved from 32.1 
(range: 42 to19) points pre-operatively to 43.2 (range: 48 to 39) at first MRI 
follow-up time point (40.7, range: 48 to-31 at second MRI time point). In the 
control group OHS improved from 28.9 (range: 39 to 11) points pre-operatively to 
42.1 (range: 48-27) at first MRI follow-up time point (42.2, range: 48 to 27 at 
second MRI time point). 
 
 
*median value is presented with IQR between brackets. Pseud.: indicates Pseudotumour 
Figure 9.1, Absolute change pseudotumor size. 
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Change in treatment 
After the first MARS-MRI, one patient was considered for revisions surgery and 13 
for intense follow-up, without immediate need for revision surgery of their MoM 
implant. Based on the results of second MARS-MRI, metal ion levels and 
symptoms 6 to 12 month later, this clinical advice was not changed in any of the 
patients. 
 
Description of the 2 cases changed in Anderson grading 
Case 1 
The first MRI images of a 67 year old male patient who did not have any evidence 
for pseudotumour formation at that time (Figure 9.2A) are compared with the 
images of the second MARS-MRI (Figure 9.2B) when a C2 pseudotumour was  
detected, 3.5 years after implantation. Time between scanning was 11 months. A 
thin-walled fluid-filled cyst developed lateral to the hip joint with a maximum 
diameter of 55 mm in cranio-caudal direction and a thin dorsal connection to the 
joint space. Based on size, signal intensity and connection to the joint space, this 
cyst was classified as a C2 pseudotumour. Between MRI scanning, OHS score 
deteriorated from 41 points to 33 points, although hip pain was unchanged (mild). 
Chromium and Cobalt levels remained stable at 0.9 and 0.8ppb respectively. 
 
Case 2 
In a 57 year old male patient, the pseudotumour was downgraded from C2 to C1, 
see figure 9.3A and 9.3B. This patient had bilateral MoM hip resurfacing, with 
bilaterally a pseudotumour observed. The pseudotumour on the right hip, 
reduced from 53 mm to 39 mm in the six months between MRI scanning. 
Consequently, the Anderson classification changed from C2 to C1. Between MRI 
scanning, OHS deteriorated from 44 to 36 points, with hip pain deteriorating from 
very mild to mild, while Chromium and Cobalt levels improved from 6.4 to 3.6ppb 
and from 5.3 to 3.9ppb respectively. 
 
Figure 9.2B, Second MARS-MRI. 




Figure 9.2A, First MARS-MRI. 





























Figure 9.3A, First MARS-MRI. 




We found that only 5% of the included, small to moderate sized, asymptomatic 
pseudotumours after MoM hip resurfacing, changed in severity using a six to 
twelve months interval to repeat MARS-MRI. In the control group without 
pseudotumour (23 hips), one new pseudotumour was detected (Anderson grade 
C2) but this patient had no change in metal ion levels or hip pain. In the 
pseudotumour group (n=14), pseudotumour severity was downgraded in one case 
(from Anderson grade C2 to C1). Accordingly, metal ion levels decreased in this 
patient but in contrast his hip pain deteriorated from very mild to mild.  
Based on these results clinical treatment was left unchanged for all included 
patients, indicating that a >1 year interval between consecutive cross-sectional 
imaging appears to be safe. On this last topic no evidence is available. How much 
deterioration of symptoms and metal ion levels should trigger additional cross-
sectional imaging cannot be concluded from our results, since we observed only a 
very small variation and sometimes contradictive development in metal ion levels 
and symptoms between both MRI time points. Longer follow up with an extensive 
screening protocol is needed. Analysing all included pseudotumours, maximum 
diameter both increased (n=6) and decreased (n=6), although the observed 
differences were small to very small. None of the pseudotumours changed in 
appearance or location.  
Previous studies using cross-sectional imaging of pseudotumours after MoM hip 
arthroplasty were retrospective in design, used only one time point for imaging 
and had considerable variation in follow up duration.3,16-18 Recently, Almousa et al 
published the first report using repeated ultrasonography (US) in a cohort of 15 
pseudotumours and five isolated fluid collections in a variety of hip replacement 
types (13 MoM THA, four MoM hip resurfacings and three metal-on-polyethylene 
bearings).11 In their series, three pseudotumours had such an increase in size (2.2-
fold to 11.4-fold) that it was deemed clinically significant. In our series, we 
observed no clinically relevant change in pseudotumour size or severity. This 
might be explained by the shorter follow-up in our study (mean of eight months 
versus 25.8 months). 
There is limited data available on when pseudotumours develop and on how fast 
pseudotumours change over time. There is also no consensus on the exact 
definition of a pseudotumor, with different lesions included such as solid 
pseudotumors or fluid-filled lesions (which might fluctuate more in time), making 
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it more difficult to guide clinical management of pseudotumours after MoM 
arthroplasty. Most orthopedic societies and national boards advise computer 
tomography (CT) or MARS-MRI only in symptomatic patients.19-21 However, high 
prevalence rates of asymptomatic pseudotumours after cross-sectional imaging 
were reported by Kwon et al (6.5%), Wynn-Jones et al (36%) and Mistry et al 
(58.3%).3,4,18 How pseudotumours can remain asymptomatic is not known. To our 
knowledge, no explanation for the absence of symptoms in case of 
pseudotumours has been presented in literature. Since we know that 
asymptomatic pseudotumours will be missed12, the validity of the advices issued 
by the FDA and national boards can be questioned. Accepting the risk of missing 
pseudotumours might outweigh the potential risk of overtreatment based on 
positive MRI findings, since the clinical relevance of mild to moderate 
pseudotumours is not yet fully known. On the other hand, one can state that all 
MoM patients need to be investigated with cross-sectional imaging at least once, 
to establish a pseudotumour baseline status for each individual patient. 
Furthermore the FDA MoM safety communication does provide little detail on 
how to interpret more detailed cross-sectional imaging results and how observed 
pseudotumours should be treated. There is no study comparing the effectiveness 
of US, MRI or CT for detecting pseudotumors. US diagnostics is user dependent 
and provides less detailed imaging compared to MRI but the presence of a metal 
prosthesis does not compromise US imaging, it is relatively cheap to perform and 
is widely available, and is therefore considered the preferred initial investigative 
tool by several authors.22,23 According to Fary et al CT diagnostics is not suitable as 
a screening tool for pseudotumor detection but they consider MRI a suitable tool 
for making a definitive diagnosis of a mass resulting from an adverse reaction to 
metal debris.23 All three modalities have advantages and disadvantages regarding 
radiation, costs and accuracy and therefore it remains debatable which modality 
is best for (initial) screening for pseudotumor occurrence.  
The exact description and grading of pseudotumours has not fully matured. As 
pointed out by Anderson et al, validation of a grading system is likely to take 
several years, since mild degrees of disease in asymptomatic patients do not 
warrant intervention, thereby preventing surgical or histopathological outcome 
data for this group. Only stability in a longitudinal study will be a useful marker of 
the validity of mild disease grades.13 In our own studies experienced 
musculoskeletal radiologists reported a learning curve evaluating pseudotumours. 
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We therefore recommend that more than one radiologist is involved in analysing 
MARS-MRI’s. Also, the use of maximum diameter as an important part of grading 
pseudotumour severity has limitations, and since the changes in pseudotumour 
size are very small during a six to 12 months period, measurement error has to be 
taken into account. Possible factors influencing the MR images when a 
pseudotumour is present, such as time of day or any physical activity shortly 
before acquiring the images need to be established. Furthermore, a long thin 
pseudotumour might be considered a grade C2 (moderate) or C3 (severe) 
pseudotumour based on maximum diameter, without actually involving a large 
volume. Besides maximum diameter, other considerations such as MRI signal 
intensity, cyst wall thickness and position might also be important to evaluate 
pseudotumour changes in time. The observation within our series that mild to 
moderate pseudotumours remained fairly stable with MARS-MRI evaluation over 
a six to 12 month period, for now validates our conservative approach for these 
pseudotumours, which is in agreement with other authors.13,24 Using a >12 
months interval to repeat cross-sectional imaging for smaller, non-revised 
asymptomatic pseudotumours, might help to control the enormous worldwide 
costs involved. Lloyd et al estimated that annual metal ion analysis and MRI 
scanning of MoM patients would increase UK nationwide costs with 72.6 million 
UK pounds for a 5 year period, compared to standard THA follow up costs.25 
One even has to consider the possibility to treat larger asymptomatic 
pseudotumours conservatively if metal ion levels are normal and the 
pseudotumour is positioned in a relative safe position, although the current 
consensus is that larger pseudotumours need to be revised.17,27,28 The need for 
revision is unquestioned for more extensive pseudotumours which cause 
symptoms, extensive soft tissue damage and compromise other structures such as 
blood vessels and nerves.  
In conclusion, we show little value to repeat MRI within one year for mild to 
moderate sized asymptomatic pseudotumours after MoM hip resurfacing, since 
the few observed changes were minimal and did not change clinical treatment. 
But there is a value for repeated examinations with longer term follow-up as was 
shown by Almousa et al.11 Since our study is the first longitudinal study on 
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Objectives: To validate clinical measurements of (change in) pseudotumor 
maximum diameter and estimated volume with three-dimensional region-of-
interest (3-D ROI) volume measurements. 
Methods: Repeated Metal-Artefact Reduction Sequence (MARS)-Magnetic 
Resonance Imaging (MRI) scans of 13 cases of non-revised pseudotumors after 
Metal-on-Metal hip resurfacing were reviewed. Mean time between first and 
second MARS-MRI was 7.5 months (range: 6 to 12 months). Pseudotumor 
dimensions were measured by: (1) Maximum diameter in one plane (MD); (2) 
Estimating pseudotumor volume based on maximum diameter in three different 
planes (EV); (3) Three-dimensional (3-D) Region-Of-Interest (ROI) based volume 
(V) method.  
Results: Correlation was strongest between EV and V (0.86, p<0.000). EV 
overestimated V with a mean of 72.6%, more so in non-ellipsoid pseudotumors 
than in ellipsoid pseudotumors.  Median change for MD between first and second 
MARS-MRI was 0.0cm (range: -1.5 to 3.4); -0.5ml for EV (range: -16.4 to 45.5); and 
0.5ml for V (range: -7.7 to 5.2). The percent change in pseudotumor dimensions 
was not significantly different between MD, EV and V. 
Conclusion: Estimating pseudotumor volume in clinical practice using maximum 
diameter in three different planes is easily attainable, has a strong correlation 
with a 3D-ROI method, and can be used for monitoring pseudotumor volume over 
time. Clinicians need to be aware of overestimating pseudotumor volume when 





Pseudotumors, defined as a peri-articular mass caused by an immunological 
delayed hypersensitivity response to metal particles and characterised by a 
lymphocyte-dominated histological pattern1, are regularly observed after Metal-
on-Metal (MoM) hip arthroplasty.2,3 They may cause severe symptoms, have been 
found to be locally destructive and might require revision surgery.4-6 The clinical 
relevance of pseudotumors is however not fully understood. For that purpose, 
clinicians need to know if pseudotumors containing fluid are less destructive than 
more solid pseudotumors, if thick-walled pseudotumors are more aggressive than 
thin-walled pseudotumors. Furthermore the location of the pseudotumor (i.e. 
near nerves or blood vessels) influences the need for re-operation. The clinical 
relevance of these details are validated by recent publications.7,8 
Another important clinical issue in these patients with MoM bearing is 
pseudotumor size. The latter is taken into account for the assessment of 
pseudotumor severity and to determine if revision surgery is indicated.7,9 Most 
reports on pseudotumors are cross sectional studies, only two longitudinal 
reports (one with sonography and one with MRI) on pseudotumor development 
exist. These indicate that pseudotumors with time not only can increase in size 
but that some pseudotumors can diminish in size or even disappear.7,10 To study 
these changes in pseudotumor size over time, it is important that pseudotumor 
dimensions can be measured accurately. 
Although with cross-sectional imaging measuring maximum pseudotumor 
diameter in clinical practice is straightforward, it might be that this is not accurate 
enough for detecting changes in pseudotumor size over time. Measuring 
pseudotumor volume could potentially detect changes in pseudotumor size over 
time more accurately. 
Pseudotumor volume might also be more relevant than maximum diameter to 
grade pseudotumor severity and to quantify the potential for soft tissue damage. 
Although this issue is not yet discussed in MoM pseudotumor literature or 
incorporated in current pseudotumor grading systems2,11,12, authors have used 
estimated pseudotumor volume to describe their cross-sectional imaging 
results.7,8,13  Lack of experience on measuring volume can partly be explained by 
the relative short period of research into pseudotumors after MoM hip 
arthroplasty. In other medical fields, like oncology, much more experience with 
tumor volume measurements is available. Imaging-based tumor volume 
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measurements before, during, and after therapy have become essential 
components of cancer management.14 
Since volume measurements in oncology are that vital, the technique of volume 
measuring has evolved enormously over the last decade. With the advancement 
and availability of commercially available computer software for quantitative 
analysis in cross-sectional imaging, the entire tumor, regardless of its shape, can 
be identified and traced as a region of interest (ROI) on each imaging slice, 
allowing 3-dimensional (3D) ROI-based quantitative measurement of tumor 
volume.14-16 
The primary aim of our study was to validate clinical measurements of (change in) 
pseudotumor dimensions (maximum diameter and estimated volume) with a 
three-dimensional region-of-interest-based volume (V) method. 
 
Patients and methods 
Patient population 
All patients treated with a MoM hip resurfacing in our institution were part of a 
registration study for which ethical approval was obtained from the Institutional 
Ethics Committee. Metal-Artefact Reducing Sequence (MARS)-Magnetic 
Resonance Imaging (MRI) was made for routine follow up for all patients with 
MoM hip resurfacing arthroplasty, after a pilot study showed a high pseudotumor 
prevalence.17 All MARS-MRI’s were evaluated by an experienced musculoskeletal 
radiologist who used the Anderson classification11 to grade pseudotumor severity. 
For this study, 11 patients (13 hips) with mild (n=6) to moderate (n=7) 
pseudotumors which were treated conservatively, were available for follow-up 
(Figure 10.1). None of these patients had elevated metal ion levels and all were 
asymptomatic, mean follow-up at the first MARS-MRI was 5.3 years (range: 2.4 to 
7.5 years). To monitor the course of pseudotumor development, a sequential MRI 





















All MARS-MRI studies were performed on a 1.5 T scanner (Philips Gyroscan, Best, 
The Netherlands) using the system’s body coil. All patients were scanned supine. 
On the acquired DICOM images, stored in the Picture Archiving and 
Communication System (PACS), maximum diameter was measured on the work 
station. Maximum pseudotumor diameter was measured three times: once in the 
transversal, once in the coronal and once in the sagittal plane. For analysis, the 
largest diameter of these three measurements was used, resulting in a clinically 
measured maximum diameter (MD). All clinical distance measurements were 
done by one observer (WvdW) and independently repeated by a second observer 
(PP). Pseudotumor volume was measured using a ROI-based volume 
measurement (V). V was derived from the MRI data in the three different 
directions, which were combined to generate one single 3D image with high 
resolution and isotropic sampling (Figure 10.2). For this, the coronal, sagittal, and 
transverse MRI datasets were rigidly transformed to one single dataset using 
translation and rotation. This was possible because the images were acquired 
during one image session and at the location of the hip, the effect of movement 
artefacts caused by for example the breathing of the patient was minimal. The 
parameters for the transformations were obtained from the MRI image header 
information.18 The voxel values of the newly generated image were calculated by 
averaging the values of the aligned MRI images. A ROI-based method was used to 
Cases MRI scanned in pilot study: n=44 
Excluded cases: n=31;  
 Cases without pseudotumor (n=29) 
 Cases revised after pilot study (n=2) 
Cases available for pseudotumor dimension measurements: n=13 
Figure 10.1, study flow. 
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calculate pseudotumor volume from the newly generated images. For this, the 
entire pseudotumor region was identified and traced using Amira software 
(Visualization Sciences Group, Bordeaux, France). A 3D ROI-based volume was 
calculated by the summation of all pseudotumor areas in each slice and 
multiplication by the slice profile. Correction for partial volume effects was done 
by multiplying the volume of the surface voxels by a filling fraction. Filling Fraction 
= 0.5*(MAX pixel intensity + MIN pixel intensity) / (MAX pixel intensity).  
A less complicated measurement of pseudotumor volume is to multiply the 
transversal maximum diameter with the coronal and sagittal maximum diameters, 
resulting in a clinically estimated volume (EV) representing a simple box model. To 
test how much this method of measuring EV is influenced by pseudotumor shape, 
we classified pseudotumors into two categories: ellipsoid (Figure 10.3) and non-
ellipsoid shape (Figure 10.4). Outcomes of EV for ellipsoid and non-ellipsoid were 








For comparison, all three measurements (MD, EV and V) were done with the first 
and second MRI dataset of each included patient. Outcomes >2 standard 































Descriptive statistics were used to report MD, EV and V, with subgroup analysis 
for ellipsoid versus non-ellipsoid pseudotumors. Diameter and volume data were 
Figure 10.4, Non-ellipsoid 
pseudotumor. 
Figure 10.3, Ellipsoid pseudotumor. 
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tested for normal distribution using the Shapiro-Wilk test. The relationship 
between MD, EV and V was calculated using Spearman’s rank correlation 
coefficient. Change in MD, EV or V between the first and second MRI dataset were 
tested with a Wilcoxon signed rank test. The Friedman test was used to test if 
using a different measuring method (MD, EV or V) influenced the observed 
change significantly. For this purpose, the percent change per case was calculated. 
The significance level α was set at 0.05. All statistics were carried out using SPSS 
19.0 software (SPSS Inc., Chicago, Illinois). 
 
Results 
MR Imaging Analysis per cases 
By using 3D images with high resolution and isotropic sampling, identification of 
the entire pseudotumor region using Amira was easier than by using the coronal, 
sagittal and transverse MRI datasets separately. This is because the voxels 
belonging to the pseudotumor were better connected with each other in the 
adjacent slices and it was easier to review the pseudotumor shape in the different 
views (x, y and z) because of the isotropic sampling. Eight pseudotumors were 
ellipsoid, MD ranged from 1.7cm to 8.6cm, EV from 1.5ml to 87ml and V ranged 
from 1.1ml to 35.4ml (Table 10.2).  
 
Table 10.2, Measurement details per case 

















1 Yes 1.80 2.48 1.33 C1 1.74 1.97 1.10 C1 
2 No 4.46 67.51 35.37 C2 6.65 51.11 27.69 C2 
3 No 3.57 7.87 11.13 C2 6.93 31.62 16.36 C3 
4 No 8.63 41.52 15.09 C2 8.63 86.99 15.56 C2 
5 Yes 7.40 18.15 10.07 C2 6.33 7.82 9.56 C2 
6 No 5.43 24.97 9.42 C2 3.91 8.61 9.66 C1 
7 Yes 4.96 8.70 2.79 C1 4.41 4.15 2.75 C1 
8 No 4.15 9.80 5.74 C1 3.91 6.71 6.36 C1 
9 Yes 5.04 9.69 3.63 C1 5 15.45 4.57 C1 
10 Yes 3.24 2.34 1.58 C1 2.95 1.45 1.29 C1 
11 Yes 5.95 10.40 18.12 C2 7.89 23.39 22.85 C2 
12 Yes 6.43 32.90 23.14 C2 6.68 46.52 27.37 C1 
13 Yes 3.02 2.78 2.18 C1 3.89 10.10 4.70 C1 
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Pseudotumor maximum diameter and volume data had a non-parametric 
distribution. Between both time points, median values for MD, EV and V were not 
significantly different (Table 10.3). 
 
Table 10.3, Median values at both MARS-MRI time points 





MD (cm) 5.0 (1.8 – 8.6) 5.0 (1.7 – 8.6) 0.70 
EV (ml) 9.8 (2.3 – 67.5) 10.1 (1.5 – 87.0) 0.60 
V (ml) 9.4 (1.3 – 35.4) 9.6 (1.1 – 27.7) 0.17 
* Wilcoxon signed rank test 
 
Relationships between MD, EV and V 
MD, EV and V were all highly correlated, with the strongest correlation for EV and 
V (Table 10.4). EV was larger than V in 22 case, and smaller in 4 cases. On average, 
EV was 72,6% larger than V (range: -42,6% to 238,1%). Boxplots based on the data 
from the first MRI measurements show a distinct difference for MD, EV and V 
results per Anderson pseudotumor classification (Figure 10.5). 
 
Table 10.4, Correlations for MD, EV and V 
 Spearman correlation p 
MD – EV 0.82 <0.000 
MD– V 0.74 <0.000 





Figure 10.5, Boxplot of maximum diameter (A), estimated volume (B) and 3-D volume (C) 
versus Anderson classification. 
  
Figure 10.5A, Boxplot of maximum 
diameter versus Anderson classification 
Figure 10.5B, Boxplot of estimated 
volume versus Anderson classification 
Figure 10.5B, Boxplot of 3-D volume 
versus Anderson classification 
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EV in ellipsoid versus non-ellipsoid shaped pseudotumors 
With 3-D ROI-based V results considered the reference value, the median 
percentage difference between EV and V for ellipsoid pseudotumors was 64.2% 
(range: -42.6 to 211.8), and 90.9% (range: -29.3 to 175.2) for non-ellipsoid 
pseudotumors.  
 
Comparison of Anderson score, MD, EV and V between first and second MARS-
MRI. 
There were 10 cases with unchanged Anderson score, one case was upgraded 
from C2 to C3 and two cases downgraded from C2 to C1. For the upgraded case 
(Case 3), MD, EV and V had increased at the second MARS-MRI (MD: 3.57cm -> 
6.93cm, EV: 7.87ml -> 31.62ml, V: 11.13ml -> 16.36ml). For one downgraded case 
(Case 12), MD, EV and V had also increased with the second MARS-MRI (MD: 
6.43cm -> 6.68cm, EV: 32.90ml -> 46.52ml, V: 23.14ml -> 27.37ml) . The other 
downgraded case (Case 6) had increased V but decreased MD and EV (MD: 
5.43cm -> 3.91cm, EV: 24.97ml -> 8.61ml, V: 9.42ml -> 9.66ml). See table 10.2. 
Median MD, EV and V for both time points are presented in table 10.3. There 
were no statistically significant differences in median values for either MD, EV or 
V. Median change in MD was 0.0cm (range: -1.5 to 3.4), median change in EV was 
-0.5ml (range: -16.4 to 45.5) and median change in V was 0.5ml (range: -7.7 to 
5.2). Three pseudotumors had not changed in MD, in 5 cases MD was decreased 
and in 5 cases MD was increased (Figure 10.6). The median percentage difference 
in MD was -0.8% (range: -28% to +94. 1%). In 6 cases EV had increased, and 5 
cases had decreased EV. The median percentage change in EV was of -20.6% 
(range: -65.5% to +301.8%). In 6 cases, V had increased and in 1 case V had 
decreased. The median percentage change in V was 3.1% (range: -21.7% to 
115.6%). To detect change in pseudotumor dimension between two time points, 
there was no significantly different result if either of the three methods (MD, EV 






Figure 10.6, Scatterplot comparing MD1 with MD2 (10.6A), EV1 with EV2 (10.6B) and V1 
with V2 (10.6C). 
 
  
Figure 10.6A, Scatterplot comparing MD1 
with MD2 
Figure 10.6B, Scatterplot comparing EV1 
with EV2 





The clinical relevance of pseudotumors after MoM hip arthroplasty detected with 
cross-sectional imaging is still debated.3,19 However, several authors have 
published reports on extensive soft tissue damage due to pseudotumors after 
MoM hip arthroplasty20,21, resulting in muscle necrosis, nerve compression and 
Deep Venous Thrombosis. Which aspects (i.e. volume or presence of solid masses 
rather than fluid-filled cysts) of pseudotumors are predictors for subsequent 
tissue lesions are not yet determined, although a common feature of these 
reports is that compression by the pseudotumor plays a role. To this end also a 
follow-up on how dimensions of conservatively managed pseudotumors develop 
through time, is of importance. 
In a clinical setting, measuring pseudotumor dimensions on MRI slices is limited to 
either the maximum diameter (MD) in one plane, or an estimate of volume (EV) 
based on maximum diameter in three directions, representing a simple box 
model. This is an established method in oncology that is easy and fast to perform 
in a busy clinical practice.22 As expected, EV overestimated V more in non-ellipsoid 
pseudotumors (91%) than in ellipsoid pseudotumors (64%). From our results it is 
also clear that although there is a high correlation between EV and measuring 
volume with a three-dimensional region-of-interest (3D-ROI) per MRI slice 
method, the difference between these two methods can be substantial. In our 
study, EV overestimated pseudotumor volume by approximately 70%, which is 
something to consider in clinical practice when managing individual cases of 
pseudotumors. 
Compared to MD, EV had a higher correlation with V and we therefore propose to 
use EV rather than MD to quantify pseudotumor dimensions in clinical practice. 
And although EV is partially dependent on MD, explaining the strong correlation 
between MD and EV, there are individual cases with a large MD who have only a 
relatively small volume (3D-ROI volume measurement). It is therefore evident that 
EV rather than MD is a more valid approach to assess the severity of 
pseudotumors, but clinical studies need to validate this approach. For assessing 
change in pseudotumor dimensions in sequential MARS-MRI scans, there was no 
significant difference between methods in the percentage change each method 
measured, although in clinical practice absolute changes might be more relevant 
than percentage change. 
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Although 3D-ROI volume measurements can be performed in a clinical setting 
using standard radiology software, they are very time consuming. This prohibits 
the use of this method for routine MARS-MRI evaluation of MoM patients. 
Estimated pseudotumor volumes were previously used in clinical studies.7,13 Hart 
et al used the maximal anterior-posterior, superior-inferior, and medial-lateral 
diameters to approximate a cuboid-base volume. Their median value was 25.1ml 
with a range from 0.9 to 594.0 ml, which is considerably higher than our median 
value for EV (9.8ml, range: 1.5 to 87ml). This might be explained their study 
involving only a single MARS-MRI per case, and included painful MoM patients 
who were revised later on. In our study only small to moderate pseudotumors 
which were not considered for revision surgery after the first MARS-MRI were 
included, thereby excluding more extensive pseudotumors. Almousa et al used 
ultrasound imaging to report on estimated pseudotumor volume development in 
15 unrevised and five revised patients. Similar to our findings, they reported both 
increased volume (n=6) and decreased volume (n=1) with repeated cross-
sectional imaging, but they also observed pseudotumor disappearance (n=3) if left 
untreated.7 They considered three pseudotumors to have a clinical important 
increase in volume (46ml, 56ml and 134 ml respectively) but in contrast, we did 
not find such a change in pseudotumor dimensions between repeated MARS-
MRI’s when using a more sophisticated 3-D ROI volume measurement. Using this 
method we observed a maximum increase of 5.2ml, but with estimating volume 
using a similar approach as by Almousa et al, we also observed a 46ml increase in 
one case. Another explanation might be by the difference in time between first 
and second cross-sectional imaging. In their study it was almost four times longer 
than in our study (25.8 months versus 7.5 months).  
Our study was limited by the small number of included patients, and the inclusion 
of small to moderately sized pseudotumors only. Also, metal ion levels in all 
included patients were not elevated, and in theory pseudotumor development 
over time might be different in patients with elevated metal ion levels. This issue 
needs to be addressed in future studies. Our study is however the first to use 3D-
ROI-based volume method for measuring pseudotumor dimensions after MoM 
hip arthroplasty. It also benefits from the use of MARS-MRI, allowing for more 
detailed imaging compared to ultrasound and less dependence on technician 
experience, although still manual input is required. This manual input might 
explain the four cases where V was smaller than EV. By definition, EV should be 
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equal or larger than V since it uses a box model. MARS-MRI for MoM 
pseudotumor analysis also allows the use of a pseudotumor severity grading 
system, which incorporates more details of pseudotumors than only dimensions, 
such as pseudotumor wall thickness and pseudotumor content. A second issue 
would be to quantify the degree of solid mass of the pseudotumor.  
In conclusion, estimating pseudotumor volume based on maximum diameter in 
three orthogonal planes is a feasible method in clinical practice and superior to 
measuring maximum diameter in one plane to evaluate (change in) pseudotumor 
dimensions. Clinicians however need to consider that this method overestimates 
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Survival of hip arthroplasty in young patients is not as excellent as in elderly hip 
arthroplasty patients. This can be explained by the higher demands younger 
patients have. Larger and different biomechanical stresses are put to the 
prosthesis and a longer life of the prosthesis is needed due to patient’s longer life 
expectancy. These higher biomechanical stresses result in increased implant wear, 
and challenges the long term durability of artificial hip joints. Surgeons, 
biomedical engineers and scientists constantly strive to develop and improve 
designs and used materials that are better able to withstand these stresses and 
show reduced bearing surface wear characteristics. These materials are tested 
first in the laboratory using wear simulators and computerized models. When 
these materials are introduced in clinical practice, post market surveillance of 
their performance is limited and often left to individual surgeons. Increasingly 
however, national joint replacement registers report on the long term implant 
survival. 
The constant drive to improve the clinical performance of hip prostheses has 
resulted in the re-introduction of Metal-on-Metal (MoM) implants during the late 
1990s. Surgeons used this type of surface bearing previously between 1950 and 
1970, but almost completely discontinued its use due to high failure rates. In the 
same period the successful concept of “low friction” arthroplasty was developed 
by sir John Charnley, using Ultra High Molecular Weight Polyethylene (UHMWPE) 
as a bearing surface. This became the most widely used bearing material. But 
wear rates for standard UHMWPE proved to be high in younger, more active 
patients, resulting in osteolysis, implant loosening and ultimately revision surgery. 
This high wear resulted in less favorable implant survival rates in these younger 
patients. This gave MoM bearings a second chance. With advanced production 
techniques allowing tighter material tolerances, these implants now were 
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believed to have reduced wear rates, as demonstrated in wear simulators. Wear 
rates were so much lower that the second generation of MoM bearings were 
introduced as “a life-time implant”, and were to be considered for the younger 
and more active patient. The issue of hip implant failure in younger patients is a 
concern of each surgeon. When a younger patient presents himself with severe 
clinical and radiological hip osteoarthritis and failed conservative treatment, hip 
surgery can be considered. In this case, the surgeon has to choose a bearing 
surface which will last as long as possible and leaves room for future revision 
surgery. When the research in this thesis was initiated, hip resurfacing became a 
popular option around the world. However, the clinical results achieved by this 
second generation MoM hip resurfacing were still under debate. We therefore 
started with prospectively collecting clinical outcomes and radiological data on 
our complete cohort of MoM hip resurfacing patients. Most chapters in this thesis 
present clinical results of implants using a MoM bearing surface, but we also 
report on implants using UHMWPE in age-matched patients with the MoM group, 
to have a baseline comparator. These results confirmed our assumption that 
survival in young patients is not as optimal as we expected. We found a high 
proportion (53.4%) of implants being above the accelerated wear threshold rate 
of >0.2 mm per year, after a mean follow-up of 8.3 years. Somewhat in contrast, 
implant survival at a maximum of 12 years was acceptable (Kaplan-Meier survival 
probability 90.1%), and just compliant to international guidelines such as the NICE 
criteria. To benchmark the results of our MoM hip resurfacing cohort, we 
systematically reviewed the peer-reviewed literature on the survival of these 
resurfacing implants. We found that aseptic loosening was the most frequent 
failure mode and that none of the contemporaty hip resurfacing designs met the 
full 10 year NICE benchmark for survival. With the increasing attention in the 
international literature on the adverse reactions to metal debris (ARMD) in soft 
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tissue surrounding the MoM implant, we intensified our research on MoM 
resurfacing and focussed the research more to the role of cross-sectional imaging 
in diagnosing these reactions. The results of several investigations on the role of 
cross-sectional imaging in detecting and grading of these adverse reactions are 
presented in of the second part of this thesis and will be discussed in detail in this 
general discussion. 
 
Hip implant survival in younger patients using different bearing materials 
As described in chapter 2, long term hip joint replacement survival is often 
disappointing in younger patients and usually fails to meet the criteria of the 
National Institute for Clinical Excellence (NICE) for implant survival.1 Wear of the 
implant bearing surfaces is seen as one of the main failure reasons. This is the 
case for implant types that use standard UHMWPE as a bearing surface but, in 
retrospect, also for so called hard-on-hard bearings such as MoM and Ceramic-on-
Ceramic (CoC).2 With the reintroduction of MoM bearings (both as THA and as hip 
resurfacing designs) during the 1990s, the main failure mode of the first 
generation MoM bearings was believed to be solved. The unacceptable high 
failure rate of the first generation MoM hip arthroplasty was mainly caused by 
short term aseptic implant loosening, due to high numbers of wear particles being 
released directly after implantation.3 The second generation MoM held the 
promise of low wear rates compared to standard UHMWPE and tighter 
production tolerances allowed the use of a thin acetabular shell with a large 
diameter femoral component, reducing the risk for dislocation. In case of MoM 
hip resurfacing, the preserved amount of bone stock compared to THA promised 
the benefit of easier future revision. These three promises of a longer lasting 
bearing surface combined with a reduced dislocation risk and easier future 
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revision surgery were tailored to the needs of younger and more active patient 
indicated for hip joint replacement surgery. 
During the introduction of MoM on the marked, the proposed benefits 
outweighed the concerns on metal ion debris released after implantation. 
Although these proposed advantages were tempting, the available evidence on 
MoM hip arthroplasty at that time was less than encouraging. In retrospect there 
is much debate about why large diameter MoM hip arthroplasty was 
(re)introduced around the millennium. With hindsight, marketing by orthopaedic 
device companies, media attention, internet and claiming patients can all be 
blamed for the introduction of MoM without the proper solid scientific evidence 
or a phased, controlled introduction in the market. Another big problem was the 
unavailability of MRI or CT that could deal with implanted metal implants. 
Scientific evidence was and still is conflicting regarding the benefits and 
complications associated with MoM arthroplasty. In 2000, Doorn, in his thesis on 
wear and biological aspects of MoM hip arthroplasty, concluded that wear volume 
was significantly less with MoM bearings compared to metal on polyethylene 
bearings, that less histocytic reactions occur with MoM bearings and that 
sensitivity and toxicity were not observed with MoM bearings.4 In 2011, Murray et 
al discussed possible risk factors for pseudotumor formation. Based on the 
argument that most of these risk factors could be avoided, they supported the 
continued use of resurfacing in appropriately selected patients by appropriately 
trained surgeons.5 However, several other authors were unable to confirm all 
these risk factors using data from their own case series.6,7 This conflicting 
evidence prompted us to study our MoM patients. In our prospective case series 
of 298 MoM hip resurfacings we found a six year survival rate of 92.7%. In 
comparison, we retrospectively found a 90.7% survival rate for implants using 
UHMWPE after 12 years. Held against the benchmark of a 90% survival rate after 
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10 years follow up as set by the NICE guideline, the first conclusion is that 
UHMWPE is compliant with this guideline, although only by a small margin, and 
the MoM implant is not meeting the 95% at five year landmark. This latter 
showed an insufficient follow up period of this particular MoM resurfacing device. 
In our systematic review of implant survival of MoM hip resurfacing devices, this 
finding was confirmed: none of the included MoM hip resurfacing designs met the 
NICE criteria. Moreover, at the time of review, there were no studies available on 
the particular hip resurfacing device used in our clinic. Later, a case series on this 
particular MoM hip resurfacing design was published by Gross.8 Although their 
survival rate, 96.4%, was better at 7 years, it was still not convincing. Another 
limiting factor of this study was that it was limited to clinical outcome scores and 
plain radiography only. This was comparable to our study first study on clinical 
follow-up of MoM resurfacing.9 In retrospect, clinical outcome scores and 
standard radiographs were insufficiently capable of detecting pseudotumors, as 
demonstrated in our pilot screening study using cross sectional imaging and 
confirmed after we screened our complete MoM hip resurfacing cohort using 
Metal-Artefact Reduction Settings (MARS) MRI. Applying MARS-MRI resulted in a 
36.3% pseudotumor prevalence patients. These results were comparable with 
other cross-sectional imaging studies using different MoM designs, for example 
28% for the Birmingham Hip Resurfacing (BHR)10, 33% for the Articular Surface 
Replacement (ASR)11 and 29% for the Durom design.12 The most severe cases 
were revised, adding a relatively new failure mechanism that negatively impacts 
implant survival of MoM hip implants.  
Although survival rates with our implants which used UHMWPE were better than 
with our MoM hip resurfacing implants, the observed mean wear rate with 
standard UHMWPE was far from satisfactory. Further follow up of this particular 
case series should provide new data on whether this high wear rate will result in 
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an increased revision rate for osteolysis and implant loosening after the first 
decade. The few studies available on wear rates of UHMWPE with 10 to 20 years 
of follow up show that after so called “bedding in phase” during the first year, 
wear rates remain fairly stable up to around 8 to 10 years, but then increase 
again. The clinical relevance of this second decade of increased wear is not fully 
known, but a number of long term studies on the survival of the acetabular 
component report revision rates of 20% at 11 years13 up to 65% at 16 years.14 
Future research should be directed towards constructing guidelines for implant 
survival in which the patients’ age at implantation is a consideration. Ideally, the 
implant survival in younger patients should not only be held against a 10 year 
benchmark but also against a 15 or 20 year benchmark, since the majority of 
younger patients will live more than 10 years after implantation. The Swedish hip 
register makes separation between different age categories, but NICE just uses 10 
years as a benchmark. 
During the last decade, more advanced UHMWPE materials have been developed 
to withstand wear and material fatigue. Clinical studies using cross-linked 
UHMWPE and second generation highly cross-linked UHMWPE are now published 
and compared to other bearings for wear performance and implant survival.15,16 
Five to ten year clinical results of highly cross-linked UHMWPE reveal excellent 
clinical and wear results. Short term reports of vitamin infused highly cross-linked 
UHMWPE (developed to reduce material aging in highly cross-linked polyethylene 
in addition to wear resistance) are also encouraging. For now, we conclude that 
both standard UHMWPE and MoM bearings still not have succeeded in 
significantly improving implant survival in hip arthroplasty for younger patients. 
For MoM the unexpected occurrence of ARMD is the most important downside, 




Surveillance for soft-tissue lesions after MoM hip arthroplasty 
The limited regulations for market introduction of hip implants have resulted in 
unforeseen problems. Currently there is attention to these deficits, but it needs to 
be seen if this is continued and applied to prevent future repetitions of this 
process, or if the orthopedic community, including surgeons, national boards and 
the medical device industry, turns its attention to a new design and forgets about 
the problems discussed in this thesis. 
Fortunately, recent scientific publications have discussed how a more controlled 
introduction of joint replacement designs could be done, while balancing the 
protection of patients with the benefits of introducing new designs which might 
outperform current designs. With this reconsideration of how new joint 
replacement designs are introduced into the market, there is the possibility to 
define the role and responsibilities of all stakeholders involved.  
The focus on improved implant introduction to the market should leave room for 
following up on the clinical results of currently used designs and on previousy 
used but discontinued designs. Ongoing research on (discontinued) implant 
designs will benefit patients by making the optimal selection of revision implant 
designs and will learn us at what time point after the index surgery, revision 
surgery is best done if indicated in these cases. For example, if clinical results from 
early revisions for pseudotumor formation after MoM THA are worse than 
expected, surgeons should be more resistant to perform revision surgery.  
To objectively study these issues, there are several needs. First there is a need for 
further development of pseudotumor classification systems and these systems 
should be more rigorously validated researching the consequent clinical actions 
based on the classification systems and other findings. These developments need 
to be incorporated into national guidelines to help clinicians treating their MoM 
patients. Secondly, more knowledge is needed on the development of 
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pseudotumors over time, their occurrence in non-MoM THA and which details of 
pseudotumors are predictive for the clinical outcome of conservative therapy and 
revision surgery. More research is also needed on the validation of imaging 
techniques like MRI. Can the circumstances under which conditions cross-
sectional imaging was done, such as positioning of the patient, time of the day, 
etc., influence the results? In addition, not only in MoM hip arthroplasty, but also 
in non-MoM hip arthroplasty we need more insight in adverse soft tissue 
reactions incidences and consequences. Already, numerous case reports have 
been published on the occurrence of soft tissue masses near non-MoM total hip 
implants.17 So far, only very small observational studies have researched the 
occurrence of these adverse reactions in non-MoM hip arthroplasty, leaving the 
need for a larger study using cross-sectional imaging. 
It is also relevant for surgeons faced with a patient diagnosed with severe 
pseudotumor after MoM arthroplasty needing revision surgery, to have evidence 
on what bearing option to choose for the revision implant. Currently there is only 
a limited number of studies available presenting the clinical and radiological 
outcomes of MoM revision surgery for pseudotumor, all of them with only short 
follow up on a very limited number of cases.18,19 Different bearing options for 
MoM revision surgery are used such as large diameter ceramic-on-ceramic, dual 
mobility heads, or more standard THA using ceramic-on-polyethylene or metal-
on-polyethylene.20 
 
Introduction of hip implant designs into clinical practice 
The current questions around MoM implants, combined with issues like PIP (Poly 
Implant Prostheses) breast implants and failure of ICD implantable-cardioverter 
defibrillator (ICD) leads, have led to a global discussion on bringing medical 
devices to the market. Both the CE marking (Europe) and the IDE (US) process are 
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criticized.21,22 Currently a process in the European parliament is going on to 
change the CE marking legislation, however this is a quite complex process and it 
is questionable whether this will solve the current problems. 
Orthopaedic surgeons and biomedical engineers primarily question the use of 
specific implants from a performance perspective. Increasingly, national 
associations, medical insurance companies and hospital administrators also 
question the use of specific implants, often both from a performance and a costs 
perspective. All these stakeholders communicate with the medical device 
manufacturers that engineer and produce these implants, often in close 
collaboration with designer orthopaedic surgeons. In orthopaedic surgery, 
medical device companies have the infrastructure and knowledge for developing 
new orthopaedic devices, including laboratory testing. With the required testing 
standards (ASTM and ISO) and vigilance plan, the request for the CE mark is made. 
However, in contrast to pharmacy, the companies only need to present a vigilance 
plan since blinded, dose finding or placebo controlled studies are not possible. 
Dependency of post market surveillance is completely on orthopaedic surgeons 
who are the only ones that can apply these new techniques in the clinic. Many 
innovations or changes to the devices are made together and per request of the 
market (i.e. the surgeons). 
Still, in comparison to pharmaceuticals which require multiple controlled clinical 
trials prior to approval, which take a mean of nine years and cost an average of 
800 million U.S. dollars, medical devices such as a new hip implant design can be 
released onto the market after in vitro testing and limited supportive clinical 
data.23 To improve on this situation, several authors have advocated a stepwise 
clinical introduction of new implants. This involves pre-clinical testing, small 
prospective trials using high-precision methods such as Radiographic 
RadioStereometric Analysis (RSA) to assess initial fixation to predict long term 
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survival, larger multicentre trials and finally population-based register studies to 
keep devices on track.24,25 RSA studies limit the number of patients at risk while at 
the same time, with a short follow up period, provide sound predictions of long 
term implant performance.25 Uniform reporting of RSA and clear descriptions of 
the predicted migration pattern beforehand are essential to get high quality RSA 
results. 
Surveillance of implant performance after introduction onto the market is done in 
a number of countries, but not all, by national joint replacement registries. For 
example in the United States, which is one of the largest markets, less than 200 of 
the 5724 registered hospitals participate in the American Joint Replacement 
Register (AJRR). Other countries such as Sweden however have a long history of 
nationally registering joint replacement procedures, with data entry compliance 
near 100%, enabling them to identify outliers in implant performance after 
market introduction. Still, a significant number of patients are put at risk before 
national joint registries can identify underperforming implant designs. 
The re-introduction of second generations MoM bearings into clinical practice, 
which compromised the confidence of patients and professionals after reports on 
failing implants and even the recall of particular products, is now used to identify 
the shortcomings of the process governing the introduction of new THA implant 
designs in practice.25,26 There are however many considerations. For example RSA, 
a key element in the stepwise introduction of new implants, is a predictor for 
survival. The current issues raised with the MoM bearings could not have been 
prevented with RSA. For example, the RSA results of the Recap MoM resurfacing 
(the prosthesis described in this thesis) were excellent.27 It is therefore necessary 
that a balanced introduction will not only rely on clinical data of implant fixation, 
but that also both local tissue reactions and systemic reactions to released wear 
particles are monitored. 
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This phased introduction should strike a balance between optimizing patient 
safety while at the same time allowing maximum technology development. New 
testing protocols have been developed, in which THA surface bearings are tested 
in adverse conditions such as non-optimal mechanical placement, oxidative stress 
and more extreme temperatures. This should increase the validity of these test 
results for performance in clinical practice. In Europe, medical devices are allowed 
onto the marked after CE (Conformité Européenne) approval but since the 
number of medical devices regulated by CE marking is approximately 500.000, 
ranging from scoot mobiles and drapes to artificial joints or heart valves, it is 
extremely difficult to design specific guidelines for each medical device in Europe. 
Further from notified bodies cannot be expected to be experts on all devices and 
materials. They rely on the quality of the presented documents.  
Benchmark criteria on THA implant survival are nowadays used to evaluate 
implant performance. The National Institute for Health and Care Excellence (NICE) 
criteria set a rate of revision for failure of 10% or less for a given prosthesis at 10 
years.1 These guidelines however do not take into account factors such as 
indication or age. With the increasing number of patients who have received a 
THA, national benchmark guidelines should consider extending their criteria 
beyond the first decade. 
A recent study by Anand demonstrated that the level of implant performance in 
modern hip arthroplasty is hard to beat: none of the new implant designs 
outperformed current hip implant designs, most even did worse.28 But one has to 
be careful to interpret these findings in such a way that development of new 
materials and designs is not halted. Moreover, there are examples of implant 
designs of which the use was discontinued after initial reports predicted poor long 
term performance. For example, based on RSA studies, the SHP stem was 
predicted to have poor long term performance but recent clinical studies showed 
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equal implant survival compared to well-established implants.29,30 An even more 
complicated discussion is raised on the issue of implant design changes. During 
the lifecycle of a certain implant, there might be one or more modifications to the 
original design. All these changes are made to further improve products to meet 
market demands. Although these minimal changes can have major consequences, 
it is difficult to say what research is needed to back up these changes. It might be 
useful to copy the automotive industry in this matter, where small changes to a 
certain model results in the addition of ‘Mark 2’ or ‘Mark 3’ suffix to the model 
name. This would allow surgeons to better judge the available evidence for 
certain implant designs and their alterations.  
 
Future research on hip joint replacement performance 
Finally, the most difficult consideration in the management of problematic MoM 
patients are the patients’ experiences and preferences. There are patients who 
want a revision but with no or mild symptoms, normal or slightly elevated metal 
ion levels and no pseudotumor visible with imaging techniques. Other patients are 
very hesitant to revision surgery but have large, pseudotumors visible on CT or 
MRI but are without symptoms or elevated metal ion levels. The phased 
introduction of new orthopedic implant designs should prevent future recurrenc 
of these dilemma’s. Not only RSA studies on implant fixation should be a part of 
such a balanced introduction, but also local tissue reactions should also be 
monitored with either ultrasound, CT or MARS-MRI, while possible systemic 
reactions to released wear particles should be studied with blood analyses. 
Ultimately, these preliminary findings should be validated with strong clinical 
research results, thereby ensuring long term patient safety and guiding the 
orthopaedic community in which implant types to use for best results in the 
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Long term durability of hip replacement implants is mainly limited by wear of the 
bearing surfaces between the femoral and acetabular components. Different 
bearing materials have been used with the aim to reduce wear and prolong 
implant survival. Polyethylene (PE), commonly used as a bearing surface on the 
acetabular side, releases wear particles which induce osteolysis with subsequent 
component loosening and ultimately implant failure. In the constant strive to 
improve on implant design and materials, a second generation of Metal-on-Metal 
(MoM)surface bearings was introduced in the 1990s with the promise of reduced 
wear, thereby supposedly improving long term implant survival. The main support 
for this claim was achieved by in vitro testing, using wear simulators which were 
run under ideal conditions. 
This re-introduction, after the use of the first generation MoM was discontinued 
due to unacceptable high failure rates, took place in the context of limited 
requirements on supportive clinical data to release new designs into the 
orthopedic market. After approximately a million MoM hip implants were 
inserted into patients (both total hip arthroplasty (THA) and resurfacing 
procedures), it became clear that unexpected complications occurred in soft 
tissue surrounding this MoM implant. These were due to metal debris released 
from the bearing surfaces. This eventually led in 2010 to a worldwide recall of one 
of the MoM hip implant designs, followed by a ban on the use of MoM large 
diameter hip implants in several countries. Since these reactions were 
unforeseen, no evidence based guidelines on how to diagnose and to treat these 
complications were available. Since there is no final data or consensus on the risk-
benefit ratio for the use of MoM implants, the use of large diameter MoM hip 




The first chapter introduces current issues raised with implant survival and 
bearing surfaces in THA and in Hip Resurfacing Arthroplasty (HRA). The four main 
aims of this thesis are presented, being (1) To report the implant survival of the 
current THA bearing options seen as gold standard for the young and more active 
patients. (2) To review all available literature on the different resurfacing systems 
(3) To investigate complications after MoM due to soft tissue reactions to metal 
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wear debris, and (4) To study the most used diagnostic tool, MRI, and the 
classification systems used to find and rate these complications. 
 
Chapter 2 
In chapter two we reviewed the long history of MoM bearing surfaces in hip 
arthroplasty. Since younger patients tend to be physically more active than elderly 
patients, their implants have to withstand higher biomechanical stress and these 
stresses also need to be endured for a more prolonged period of time, leading to 
accelerated wear of the bearing surfaces. To reduce bearing surface wear, 
surgeons, engineers and scientists have developed different bearing surfaces. For 
this purpose, Metal-on-Metal (MoM) surface bearings have a long tradition in 
THA. The re-introduction of the second generation MoM in the 1990s took place 
after the first generation of MoM was abandonded due to unacceptable high 
failure rates and as an answer to “polyethylene disease”, occuring with standard 
Ultra High Molecular Weight Polyethylene (UHMWPE) bearings. Wear simulation 
tests of second generation MoM bearings showed that wear rates were 20 to 100 
times lower compared to metal-on-conventional polyethylene, and MoM bearing 
couples started to experience widespread clinical use in both hip resurfacing and 
total hip arthroplasty. The material properties allowed the use of large heads in 
thin acetabular shells, promising a reduced incidence of hip dislocation in younger 
and more active patients. 
Despite the biomechanical advantages of MoM bearings, metal ion release over 
time and the potential detrimental effects of accumulated metal ions in the body 
remained a concern, and research started to identify implant failure modes in 
reaction to metal wear particles. The terms ALVAL [2005], pseudotumor [2008] 
and metallosis were used, together with a new umbrella term for these modes of 
failure: Adverse Reaction to Metal Debris (“ARMD”, 2010). These unforeseen 
complications revealed serious shortcomings in how orthopaedic innovations are 
introduced into clinical practice. The conflicting interests of making promising new 
hip implant materials and designs available so patients can benefit as soon as 
possible, and the fact that these same joint replacement devices have to perform 
well for over more than 10 years and preferably more than 20 years after 
implantation in the patient, make it difficult to design a model for market 
introduction that effectively and safely guards all these requirements. In 
comparison to pharmaceuticals which require multiple controlled clinical trials 
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prior to approval, which take a mean of nine years and cost an average of 800 
million U.S. dollars, medical devices such as a new hip implant design can be 
released onto the market after in vitro testing and very limited clinical trials. As 
witnessed with the re-introduction of MoM bearings in THA, serious 
complications which were unforeseen at the time of introduction became only 
became known after a large number of patients (worldwide an estimated one 
million patients) had become at risk. 
 
Chapter 3 
Before MoM hip arthroplasty became available for clinical use in the Netherlands, 
uncemented THA with standard UHMWPE was the gold standard for younger 
patients. With this prosthesis design, PE wear remained an important clinical 
observation and to evaluate implant performance, we retrospectively measured 
radiographic wear and implant survival of the first 200 consecutative uncemented 
hip arthroplasties with standard UHMWPE used in our clinic. In this series we 
found a high proportion (53.4%) of implants with a wear rate of >0.2 mm per year, 
which is considered a threshold for accelerated wear. This was after a mean 
follow-up of 8.3 years. Somewhat in contrast, implant survival at a maximum of 12 
years was acceptable (Kaplan-Meier survival probability 90.1%), and compliant to 
international guidelines such as the NICE criteria.  
 
Chapter 4 
With the re-introduction of MoM arthroplasty, all major orthopedic device 
manufacturers designed and introduced, sometimes slightly, different hip 
resurfacing implants. Individual studies using different resurfacing designs 
reported marked differences in short term implant performance, so we decided to 
sytematically review the peer-reviewed literature on implant survival of all 
contemporary MoM hybrid hip resurfacing designs. A total of 29 studies, 
compromising 10,621 patients, were included. All but one of the implants studied 
had insufficient follow up to be compliant with the NICE benchmark, of a revision 
rate of less than 10% at ten years, for choosing a prosthesis for primary THR. The 
study reporting a follow-up of longer than ten years had a revision rate of 16%, 
mainly for aseptic loosening of the implant. This high failure rate was attributed to 
the double-heat-treatment manufacturing process which is no longer in use. The 
prosthesis was superseded by the Cormet 2000 implant in 1996. Compared with 
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the three-year NICE entry-benchmark of implant survival ≥97%, 13 studies (44.8%) 
showed satisfactory survival. Eight used the BHR implant, two the Conserve plus, 
one the Durom, one the Cormet 2000 and one both the McMinn and BHR 
implants. Based on the results of this review we concluded that aseptic loosening 
was the most frequent failure mode and that none of the contemporaty hip 
resurfacing designs met the full 10 year NICE benchmark for survival. In this 
systematic review we were unable to include studies on the resurfacing implant 
used in our clinic. 
 
Chapter 5 
In this chapter we present the results of data prospectively collected in a series of 
280 consecutative hip resurfacing procedures (ReCap, Biomet, Warsaw, USA) 
performed in our clinic. Mean follow up was 3.3 years (range: 1.0 to 6.3) and four 
patients were lost to follow-up. All patients were diagnosed with end-stage hip 
osteoarthritis, their mean age was 54 years and 76.4% of all patients were male. 
All were evaluated with standard radiographic imaging and clinical outcome 
scores before surgery and yearly after the index surgery. There were 16 revisions 
and four patients reported a Harris Hip Score <70 points at their latest follow up. 
Kaplan-Meier implant survival probability, with revision for any reason as 
endpoint, was 93.5% at six years follow-up (95%-CI: 88.8-95.3). There were no 
revisions for Adverse Reactions to Metal Debris (ARMD) and no indications of 
ARMD in symptomatic non-revised patients, although diagnostics were limited to 
ultrasound scans. We concluded that hip resurfacing is a demanding procedure, 
and that implant survival of the ReCap hip resurfacing system is on a critical level 




In chapter six we presented the results of a pilot study in which we used an 
intensified screening protocol to detect pseudotumor formation after MoM hip 
resurfacing in three selected groups of patients: a group with a theoretically high 
risk for pseudotumor formation, a group with a very low risk for pseudotumor 
formation and a group scheduled for routine follow up with a mix of risk factors 
present. Risk factors were based on component size and orientation, gender, 
bilateral or unilateral MoM surgery and clinical symptoms. All selected patients 
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underwent blood metal ion level analysis and cross-sectional imaging using MARS-
MRI. In this study we used a pseudotumor classification system devised by 
Anderson et al to grade pseudotumor severity. Pseudotumor formation was 
observed in all three groups, even in asymptomatic patients with normal blood 
metal ion levels. In 15 out of 44 MRI scans pseudotumors were observed (34.1%), 
of which six were graded with mild (13.6%), eight with moderate (18.2%) and one 
with severe MoM disease (2.3%). Twelve pseudotumors were present in 
asymptomatic patients (27.3%). Metal ion levels were normal in 80% of the 
MARS-MRI screened patients. As a consequence to our intensified screening 
protocol, one patient was revised for pseudotumor occurence and another 
patient scheduled for revision. Asymptomatic pseudotumors were observed in all 
three groups. We concluded that clinical outcomes and plain radiographs for 
screening MoM patients severely underestimated the presence of pseudotumors 
in MoM patients.  
 
Chapter 7 
Different pseudotumor grading systems had been described in the scientific 
literature, but no studies had compared these different systems for use in clinical 
practice and only limited data on the reliability of these grading systems was 
available. In chapter 7 we investigated the influence of using these different 
pseudotumor grading systems on how severe pseudotumors were classified. For 
this study we evaluated a cohort of 42 THA patients (49 MoM hips) using three 
different pseudotumor grading systems designed respectively by Anderson et al, 
by Matthies et al and by Hauptfleisch et al. Two experienced musculoskeletal 
radiologists evaluated all MARS-MRI scans with these systems, allowing us to 
calculate the interobserver reliability for each system. Our results showed that, 
regardless of the classification system used, grading pseudotumor severity on 
MARS-MRI had only a moderate interobserver reliability (ICC 0.65 to 0.68). The 
reliability of pseudotumor severity grading was high between the Matthies an 
Hauptfleisch system but low between the Anderson and the other two systems. 
We concluded that a more succinct pseudotumor severity grading system is 







Since we demonstrated in chapter 6 that standard radiographic follow up 
combined with clinical outcomes was not sensitive enough to detect 
pseudotumor formation after MoM hip arthroplasty, we extended our intensitied 
screening protocol to our complete cohort of MoM hip resurfacing patients. This 
study is presented in chapter 8. At the time this study was started, 248 MoM hip 
resurfacing procedures (214 patients, mean follow-up 4.6 years, range: 1 to 8.2) 
were available for follow up. Again the Anderson classification for pseudotumors 
was used. We found a pseudotumor prevalence of 36.3%: 61 pseudotumors were 
graded mild, 25 moderate and four were graded severe. Five revisions followed, 
all in symptomatic patients with elevated metal ion levels. Since the natural 
course of pseudotumors is largely unknown, and no validated treatment regime 
for pseudotumors after MoM hip arthroplasty exists, we suggested to repeat 
MARS-MRI in asymptomatic patients with mild to moderately severe 
pseudotumors combined with normal metal ion levels, rather than to immediately 
revise these cases. The use of this screening protocol and this pseudotumor 
grading system allowed us to be conservative with revision surgery for mild and 
moderate MoM disease. Of course patients with non-revised pseudotumors were 
kept under increased surveillance. These results could be used as a clinical 
guideline for management of observed pseudotumor after MoM hip resurfacing. 
 
Chapter 9 
As stated in the previous chapter, intensified follow up of cases with non-revised 
pseudotumors was needed to validate a more conservative approach in the 
management of observed pseudotumors. In chapter 9 we present the results of 
repeated MARS-MRI’s which were used to follow up on identified pseudotumors 
from our previous studies. To monitor how pseudotumors developed in time, we 
repeated cross-sectional imaging 6 to 12 months after the initial MARS-MRI, 
together with repeated metal ion analysis and clinical examination. In this study, 
14 unrevised cases with pseudotumour and a control group of 23 cases without 
pseudotumour on the first MARS-MRI were evaluated. The mean postoperative 
time to the first MARS-MRI was 4.3 years (range: 2.2 to 8.3) and mean time 
between first and second MARS-MRI was 8 months (range: 6 to 12). The majority 
of patients (35/37) showed no change in pseudotumor severity with the second 
MRI, one new pseudotumour was observed (Anderson C2 score, moderate) and 
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one pseudotumour was downgraded from C2 (moderate) to C1 (mild). We 
concluded that repeating of MARS-MRI within one year, in unrevised patients with 
asymptomatic pseudotumours after MoM hip resurfacing, was of limited use. But, 
since this was the first longitudinal study on pseudotumours using MARS-MRI, our 
findings need to be interpreted with caution. 
 
Chapter 10 
Since management of non-revised pseudotumors depends on both severity 
(based on location, type of content, growth rate) and on pseudotumor 
dimensions, it is relevant to have an accurate clinical measurement method of 
pseudotumor dimensions. In this chapter our objective was to validate clinical 
measurements of (change in) pseudotumor dimensions (maximum diameter and 
estimated volume) against three-dimensional region-of-interest (3-D ROI) volume 
measurements. Therefore, we had MARS-MRI scans available for 13 cases of non-
revised pseudotumors after Metal-on-Metal hip resurfacing. Mean follow-up at 
the first MARS-MRI was 5.3 years (range: 2.4 to 7.5), a second MARS-MRI was 
acquired after a mean of 7.5 months (range: 6 to 12). On all scans pseudotumor 
dimensions were measured by (1) maximum diameter in one plane (MD) and (2) 
by estimating pseudotumor volume based on maximum diameter in three 
different planes (EV). (3) For validation, a 3-D ROI based volume (V) was calculated 
by the summation of all pseudotumor areas in each slice and multiplication by the 
slice profile. Correlations between MD, EV and V were calculated. Correlation was 
high between all three measurement methods, but the correlation was strongest 
between EV and V. EV overestimated V with a mean of 72.6%, and more so in 
non-ellipsoid pseudotumors than in ellipsoid pseudotumors. Median values for 
MD, EV or V were not significantly different between first and second MARS-MRI. 
Median change for MD was 0.0cm (range: -1.5 to 3.4), -0.5ml for EV (range: -16.4 
to 45.5) and 0.5ml for V (range: -7.7 to 5.2). Percent change in pseudotumor 
dimensions was not significantly different between MD, EV and V.  
We concluded that estimating pseudotumor volume in clinical practice using 
maximum pseudotumor diameter in three different planes has a strong 
correlation with a more elaborate 3D-ROI method. This method of estimating 
volume is easily attainable in clinical practice and can be used for monitoring 





In this chapter, the findings of all studies conducted for this thesis are synthesized 
and discussed in their context, resulting in answers to the main study aims and 
propositions for future research. The first aim of this thesis was to report the 
implant survival of the current THA bearing options seen as gold standard for the 
young and more active patients. We concluded that for these patients, hip 
resurfacing with MoM bearing surfaces was not compliant with the international 
benchmarks for 10 year implant survival and uncemented, standard UHMWPE hip 
prostheses just barely reached this benchmark. For the UHMWPE prostheses, the 
high amount of wear was noticed as the biggest downside with a potential 
accelerated wear in the second decade after implantation. 
The second aim of this thesis was to review all the different resurfacing systems 
on the market for implant survival results. After systematically reviewing the 
literature, we concluded that all reviewed hip resurfacing systems did not meet 
the international benchmark, and that there were hip resurfacing systems on the 
market of which no clinical studies were available for our review. It is noteworthy 
that the data presented in the studies we reviewed were collected before the 
unexpected adverse reactions to metal debris released by the MoM bearing 
surfaces were investigated. Therefore our conclusion that aseptic loosening was 
the main failure mode of MoM hip resurfacings needs to be seen in this context, 
and a future update of this review based on current knowledge might change the 
view on failure of reasons for current MoM systems. 
The third aim of this thesis was to investigate complications after MoM due to 
soft tissue reactions to metal wear debris. We concluded that the incidence of 
these complications, diagnosed as pseudotumors, was higher than expected, that 
risk factors were difficult to interpret, and that cross-sectional imaging is 
necessary to find the true incidence, since many patients have these reactions 
without being symptomatic. We also found that the use of a pseudotumor 
classification system was helpful in managing treatment of these complications. 
The fourth aim of this thesis was to study the most used diagnostic tool, MRI, and 
the classification systems used to find and rate these complications. Based on our 
validation studies we concluded that using these systems observers were able to 
idenfity pseudotumors but that the classification of pseudotumors severity 
needed more refinement. Therefore future studies need to validate the treatment 
which was chosen upon the pseudotumor severity grade that was seen with 
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MARS-MRI. For clinical practice, we found that a simple box model for estimating 
pseudotumor volume correlated well with a more elaborate three-dimensional 
region-of-interest system and was easily used in clinical practice, althoug clinicians 













De levensduur van heupprotheses wordt beperkt door slijtage van de 
contactoppervlakken van de femorale en de acetabulaire component. Er zijn dan 
ook verschillende materialen toegepast om deze slijtage te minimaliseren, en 
daarmee de overleving van het implantaat te verlengen. Polyethyleen (PE) is het 
meest gebruikte materiaal als oppervlak aan de acetabulaire zijde, maar de 
slijtage deeltjes die daarvan vrijkomen kunnen osteolyse induceren, waardoor 
uiteindelijk de prothese los laat en daarmee het implantaat faalt. In het 
voortdurend streven naar verbeteringen in het ontwerp en de duurzaamheid van 
de gebruikte materialen, werd rond 1990 een tweede generatie van Metaal-op-
Metaal (MoM) implantaten geïntroduceerd, met daarbij de belofte van minder 
slijtage en een verbeterde lange termijn overleving van het implantaat. De 
belangrijkste onderbouwing hiervoor werd geleverd door de resultaten van in-
vitro testen, uitgevoerd met behulp van slijtage-simulatoren. 
Deze herintroductie van MoM protheses vond plaatst nadat het gebruik van de 
eerste generatie MoM protheses was gestaakt na onaanvaardbaar hoge 
revisiepercentages, en waarbij de regelgeving maar beperkt eisen stelde aan de 
introductie van nieuwe prothese-ontwerpen. Nadat van deze tweede generatie 
MoM protheses wereldwijd ongeveer een miljoen operaties waren gedaan (zowel 
in de vorm van een totale heupprothese (THP), als in de vorm van een resurfacing 
prothese), werd het langzaam duidelijk dat er onverwachte complicaties konden 
optreden in de weefsels rondom deze implantaten. Deze reacties waren het 
gevolg van vrijkomende slijtagedeeltjes van de metalen oppervlakken. Deze 
reacties bleken voor specifieke MoM heupprotheses zo vaak voor te komen, dat 
in 2010 een wereldwijde terugroep actie (‘recall’) werd uitgevaardigd voor een 
van deze MoM heup implantaten. Dit werd later gevolgd door een verbod in 
verschillende landen, waaronder Nederland, op het gebruik van MoM 
heupprotheses met een grote diameter, ongeacht het merk van de prothese. 
Aangezien deze reacties onvoorzien waren, waren er geen richtlijnen over hoe het 
beste deze afwijkingen te diagnosticeren en te behandelen. Nog steeds is er geen 
consensus over de verhouding tussen het risico van een MoM prothese en de 
mogelijke voordelen, waardoor het gebruik van grote diameter MoM heup 
implantaten momenteel in enkele landen verboden is terwijl dit type prothese 






In het eerste hoofdstuk wordt de toepassing van heupprotheses bij relatief jonge 
patiënten met ernstige arthrose van de heup besproken, met als belangrijkste 
aandachtspunt de overleving van het implantaat bij deze patiënten. Doordat het 
implantaat bij deze jongere patiënt zwaarder wordt belast dan bij de veel oudere 
patiënt, is de kans op slijtage van de gewrichtsoppervlakken groter. Daarnaast 
moet de prothese bij deze relatief jonge patiënten, vanwege hun langere 
levensverwachting, ook langer in situ kunnen blijven. Door deze zwaardere eisen 
die hiermee worden gesteld aan de prothese, is er veel aandacht voor de slijtage 
van de gewrichtsoppervlakken van deze protheses. Het gebrek aan onderbouwing 
van welk type prothese voor deze relatief jonge patiënten het meest geschikt zou 
zijn, leidde dan ook tot de vier belangrijkste doelstellingen van dit proefschrift, 
namelijk; (1) Te analyseren wat de slijtage en overleving was van de 
ongecementeerde THP, die voor het gebruik van MoM als de gouden standaard 
werd gezien voor de jonge, actieve patiënten met invaliderende heuparthrose; (2) 
De beschikbare wetenschappelijke literatuur over de resultaten van MoM heup 
resurfacing implantaten systematisch te analyseren; (3) Het optreden van 
complicaties in de weke delen rondom de MoM prothese te bestuderen, en (4) de 
toepassing en resultaten van ‘Metal-Artefact Reducing Sequence - Magnetic 
Resonance Imaging’ (MARS-MRI) als diagnostische instrument voor deze 
complicaties na het plaatsen van een MoM heupprothese te bestuderen. 
 
Hoofdstuk 2 
In hoofdstuk twee wordt de geschiedenis van MoM heupprothese besproken. 
Aangezien jongere patiënten in het algemeen fysiek actiever zijn dan de meeste 
oudere patiënten, moeten hun prothese gedurende langere tijd meer 
biomechanische stress doorstaan, waardoor er versnelde slijtage van de 
gewrichtsoppervlakken kan optreden. Om deze slijtage te verminderen, hebben 
orthopeden, ingenieurs en wetenschappers verschillende kunstmatige 
gewrichtsoppervlakken ontwikkeld, waaronder MoM. De introductie van de 
tweede generatie MoM in de jaren 1990 vond plaats nadat het gebruik van de 
eerste generatie MoM was gestaakt vanwege onaanvaardbaar hoge 
revisiepercentages, en als antwoord op de zogenaamde "polyethyleen ziekte", die 
op kon treden bij het gebruik van standaard Ultra Hoog Moleculair Polyethyleen 
(UHMWPE) gewrichtsoppervlakken. Na laboratorium tests van de tweede 
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generatie MoM gewrichtsoppervlakken bleek de slijtage 20 tot 100 keer minder te 
zijn dan bij UHMWPE. Vanaf 2000 nam het gebruik van MoM wereldwijd sterk 
toe. Dit gebeurde zowel als heup resurfacing en als totale heupvervanging. Door 
de materiaaleigenschappen kon ook een grote diameter heupkop worden 
gebruikt, waardoor in theorie de kans op heupluxatie sterk afnam, hetgeen dit 
type prothese met name geschikt maakte voor de jongere, actieve patiënt. 
Ondanks deze biomechanische voordelen van MoM gewrichtsoppervlakken, bleef 
het vrijkomen van metaalionen na implantatie en de mogelijke schadelijke 
effecten hiervan een punt van zorg. Geleidelijk aan werden meer 
wetenschappelijke resultaten gepubliceerd die reacties op vrijgekomen 
metaaldeeltjes beschreven. De termen ALVAL (2005), pseudotumor (2008) en 
metallosis werden hiervoor geïntroduceerd, met daarbij een nieuwe, 
overkoepelende term: “Adverse Reactions to Metal Debris” (ARMD, 2010). Deze 
onvoorziene complicaties toonden tevens aan dat er tekortkomingen waren in de 
wijze waarop orthopedische innovaties werden geïntroduceerd in de klinische 
praktijk. De tegenstrijdige belangen bij dergelijke introducties van een nieuw 
ontwerp heupprothese zijn evident: het introduceren van betere ontwerpen en 
materialen laat patiënten direct profiteren van deze innovaties; Daarentegen 
moet ook op langer termijn worden aangetoond dat nieuwe implantaten goed 
presteren. Bij voorkeur langer dan 10 jaar en liefst zelfs meer dan 20 jaar na 
implantatie. Deze tegenstrijdigheid maakt het moeilijk om een model voor 
marktintroductie te hanteren dat tegelijkertijd innovaties zo snel mogelijk toelaat 
tot de klinische praktijk om zoveel mogelijk patiënten te laten profiteren, waarbij 
tegelijkertijd de veiligheid van de patiënten optimaal wordt bewaakt. In 
vergelijking met de introductie van nieuwe geneesmiddelen, waarbij een strikte 
regelgeving met meerdere gecontroleerde klinische studies vóór toelating tot de 
markt er toe leidt dat dit proces gemiddeld negen jaar duurt en $800.000.000 kost 
kunnen medische hulpmiddelen, zoals een nieuwe heupprothese, worden 
vrijgegeven in de klinische markt na een beperkt aantal klinische trials, vaak van 
geringe omvang. Met de herintroductie van MoM heupprotheses konden ernstige 
complicaties ontstaan die op het moment van introductie niet waren voorzien, 
waardoor een groot aantal patiënten, wereldwijd naar schatting 1 miljoen, ‘at risk’ 






Voordat MoM heupprothese werden geïntroduceerd in de kliniek was de 
gecementeerde THA met UHMWPE de “gouden standaard” voor jongere 
patiënten met invaliderende heuparthrose. PE slijtage was hierbij de belangrijke 
klinische observatie in lange termijn studies. Om deze resultaten te evalueren in 
de eigen kliniek, hebben we retrospectief onderzocht wat de radiologische slijtage 
en de implantaatoverleving was van de eerste 200 achtereenvolgende 
ongecementeerde heupprothesen met standaard UHMWPE geplaatst in onze 
kliniek. In deze serie vonden we dat 53% van de geplaatste protheses een 
versnelde slijtage (>0,2 mm per jaar) liet zien, bij een gemiddelde “follow-up” van 
8.3 jaar. Enigszins in tegenstelling tot deze resultaten bleek de overleving van dit 
type implantaat acceptabel te zijn volgens de internationale richtlijnen van de 
(National Institute for Clinical Excellence) NICE- criteria, zelfs bij de maximale 
“follow-up” duur van 12 jaar (Kaplan-Meier overlevingskans 90.1%) 
 
Hoofdstuk 4 
Met de herintroductie van MoM heupresurfacing protheses, brachten alle grote 
orthopedische fabrikanten een eigen variant hiervan op de markt. In 
wetenschappelijk onderzoek naar de resultaten van de verschillende ontwerpen, 
leek het er op dat er tussen de verschillende merken verschillen waren op te 
merken in de korte termijn overlevings resultaten. Hierop besloten we om een 
systematisch literatuuronderzoek te doen naar de “peer-reviewed” literatuur over 
implantaatoverleving van alle hedendaagse MoM heupresurfacings. In totaal 
includeerden we 29 studies, die gezamenlijk de resultaten van 10.621 patiënten 
beschreven. Alle merken heupresurfacing, op één na, bleken onvoldoende lange 
termijn resultaten te presenteren om te kunnen voldoen aan het NICE criterium 
(maximaal 10% revisie in 10 jaar). Het merk heupresurfacing met wel een “follow-
up” van meer dan tien jaar had een revisiepercentage van 16%, hoofdzakelijk door 
aseptische loslating van het implantaat. Dit hoge percentage werd toegeschreven 
aan het specifieke productieproces (dubbele warmtebehandeling) en deze 
werkwijze werd dan ook niet meer toegepast. Naast de 10 jaar benchmark kent 
NICE ook nog de 3-jaar benchmark. Vergeleken met dit criterium (maximaal 3% 
revisie na drie jaar), bleken er 13 studies (44.8 %) een positief resultaat te halen: 
Acht gebruikten het BHR implantaat, twee de Conserve plus, een de Durom, een 
de Cormet 2000 en een zowel het McMinn als het BHR implantaat. 
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Op basis van deze resultaten konden we concluderen dat geen van de huidige 
heup resurfacing ontwerpen voldeed aan het 10 jaar NICE criterium, en de 
minderheid voldeed aan het 3 jaar criterium. Aseptische loslating van de 
componenten was daar de meest frequente reden van falen Daarnaast konden we 
met deze systematische review geen studies includeren die rapporteerden over 
het specifieke resurfacing implantaat dat in onze kliniek werd gebruikt. 
 
Hoofdstuk 5 
In hoofdstuk vijf presenteren we de resultaten van prospectief verzamelde data 
van een reeks van 280 achtereenvolgende heupresurfacing operaties in onze 
eigen kliniek, waarbij in alle procedures het ReCap heup resurfacing systeem 
(Biomet, Warsaw, USA) was gebruikt. De gemiddelde “follow–up” was 3.3 jaar 
(range: 1.0 tot 6.3) waarbij vier patiënten “lost to follow-up” waren. Alle 
patiënten waren voor de operatie gediagnosticeerd met ernstige heuparthrose 
(gemiddelde leeftijd: 54 jaar, 76.4% mannen). Alle patiënten waren voor de 
operatie onderzocht met standaard radiologische onderzoek en de afname van 
gevalideerde klinische meetinstrumenten, en dit werd jaarlijks herhaald na 
operatie. Uiteindelijk waren er 16 revisies. Vier ongereviseerde patiënten 
scoorden slecht op de klinische uitkomstmaten tijdens hun laatste follow up (o.a. 
Harris Hip Score <70 punten). Dit resulteerde in een Kaplan-Meier overlevingskans 
voor het implantaat, met revisie om welke reden dan ook als eindpunt, van 93.5% 
na zes jaar “follow-up” (95%-BI: 88.8-95.3). Ten tijde van dit onderzoek werd er 
geen ARMD geconstateerd, waarbij moet worden opgemerkt dat aanvullende 
diagnostiek voor deze problematiek bij symptomatische patiënten beperkt bleef 
tot echografie. De conclusie van dit onderzoek was dat heupresurfacing een 
veeleisende procedure is, en dat implantaatoverleving van de ReCap heup 
resurfacing in onze kliniek op een kritisch niveau bleek te zijn. Echter, in niet 




In hoofdstuk zes presenteren we de resultaten van een pilotstudie met een 
intensief screening protocol naar pseudotumoren als gevolg van een MoM 
heupresurfacing. Daarbij vergeleken we de resultaten van drie groepen: (1) 
patiënten met een theoretisch hoog risico op pseudotumorvorming, (2) patiënten 
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met een zeer laag risico en (3) patiënten die voor routine “follow-up” in de kliniek 
kwamen, met daardoor een mix van risicofactoren. Risicofactoren waren 
gebaseerd op poitionering en grootte van de gebruikte componenten, geslacht 
van de patiënt, het uni of bilateraal hebben van een MoM heupprothese en 
klinische symptomen. Alle deelnemende patiënten kregen bloedonderzoek om de 
concentratie metaalionen te bepalen en een Metal-Artefact Reducing Sequence 
(MARS)-MRI. In dit onderzoek gebruikten we een pseudotumor 
classificatiesysteem dat door Anderson et al was beschreven waarmee de ernst 
van de pseudotumor kon worden vastgesteld. Tot onze verrassing werden in alle 
drie de groepen pseudotumoren waargenomen, ook bij asymptomatische 
patiënten met normale concentraties metaalionen in het bloed. In 15 van de 44 
MRI-scans werden pseudotumoren waargenomen (34.1%), waarvan er zes 
werden beoordeeld als niet ernstig (13.6%), acht als matig ernstig (18.2%) en één 
als ernstig (2.3%). Van de waargenomen pseudotumoren waren er 12 aanwezig bij 
asymptomatische patiënten (27.3%) en deze “asymptomatische pseudotumoren” 
werden waargenomen in alle drie de groepen. Bij 80% van de onderzochte 
patiënten waren de concentraties metaalionen niet afwijkend. Ten gevolge van 
deze observaties werd bij één patient een revisie van de MoM heupresurfacing 
gedaan. We concludeerden dat klinisch onderzoek met daarbij alleen het maken 




In de wetenschappelijk literatuur werden ondertussen verschillende systemen 
beschreven om waargenomen pseudotumoren na een MOM heupprothese te 
classificeren, maar er was nog geen onderzoek gedaan waarin deze systemen 
werden vergeleken. Daardoor was er voor de kliniek maar beperkt informatie 
voorhanden over de betrouwbaarheid van deze classificatiesystemen. In 
hoofdstuk zeven hebben we onderzocht hoe betrouwbaar deze systemen waren 
in het classificeren van de ernst van de geobserveerde pseudotumoren, en wat de 
invloed was van de keuze voor een bepaald systeem. Voor deze studie hebben we 
een cohort van 42 THA patiënten (49 MoM heupen) onderzocht met behulp van 
drie verschillende pseudotumor graderingssystemen: (1) het systeem van 




De resultaten van twee ervaren musculoskeletale radiologen werden vergeleken 
(interbeoordelaarsbetrouwbaarheid) waarbij zij de MARS-MRI beelden steeds met 
deze drie systemen beoordeelden Daarnaast herhaalden zij hun beoordelingen 
enige tijd later, zodat we ook de intrabeoordeelaarsbetrouwbaarheid konden 
berekenen. Onze resultaten toonden aan dat, ongeacht het gebruikte 
classificatiesysteem, de betrouwbaarheid van de beoordeling van de 
pseudotumor matig was. De uiteindelijke conclusie kon dan ook niet anders zijn 
dan dat er behoeft is aan een beknopt pseudotumor graderings systeem voor 
klinisch gebruik dat een hogere betrouwbaarheid laat zien. 
 
Hoofdstuk 8 
In hoofdstuk zes toonden we in een kleine groep MoM patiënten aan dat 
standaard röntgenologische follow-up in combinatie met klinisch onderzoek niet 
voldoende gevoelig was om pseudotumorvorming op te sporen. Daarop hebben 
we het intensitieve screenings protocol toegepast op het volledige cohort van 
MoM heup resurfacing patiënten in onze praktijk. De resultaten van dit onderzoek 
worden beschreven in hoofdstuk acht. Bij de start van dit onderzoek, waren er 
248 MoM heup resurfacings beschikbaar (214 patiënten, gemiddelde follow-up 
4.6 jaar, range: 1 tot 8.2). In dit onderzoek vonden we een pseudotumor 
prevalentie van 36.3%: hierbij werd de ernst van 61 pseudotumoren beoordeeld 
als zijnde mild, 25 als zijnde matig ernstig en vier pseudotumoren als ernstig 
(Anderson classificatie). Vijf revisie-operaties volgden, allemaal bij 
symptomatische patiënten met verhoogde concentraties metaalionen. Aangezien 
het natuurlijke beloop van pseudotumoren nog grotendeels onbekend is, en er 
geen consensus over de optimale behandeling van pseudotumoren na MoM 
heupprothese bestaat, werd er bij asymptomatische patiënten met een milde tot 
matig ernstige pseudotumor en normale concentraties metaalionen gekozen voor 
een voorlopig conservatief beleid. Het gebruik van dit intensieve 
screeningsprotocol en het indelen van de ernst van de pseudotumor liet ons 
vooralsnog toe om dit conservatieve beleid te voeren. De patiënten met niet-







Zoals gesteld in hoofdstuk acht was een intensieve controle van de patiënten met 
niet-gereviseerde pseudotumoren nodig om de, voorlopig, conservatieve 
behandeling te valideren. Om het natuurlijke beloop van pseudotumoren in de 
tijd te volgen, herhaalden we deze onderzoeken zes tot 12 maanden na de eerste 
MARS-MRI, waarbij ook de metaal-ionen concentraties opnieuw werden gemeten 
en het klinisch onderzoek werd herhaald. In deze studie werden 14 niet-
gereviseerde pseudotumoren bestudeerd evenals een controlegroep van 23 
patiënten waarbij er geen pseudotumor aanwezig was op de eerste MARS-MRI. 
De gemiddelde postoperatieve tijd tot de eerste MARS-MRI was 4.3 jaar (range: 
2.2 tot 8.3), en de gemiddelde tijd tussen de eerste en tweede MARS-MRI was 
acht maanden (range: 6 tot 12). Bij de meerderheid van de patiënten (35/37) was 
er geen verschil te zien in de ernst van de pseudotumor, eenmaal werd een 
nieuwe pseudotumor waargenomen (Anderson C2 score, matig ernstig) en 
eenmaal was de ernst van de pseudotumor afgenomen (van C2, matig ernstig, 
naar tot C1, mild). De conclusie van dit onderzoek was dat het herhalen van een 
MARS-MRI binnen een jaar bij niet-gereviseerde MoM patiënten met milde, tot 
matig ernstige asymptomatische pseudotumor na MoM resurfacing heup, van 
weinig nut is. Tegelijkertijd is het belangrijk deze conclusie voorzichtig te 
interpreteren omdat dit de eerste longitudinale MARS-MRI studie is naar het 
natuurlijk beloop van pseudotumouren. 
 
Hoofdstuk 10 
Aangezien de behandeling van de niet-gereviseerde pseudotumoren afhankelijk is 
van zowel de ernst (gebaseerd op locatie, inhoud en groeisnelheid) als van de 
afmetingen van de pseudotumor, is het relevant om een nauwkeurige klinische 
meetmethode beschikbaar te hebben die de dimensies van een pseudotumor 
goed kan meten. Het doel van de studie beschreven in hoofdstuk 10 was om 
klinische methoden waarmee (veranderingen in) afmetingen van pseudotumor 
kunnen worden gemeten te valideren met een laboratorium methode die als 
gouden standaard kan worden gebruikt. Deze laboratorium methode was een 
drie-dimensionale, region- of-interest (3-D ROI) volume meting. Voor deze studie 
waren er 13 MARS-MRI scans beschikbaar van niet-gereviseerde pseudotumoren, 
ontstaan na MoM heup resurfacing. Van deze patiënten was ook een tweede 
MARS-MRI beschikbaar voor de metingen. De gemiddelde follow-up bij de eerste 
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MARS-MRI was 5.3 jaar (range: 2.4 tot 7.5), en de tweede MARS-MRI was 
verkregen na gemiddeld 7.5 maanden (range: 6 tot 12). Op alle beschikbare scans 
werden de pseudotumor afmetingen gemeten middels: (1) maximale diameter in 
één vlak (MD), (2) door een schatting van het pseudotumor volume gebaseerd op 
de gemeten maximale diameter in drie verschillende vlakken (“Estimated volume, 
EV”). (3) Ter validatie werd van elke scan een 3-D ROI volume (V) berekend door 
de som van de oppervlakte van het pseudotumor gebied per MRI-segment te 
vermenigvuldigen met de MRI-segment dikte. De correlatie was het sterkst tussen 
EV en V, maar EV overschatte V gemiddeld met 72.6 %, vooral in niet-ellipsoïd 
gevormde pseudotumoren. De mediane waarden voor MD, EV of V waren niet 
significant verschillend tussen de eerste en tweede MARS-MRI. De mediane 
verandering voor MD was 0 cm (range: -1.5 tot 3.4), 0.5 ml voor EV (range: -16.4 
tot 45.5) en ook 0.5 ml voor V (range: -7.7 tot 5.2). Dit leidde tot de conclusie dat 
in de klinische praktijk de methode waarbij het pseudotumor volume (EV) werd 
geschat aan de hand van de maximale diameter gemeten in drie vlakken, beter 
kan worden gebruikt dan het meten van de maximale pseudotumor diameter in 
één vlak, en dat deze methode een sterke correlatie heeft met een meer 
complexere 3D-ROI methode. Klinisch moeten we daarbij wel rekening houden 
met een overschatting van de grootte van de pseudotumor, vooral in niet-
ellipsoïde pseudotumoren. Daarnaast lijkt deze methode gemakkelijk toepasbaar 
in de klinische praktijk en kan dan ook worden gebruikt voor het monitoren van 
verandering in de grootte van geobserveerde pseudotumoren. 
 
Hoofdstuk 11 
Hoofdstuk 11 vat de resultaten van alle studies beschreven in dit proefschrift 
samen, en worden daarnaast de vraagstellingen beantwoord en worden 
voorstellen voor toekomstig onderzoek worden gedaan. De eerste doelstelling 
van dit proefschrift was om de implantaatoverleving van heupprotheses gebruikt 
voor de behandeling van ernstige heuparthrose bij jonge en actieve patiënten te 
onderzoeken. We concludeerden dat voor deze patiënten, de overleving van 
MoM heupresurfacing niet voldeed aan de internationale richtlijn, terwijl de 
ongecementeerde heupprothese met UHMWPE net voldeed aan deze richtlijn. 
Echter, bij deze laatste werd wel een hoge mate van slijtage opgemerkt in de 
eerste 10 jaar, waarbij er mogelijk nog een potentiële versnelde slijtage in het 
tweede decennium na implantatie zou kunnen optreden. 
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Het tweede doel van dit proefschrift was om de overleving van alle bekende 
heupresurfacing systemen te beoordelen. Na het systematisch analyseren van de 
wetenschappelijke literatuur, was de conclusie dat geen van deze implantaten aan 
de internationale richtlijn voor implantaatoverleving voldeed, en dat er 
heupresurfacing systemen in de kliniek werden gebruikt zonder dat daarvoor 
adequate klinische studies beschikbaar waren. Tevens kon worden vastgesteld 
dat, ten tijde van dit onderzoek, aseptische loslating de belangrijkste reden van 
falen was voor de verschillende MoM heupresurfacing systemen. De derde 
doelstelling van dit proefschrift was om onderzoek te doen naar complicaties die 
optraden na het plaatsen van een MoM heupprothese en die te wijten waren aan 
reacties op metalen slijtagedeeltjes. Na intensieve controle van alle patiënten met 
een dergelijke prothese in onze kliniek, konden wij concluderen dat de prevalentie 
van deze complicaties hoger was dan verwacht, en dat er geen eenduidige 
risicofactoren voor het ontstaan van deze complicaties konden worden 
vastgesteld. Ook concludeerden we dat het gebruik van MARS-MRI belangrijk was 
aangezien bij een aanzienlijk deel van deze complicaties werd waargenomen bij 
asymptomatische patiënten. Daarnaast bleek het toepassen van een 
pseudotumor classificatiesysteem een waardevolle aanvulling in de klinische 
praktijk. De vierde en laatste doelstelling van dit proefschrift was om de 
toepassing van MARS-MRI, het diagnostisch instrument voor deze complicaties, 
en de daarvoor beschikbare pseudotumor classificatiesystemen te onderzoeken. 
Op basis van onze studies concludeerden we dat met MARS-MRI en bij behorende 
classificatiesystemen de pseudotumoren goed konden worden geïdentificeerd 
maar dat er voor het vaststellen van de ernst van de pseudotumor nog een 
verdere verfijning nodig is. Toekomstige studies zouden de behandeling van 
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